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MSP-1 Merozoite surface protein-1
MSP-I42 42 kDa primary processing fragment of MSP-1
MSP-119 19 kDa secondary processing fragment of MSP-142
MSP-I33 33 kDa secondary processing fragment of MSP-I42
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NMR Nuclear magnetic resonance
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P. Plasmodium
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scFv Single-chain variable fragment
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VH Variable region of the immunoglobulin heavy chain
Vl Variable region of the immunoglobulin light chain
Vk Variable region of the immunoglobulin (light) kappa chain
V* Variable region of the immunoglobulin (light) lambda chain
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ABSTRACT
A major surface protein complex on the Plasmodium falciparum merozoite, 
Merozoite Surface Protein-1 (MSP-1) undergoes a proteolytic cleavage at the time of 
erythrocyte invasion by the parasite. Two murine monoclonal antibodies, mAb 12.8 and 
mAb 12.10, are specific for a 19 kDa subunit of MSP-1 (MSP-119) and can prevent both 
this proteolytic cleavage and erythrocyte invasion. Such invasion-inhibitory mAbs may be 
generated by natural P. falciparum infection in man and may contribute to protection 
against malaria.
To isolate naturally occurring human anti-MSP-li9 monoclonal antibodies, two 
phage display libraries were constructed, consisting of single chain Fv antibody fragments 
(scFvs) derived from malaria-exposed donors in The Gambia, West Africa. The libraries 
were panned with recombinant MSP-119 and a number of anti-MSP-li9 scFvs were 
identified. Their ability to bind recombinant MSP-119 and native parasite antigen was 
demonstrated and their sequences were found to be diverse. The anti-MSP-li9 scFv were 
shown to partially block the binding of mAbs 12.8 and 12.10 to MSP-119 but none of the 
scFvs isolated could be shown to inhibit erythrocyte invasion in vitro.
In order to further characterise the invasion-inhibitory murine hybridoma mAbs 
12.8 and 12.10, the DNA sequences encoding the variable, antigen-binding, regions of 
these mAbs were obtained and confirmed by mass spectrometry of the antibodies 
themselves. The mAbs 12.8 and 12.10 were reconfigured into scFv format to serve as a 
future model in which to test ways of restoring invasion-inhibitory activity to scFvs. The 
scFv 12.10 was shown to bind its target antigen but could not be shown to inhibit 
erythrocyte invasion in vitro. Preliminary experiments were performed to examine ways in
21
which any invasion-inhibitory properties of the parent mAbs might be restored to the 
human and murine scFvs.
Chimeric murine/human versions of mAbs 12.8 and 12.10, engineered from the 
mAb sequences obtained, were shown to bind recombinant and native antigen, and were 
also shown to inhibit erythrocyte invasion in vitro.
In the future, the chimeric mAbs will be suitable reagents to test the ability of 
invasion-inhibitory mAbs to modify P. falciparum infection in a primate model, and the 
phage display libraries should provide a resource from which naturally occurring human 
invasion-inhibitory mAbs can be isolated.
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CHAPTER 1
INTRODUCTION
1.1 Malaria
Malaria is a parasitic disease of man and other animals caused by apicomplexan 
protozoa of the genus Plasmodium. Of the four species of Plasmodium to infect man, 
Plasmodium falciparum is the cause of the great majority of morbidity and mortality due to 
malaria. The worldwide public health burden due to P. falciparum is very great (Breman, 
Egan et al. 2001). In many parts of the world that burden is increasing, both because of 
spread of the parasite into populations not previously exposed to malaria, and because of 
increasing drug resistance. There is an urgent need for new and affordable treatments and 
an effective vaccine. The fact that exposed populations develop protective, if not 
sterilising, immunity to malaria encourages the belief that an effective malaria vaccine will 
eventually be an achievable goal.
The malaria life cycle consists of a sexual stage in the anopheline mosquito and an 
asexual stage in man, with transmission occurring when the mosquito feeds on man. 
Clinical illness in man is caused by parasites in the blood stage of the life cycle. This stage 
is characterised by the invasion of host red blood cells by the P. falciparum merozoite, 
followed by intra-erythrocytic parasite growth and asexual replication to form a schizont, 
whose rupture releases many more merozoites into the plasma to continue the cycle. Most 
antimalarial drugs act exclusively on parasites in this blood stage of the life cycle. 
Vaccines have been proposed against other stages of the life cycle, but the blood stage is
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widely considered to offer a promising target for a vaccine. This is particularly true for 
vaccines which aim to produce protection mediated by antibody, since the parasite is more 
vulnerable to antibody attack during the blood stage of the life cycle, when parasite 
antigens are exposed for considerable periods in the bloodstream.
Various parasite antigens expressed during the blood stage have been proposed as 
vaccine candidates, but an antigen which is considered particularly promising is the 
merozoite antigen, Merozoite Surface Protein 1 (MSP-1).
1.2 Merozoite Surface Protein 1 (MSP-1) and erythrocyte invasion
1.2.1 Merozoite Surface Protein 1 and secondary processing
Merozoite Surface Protein 1 (MSP-1) is present on the surface of the merozoite as a 
complex of polypeptides formed by the proteolytic cleavage, or primary processing, of the 
precursor protein. The complex is anchored to the merozoite by a 42 kDa fragment 
attached to the membrane by a GPI anchor. At the time of erythrocyte invasion, the 
42 kDa fragment undergoes proteolytic cleavage, leaving a 19 kDa fragment (MSP-119) 
attached to the merozoite, which is carried into the erythrocyte as the parasite invades 
(Blackman, Heidrich et al. 1990). This proteolytic cleavage of MSP-1 is mediated by a 
parasite-derived protease, and is known as secondary processing. Secondary processing 
appears to be essential for successful erythrocyte invasion and is vulnerable to interruption 
by MSP-119-specific antibodies. Of a group of mAbs specific for epitopes within 
MSP-119, some have been shown to inhibit erythrocyte invasion, and these mAbs also
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prevent secondary processing of MSP-1 (Blackman, Scott-Finnigan et al. 1994). The 
primary and secondary processing of MSP-1 are shown schematically in Figure 1.1, and the 
relationship between secondary processing and erythrocyte invasion is shown in Figure 1.3.
The solution structure of P. falciparum MSP-119 has been determined by nuclear 
magnetic resonance (Morgan, Birdsall et al. 1999) and the crystal structure of the 
homologous molecule from P. cynomolgi has also been determined (Chitarra, Holm et al. 
1999). Both studies confirm that the protein structure has two domains with epidermal 
growth factor (EGF)-like folds. The protein has a U-shaped overall structure with the 
N-terminal proteolytic processing site close to the C-terminal GPI membrane anchor site, 
consistent with the involvement of a membrane bound protease in secondary processing. 
The structure of MSP-119 is illustrated in Figure 1.2
Many P. falciparum antigens display a high degree of sequence diversity between 
different parasite strains. The primary sequence of the MSP-1 precursor can be divided 
into 17 blocks. Blocks 15 and 16 comprise the N-terminus of MSP-I42, and there are two 
major sequence types with about 47% identity. Block 17 corresponds to MSP-119, and the 
sequence is highly conserved (Miller, Roberts et al. 1993) (Jongwutiwes, Tanabe et al. 
1993) with less than 5% variation in different alleles (Kang and Long 1995). Because of 
its role in erythrocyte invasion and its high degree of sequence conservation, MSP-119 is 
regarded as a leading candidate in a malaria vaccine.
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1.2.2 The invasion-inhibitory anti-MSP-li9 mAbs 12.8 and 12.10
In 1985 the results were published of a series of fusion experiments carried out to 
generate mAb-expressing hybridomas from the spleen cells of mice which had been 
immunised with crude P. falciparum schizont extract (McBride, Newbold et al. 1985). 
Two of the hybridomas, identified as 12.8 and 12.10, were found to secrete mAbs which 
recognise the 42 kDa component of MSP-1 (MSP-142) present on the surface of merozoites 
before erythrocyte invasion. The same mAbs also recognise the 19 kDa fragment of the 
MSP-I42 which is produced by the secondary proteolytic processing of MSP-1 and which 
remains on the merozoite surface and is carried into the newly infected erythrocyte 
(Blackman, Heidrich et al. 1990). The mAbs 12.8 and 12.10 were shown to inhibit 
merozoite invasion of erythrocytes in vitro. This inhibitory action required high a 
concentration of mAb. At a concentration of 500 pg/ml, mAb 12.10 inhibited invasion by 
the T9/94 strain of P. falciparum by 72% and inhibited invasion by the T9/96 strain by 50% 
(Blackman, Heidrich et al. 1990). It was subsequently shown that of a group of mAbs 
specific for MSP-119, the two which inhibit erythrocyte invasion, mAb 12.8 and mAb 
12.10, also inhibit the secondary processing of MSP-1 in a Western blot-based in vitro 
assay (Blackman, Scott-Finnigan et al. 1994). In the same study, other MSP-119-binding 
mAbs were identified which do not inhibit secondary processing or erythrocyte invasion, 
but which block this inhibition by mAbs 12.8 and 12.10.
These results suggest that the proteolytic cleavage or secondary processing of 
MSP-1 is necessary for erythrocyte invasion to proceed. The results also indicate that 
binding of different antibodies to adjacent but different epitopes on the EGF-like domains
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of the MSP-119 molecule can have very distinct effects on the ability of the molecule to 
undergo secondary processing.
mAb 12.8 is an IgG2b isotype antibody which recognises an epitope in the first 
EGF-like domain of MSP-119 whereas mAb 12.10 is of the IgGl isotype and recognises an 
epitope formed by the two EGF-like domains in combination (Chappel and Holder 1993). 
Both these epitopes are conserved between the two major allelic variants of MSP-119.
1.2.3 Blocking antibodies : antibodies which block inhibitory antibodies
The antibodies which inhibit erythrocyte invasion, and which would benefit the 
host, are conventionally referred to as inhibitory antibodies. The antibodies which block 
this inhibitory effect, and which would therefore be detrimental to the host, are referred to 
as blocking antibodies. Antibodies which recognise MSP-119 but neither inhibit invasion 
nor block the action of inhibitory antibodies are referred to as neutral antibodies.
Blocking antibodies may be directed against MSP-119 but they may also be directed 
to other parts of the MSP-1 complex. A series of polyclonal rabbit antibodies purified 
from immune sera raised against recombinant proteins corresponding to regions covering 
all of MSP-1 and expressed in E. coli (Holder, Sandhu et al. 1987) were examined for the 
presence of blocking antibodies (Guevara Patino, Holder et al. 1997). The ability of these 
antibodies to block the binding of mAb 12.8 and mAb 12.10 was measured using a 
competitive radio-immunoassay. Blocking activity was found in antibodies raised against 
recombinant proteins in which the EGF-like domains of MSP-119 were included, as
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expected. However blocking activity was also found in antibodies raised against 
constructs corresponding to domains outside the COOH-terminal from which MSP-119 is 
derived. Sera raised against two constructs, pME3 and pME14, which include the 
NH2-terminal of MSP-142, and sera raised against pME6 , a construct corresponding to a 
region from MSP-183, also showed potent blocking activity. Naturally acquired human 
antibodies against pME6  were then isolated from pooled Gambian adult immune serum by 
affinity chromatography on immobilised pME6  protein, and these affinity-purified 
antibodies were shown to block the processing-inhibitory effects of mAbs 12.8 and 12.10 in 
a processing assay (Guevara Patino, Holder et al. 1997).
These results show that blocking antibodies can be directed against epitopes both 
within MSP-119 and within other quite distinct regions of the molecule. They also show 
that such blocking antibodies are induced by natural infection in humans. MSP-1 epitopes 
inducing these blocking antibodies probably represent an immune evasion mechanism 
which has evolved in P. falciparum to circumvent the potentially neutralising effect of 
invasion-inhibitory antibodies (Holder, Guevara Patino et al. 1999). Naturally occurring 
polyclonal serum in malaria-exposed people probably therefore consists of a mixture of 
potentially protective inhibitory antibodies and potentially deleterious blocking antibodies. 
Assessment of the protective effect of naturally occurring polyclonal antibodies against 
MSP-119 therefore becomes difficult to interpret. Only by isolating monoclonal antibodies 
to MSP-119 generated by natural infection can the role of such antibodies in protection from 
malaria be reliably assessed.
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1.2.4 Is the protective effect of invasion-inhibitory antibodies mediated 
by antibody alone ?
There has been debate about whether anti-MSP-li9 antibodies alone confer 
protection or whether they recruit other arms of the immune system to mediate the 
protection which is observed. In the in vitro erythrocyte invasion assays used to identify 
the invasion-inhibitory activity of mAbs 12.8 and 12.10, the assay is carried out in cell-free 
medium in which there is no possibility of participation by monocytes (Blackman, Heidrich 
et al. 1990). While the medium is normally supplemented by 10% (v/v) decomplemented 
non-immune serum, the invasion-inhibitory properties can still be detected when bovine 
serum albumin, in the form of 0.5% (w/v) Albumax (GIBCO), is used instead of serum 
(Blackman 1994). Similarly, the in vitro assay of MSP-1 secondary processing used to 
demonstrate that mAbs 12.8 and 12.10 prevent the proteolytic cleavage of MSP-1 is also 
carried out in a cell-free and serum-free medium (Blackman, Scott-Finnigan et al. 1994). 
Nevertheless, there are studies suggesting that other arms of the immune system may be 
required for the protective effects of antibody to be exerted.
In a study involving passive transfer of polyclonal IgG from malaria-exposed 
African adults to eight malaria-infected non-immune Thai patients, clinical and 
parasitological improvement was reproducibly obtained in each case. In vitro before 
transfer, however, the IgG had no inhibitory effect on either erythrocyte invasion or 
intraerythrocytic development of the parasite, and even sometimes increased parasite 
growth. In contrast, IgG collected from the Thai patients 4 days after the passive transfer 
exerted an antibody-dependent cellular inhibitory (ADCI) effect in co-operation with blood
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monocytes. This was interpreted by the authors as indicating that the protective effect seen 
with antibodies is not due to antibodies alone, but involves monocytes also (Bouharoun- 
Tayoun, Attanath et al. 1990). It must be noted, however, that the antibodies transferred 
were polyclonal, and the relative contribution of antibodies specific for MSP-119 to the 
protective effect cannot be determined. Another study examined the question specifically 
in relation to anti-MSP-li9 antibodies, in mice infected with P. yoelii. The authors 
observed that while passive transfer of immune sera from mice immunised with P. yoelii 
MSP-119 protects naive mice from very high parasitaemia and death, it does not provide as 
much protection from high parasitaemia as that conferred by active immunisation. This 
was felt to suggest that other arms of the immune system beyond antibody alone are 
involved in protection. The authors transferred immune serum into malaria naive SCID, 
nude, CD4+ T-cell-depleted and B-cell knockout mice; all the mice died when challenged 
with P. yoelii (Hirunpetcharat, Vukovic et al. 1999). This study indicates that more than 
antibody alone is required to protect mice from fatal P. yoelii challenge. Whether the other 
arms of the immune system are contributing specifically to the protective effect mediated 
by anti-MSP-lj9 antibodies however, or whether they are rather involved in protected 
effects targeted to other stages or targets is not clear from this study. Anti-MSP-li9 
antibodies may exert their protective effect independently of any other arm of the immune 
system and yet not be sufficient on their own to protect against progressive infection.
Two studies suggest that protective antibodies can indeed exert their protective
effect without invoking any other arm of the immune system. To determine whether Fc
receptor-bearing cells are required to mediate the protective effect of antibodies in mice,
immune sera was passively transferred into FcR gamma-chain knockout mice, in which
macrophages were therefore unable to mediate phagocytosis or antibody-dependent
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cell-mediated cytotoxicity (ADCC) through Fey receptors. Passive transfer of either P. 
yoelii hyperimmune sera or anti-GST-PyC2 sera (directed against a recombinant 15 kDa 
protein representing the C-terminus of P. yoelii MSP-1) protected the FcR knockout mice 
against lethal P. yoelii challenge. In this experiment, with polyclonal serum, the protective 
effect is therefore mediated by antibody alone, and does not require ADCC or the 
participation of Fc receptors (Rotman, Daly et al. 1998). A similar experiment was carried 
out using a monoclonal IgG3 specific for P. yoelii MSP-119, which passively transferred 
protection to mice deficient in the alpha chain of FcyRI, whose macrophages could not 
therefore bind IgG3 (Vukovic, Hogarth et al. 2000). This shows that, in the P. yoelii 
mouse model at least, the protective effect of an anti-MSP-li9 .mAb is due to the antibody 
alone.
1.2.5 Evidence of protective role of anti-MSP-li9 antibodies in humans
The prevalence of antibodies against MSP-119 in areas of high transmission of P. 
falciparum appears to be high, although some studies have found a greater prevalence than 
others. In estimating the prevalence of anti-MSP-119 antibodies in a given population it is 
important that the conformational epitopes should be correctly folded in the antigen used 
for testing (Blackman and Holder 1993). In a study of adult Senegalese 74% of 
individuals were found to have antibodies to MSP-119 (Diallo, Nguer et al. 1999). In a 
study examining adult sera from The Gambia, 50% of donors possessed antibodies to 
MSP-119 although almost all possessed antibodies to the MSP-133 fragment which is shed at 
secondary processing of MSP-142 (Egan, Waterfall et al. 1997). In a population of 266 
3-15-year old Ghanaian children, prevalence of antibodies recognising a recombinant
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construct with both EGF-like domains of MSP-119 corresponding to the Wellcome allelic 
variant was about 30% (Dodoo, Theander et al. 1999). In another study of 111 plasma 
samples in western Kenya, using recombinant constructs representing the different allelic 
forms of MSP-119, 90% of samples reacted with the Ugandan-PA allelic form, 77% reacted 
with the MAD20 allelic form and 80% reacted with the Wellcome allelic form of MSP-119 
(Udhayakumar, Anyona et al. 1995).
Both prevalence and level of antibody to MSP-119 increase with age after infancy. 
A study of 198 infants from a Tanzanian village highly endemic for P. falciparum found 
that anti-MSP-li9 antibodies decreased for the first two months of life and then showed 
only a slight tendency to increase with age (Kitua, Urassa et al. 1999). A study of older 
children, aged between 6  months and 15 years, in Papua New Guinea found that both the 
prevalence and the concentration of antibodies to MSP-142 increased with age (al-Yaman, 
Genton et al. 1996). The same increase in prevalence and concentration with age was 
found in a study of people aged from 2 to 74 years in western Kenya (Shi, Sayed et al. 
1996). A cross-sectional survey of 387 3-8 year old children from a malaria endemic area 
of The Gambia also showed a significant positive correlation between anti-MSP-1 antibody 
levels and age (Blackman and Holder 1993). In another study of children aged from 3 to 
15 years in Ghana, however, no increase in prevalence or level of anti-MSP-119 antibodies 
with age was found (Dodoo, Theander et al. 1999).
It is not clear how long antibodies to MSP-119 persist for, but it may be that they are
quite short-lived. A longitudinal study, in which monthly serum samples were collected
from 24 infants in western Kenya from birth to one year of age, revealed several short-lived
anti-MSP-119 IgG and IgM peaks throughout the infants’ first year which correlated with
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detection of parasitaemia (Branch, Udhayakumar et al. 1998). Another study assessed the 
antibody responses of 52 children and adults seasonally exposed to malaria in eastern 
Sudan over a period of 4 years. Antibodies to a recombinant protein corresponding to 
MSP-119 were found in 6 6 % of acutely infected individuals with clinical malaria but in only 
12% of individuals without clinical malaria. These antibody responses declined within a 
few months of drug treatment and parasite clearance (Cavanagh, Elhassan et al. 1998). A 
longitudinal study of serological responses to MSP-1 in adults in the village of Brefet in 
The Gambia (another area where malaria transmission is seasonally endemic), however, 
showed that anti-MSP-1 antibody levels were much more stable over time than cellular 
responses (Riley, Morris-Jones et al. 1993).
It may be, therefore, that cross-sectional studies which detect a relatively low 
antibody prevalence in fact reflect a situation in which many people produce anti-MSP-119 
antibodies but those antibodies persist for only a short period of time after each infection 
(Holder and Riley 1996).
It seems that the majority of antibodies to MSP-119 recognise epitopes formed by a 
combination of both EGF domains rather than by one domain alone. In a study of serum 
antibodies from malaria-exposed people from The Gambia using recombinant proteins 
representing the two EGF domains both separately and in combination, 10-20% of 
individuals were found to have antibodies which recognised one or other of the EGF 
domains alone, but more than 40% of individuals had antibodies which could recognise the 
two EGF domains in combination (Egan, Chappel et al. 1995). Using the same 
recombinant proteins, a study of 266 3 to 15-year-old Ghanaian children found that the
prevalence of antibodies recognising both EGF domains in combination was about 30%
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while only about 15% of individuals had antibodies which recognised the first domain 
alone and only about 4% had antibodies which recognised the second domain alone 
(Dodoo, Theander et al. 1999).
The immunoglobulin isotype may be an important factor in protection, and the IgGl 
subclass appears to predominate in anti-MSP-119 responses. Anti-MSP-119 
immunoglobulins were found to be mainly of the subclass IgGl in a study of Africans aged 
6  months to 76 years from Sudan and Kenya (Cavanagh, Dobano et al. 2001) and the same 
was found in antibodies from malaria exposed people in The Gambia (Egan, Chappel et al. 
1995). In another study anti-MSP-119 immunoglobulins were predominantly IgGl and 
IgG3 although only IgGl antibody was associated with protection (Shi, Sayed et al. 1996).
The majority of published studies to address the issue have suggested that
anti-MSP-119 antibodies are associated with protection from clinical malaria. A
case/control study was performed in western Kenya on 75 case/control pairs of infants who
were either febrile (cases) or afebrile (controls) at the time of the first detected infection
with P. falciparum. The presence and level of anti-MSP-1 antibodies was significantly
higher in the afebrile group, both at the time of the first infection and at one month prior to
the first infection. Anti-MSP-119 IgG was also associated with lower parasite densities and
less infection-related haemoglobin loss. Mothers with anti-MSP-119 antibodies were
protected against placental infection and infection in their infants (Branch, Udhayakumar et
al. 1998). In a study of individuals aged 2 to 74 years old in western Kenya, higher levels
of anti-MSP-119 IgGl (but not IgG3) correlated with lower parasite densities among young
age groups (Shi, Sayed et al. 1996). In a prospective study of children in Papua New
Guinea antibodies against a baculovirus-expressed recombinant protein representing
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P. falciparum MSP-142 were significantly associated with protection from clinical malaria 
and severe parasitaemia, while antibodies against the N-terminal part of MSP-1 were not 
(al-Yaman, Genton et al. 1996). Antibodies to MSP-119 were found to provide 40% 
protection against clinical malaria in children in Sierra Leone, and antibodies to one of the 
EGF-like motifs of MSP-119 were strongly associated with resistance to both clinical 
malaria and high parasitaemia in Gambian children (Egan, Morris et al. 1996). When 
individuals with symptomatic malaria infection in Guadalcanal were compared with people 
with asymptomatic infections, the asymptomatic group showed significantly higher levels 
of antibody to recombinant MSP-119 (Fu, Hato et al. 2000).
A few studies, however, have failed to detect any association between anti-MSP-119 
antibodies and protection from malaria. When 266 Ghanaian children were tested for 
antibodies to recombinant proteins corresponding to the Wellcome and MAD20 allelic 
variants of MSP-119 and monitored clinically and parasitologically for 18 months, no 
protection associated with the antibodies was found (Dodoo, Theander et al. 1999). In 
another prospective study involving 198 Tanzanian infants whose antibodies to 
recombinant MSP-119 were measured, again no protective effect against clinical malaria 
was found (Kitua, Urassa et al. 1999).
1.2.6 Is the protective effect of antibody due to inhibition of invasion ?
It is difficult to demonstrate that a protective effect associated with anti-MSP-119 
antibodies is directly caused by those antibodies, or that the mechanism of protection is 
analogous to the invasion-inhibitory activities of the murine mAbs 12.8 and 12.10. The
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most direct way of demonstrating that antibodies are the cause of an associated protective 
effect is to demonstrate that the antibodies confer protection when passively transferred to a 
naive host. Some of these passive transfer experiments have already been discussed in 
section 1.2.4 above. Three of these studies dealt specifically with anti-MSP-119 antibodies, 
but they used P. yoelii infection in mice as a model system (Hirunpetcharat, Vukovic et al. 
1999) (Rotman, Daly et al. 1998) (Vukovic, Hogarth et al. 2000). The studies 
demonstrating protection against P. falciparum in human subjects examined the effect of 
passive transfer of purified total antibody rather than anti-MSP-119 antibodies specifically 
(Cohen, McGregor et al. 1961) (Bouharoun-Tayoun, Attanath et al. 1990). With the 
advent of the AIDS pandemic it is becoming less appropriate to conduct further 
experiments involving the passive transfer of immune globulin between human subjects, 
and a more practicable alternative is to study P. falciparum in a primate model. In one 
such study, purified rabbit immunoglobulin raised against yeast-expressed P. falciparum 
MSP-119 was passively transferred into malaria-naive Aotus nancymai monkeys and failed 
to protect against homologous or heterologous challenge. However, the antibody under 
test was polyclonal, and rabbit immune serum has been shown to include blocking 
antibodies (Guevara Patino, Holder et al. 1997), whose presence may have complicated the 
result. Furthermore, while the purified rabbit immunoglobulin was shown to inhibit 
parasite growth in vitro, it did so only at concentrations of at least 4.8 mg/ml, and the 
antibody concentration achieved in vivo (1 mg/ml) was considerably less than this (Gozalo, 
Lucas et al. 1998).
To demonstrate that anti-MSP-119 antibodies associated with protection exert an
effect through the inhibition of secondary processing and invasion, it is necessary to purify
polyclonal anti-MSP-119 antibodies from immune serum in sufficient quantity to
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demonstrate that they exert a protective effect in the relevant in vitro assays. Two such 
studies have been conducted. In one study, antibodies specific for the first EGF-like 
domain of MSP-119 were prepared by affinity chromatography from the total 
immunoglobulin G fraction of adult West African donors using a recombinant protein 
corresponding to this domain. These affinity-purified antibodies recognised their target 
and blocked the binding of an inhibitory mAb but did not inhibit parasite invasion in the in 
vitro invasion assay (Chappel, Egan et al. 1994). In a further study, IgG from 
malaria-exposed adults from the Ivory Coast was purified, and antibodies specific for the 
first EGF-like domain of MSP-119 were removed by affinity chromatography as above. 
Antibodies specific for the second EGF-like domain were then purified in the same way. 
The purified IgG was tested in the in vitro invasion assay. At a concentration of 100 pg/ml 
antibodies to the first EGF-like domain did not inhibit invasion but antibodies to the second 
EGF-like domain did show some invasion-inhibitory effect (Egan, Burghaus et al. 1999).
1.2.7 MSP-119 as a vaccine candidate; tests in animal models
MSP-119 -based vaccines have been tested in a number of experimental animal 
systems, with promising results. Studies have focussed mainly on Plasmodium yoelii 
infections in mice or P. falciparum infections in Aotus monkeys. The 11 kDa 
carboxyl-terminal of P. yoelii yoelii MSP-1, containing only the two EGF-like domains, 
protected mice against homologous strain blood stage (Daly and Long 1995) (De Souza, 
Ling et al. 1996) and sporozoite (Ling, Ogun et al. 1997) challenge. Furthermore, this 
resistance could be transferred passively by purified Ig, establishing the role of antibody in 
this protection (Daly and Long 1995). Some formulations of P. falciparum MSP-119 have
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been successfully employed to protect Aotus monkeys against parasite challenge. MSP-119 
expressed in Saccharomyces cerevisiae with Freund’s adjuvant protected Aotus nancymai 
against lethal P. falciparum challenge (Kumar, Collins et al. 2000). P. falciparum 
MSP-119 fused with tetanus toxoid epitopes protected Aotus vociferans monkeys against 
P. falciparum challenge, and antibodies from some of the protected monkeys inhibited 
secondary processing of MSP-1 in vitro (Egan, Blackman et al. 2000). A recombinant 
form of MSP-I42, which comprises the 42 kDa C-terminal portion of MSP-1 and includes 
MSP-119, expressed in baculovirus-infected insect cells, protected Aotus nancymai against 
P. falciparum challenge. This protection was better than that afforded by recombinant 
MSP-119 expressed in Saccharomyces cerevisiae, which was tested in the same series of 
experiments. With both antigens, however, protection was only seen when high antibody 
levels were obtained by formulation of the vaccines in Freund’s adjuvant (Stowers, Cioce et 
al. 2001). In a primate model of P. vivax infection, recombinant baculovirus-expressed 
analogues of P. falciparum MSP-142 and MSP-119 from P. cynomolgi, a primate malaria 
parasite highly analogous to the human parasite P. vivax, provided lasting protection 
against P. cynomolgi challenge in the toque monkey, Macaca sinica (Perera, Handunnetti et 
al. 1998). As in the previous study, the vaccines were formulated in complete and 
incomplete Freund’s adjuvant. Not all such studies have shown protection, however. In 
contrast to the protection afforded to Aotus nancymai in the study described above, a study 
in the same animal model using recombinant MSP-119 expressed in E. coli, incorporated 
into liposomes and adsorbed to alum as an adjuvant, failed to confer any protection 
(Burghaus, Wellde et al. 1996). These contrasting results may well reflect the importance 
of the choice of adjuvant in inducing protective immune responses.
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1 .2 . 8  MSP-119 as a vaccine candidate; trials in humans
To date, only one trial of MSP-119 vaccines in humans has been published. A 
Phase I (safety and immunogenicity) trial was conducted of two yeast-derived MSP-119 
vaccines, from the 3D7 or FVO strains of P. falciparum, fused to tetanus toxoid T-helper 
epitopes and adsorbed on alum. Serum antibody responses occurred in 5/16 and 9/16 
healthy adults given a lower and a higher dose of vaccine respectively. Hypersensitivity 
reactions occurred in 3 subjects, one developing a generalised rash and another developing 
hypotension. The authors concluded that changes in formulation would be required to 
improve the safety and immunogenicity profiles of the vaccines (Keitel, Kester et al. 1999). 
One novel approach which could be used in the future design of MSP-119-based vaccines is 
to modify the protein by removing the epitopes recognised by blocking antibodies. Amino 
acid substitutions have been made in MSP-119 which prevent the binding of known 
blocking mAbs without affection the binding of invasion-inhibitory mAbs (Uthaipibull, 
Aufiero et al. 2001). Such modified molecules may provide more effective protection in a 
vaccine than molecules based on native MSP-119 (Holder, Guevara Patino et al. 1999).
1.2.9 Further studies of the role of anti-MSP-119 antibodies in protection 
against malaria
To evaluate the likelihood of an MSP-119-based vaccine being successful, two 
important questions need to be clarified. Does malaria infection in man induce
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invasion-inhibitory antibodies to MSP-119, and if so, do such antibodies make an important 
contribution to naturally acquired immunity ?
As discussed above, it is difficult to assess the invasion-inhibitory capacity of 
polyclonal anti-MSP-119 antibodies because the natural immune response probably 
generates a mixture of protective invasion-inhibitory antibodies and deleterious blocking 
antibodies. To determine whether invasion-inhibitory antibodies to MSP-119 comprise a 
significant component of the natural immune response to malaria, it will be necessary to 
isolate and examine individual monoclonal antibodies to MSP-119. Only by examining a 
range of naturally occurring monoclonal antibodies to MSP-119 for invasion-inhibitory, 
blocking or neutral activity will it be possible to dissect the immune response in sufficient 
detail to answer this question clearly.
It is for this reason that the project described in this thesis was undertaken, namely 
to attempt to isolate and characterise monoclonal antibodies to MSP-119 from a library of 
human antibody fragments derived from malaria-immune donors and displayed on the 
surface of phage.
1.3 Obtaining monoclonal antibodies by phage display technology
1.3.1 The principles of phage display
Phage display technology offers a means of isolating high-affinity monoclonal 
antibodies of desired specificities without resort to hybridoma techniques. The power of 
the phage display technique rests upon the linkage of sequence information to selectable
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function. In this technology, combinatorial libraries of recombinant antibody fragments 
are displayed on the surface of phage particles. The phage provides a vehicle by which 
each of the library members carries its own DNA coding sequence linked to the displayed 
protein product. This also enables library members to replicate themselves. Thus library 
members can be selected according to the binding characteristics of the displayed protein 
and then amplified by replication of the coding DNA within the phage. Repeated rounds 
of selection result in increasingly specific antibodies of increasing affinity. In this way it 
therefore becomes possible to select, out of tens or hundreds of millions of clones, those 
few phages which display a peptide that binds the target molecule (Cesareni 1992). This 
technique is therefore potentially very powerful, and has been likened to “finding a 
much-needed needle in a vast molecular haystack” (Rodi and Makowski 1999).
The successive steps of the phage display technique thus mimic the natural 
processes of immune selection (Winter, Griffiths et al. 1994). The two processes of natural 
and phage-display based antibody selection are compared schematically in Figure 1.4.
In the natural immune system, a finite number of V-genes encode sections of the 
variable regions of the heavy and light chains of antibodies. As stem cells mature to B 
cells, these V-genes are rearranged in many different permutations, yielding an immense 
repertoire of different antibody antigen-binding sites. Each B cell displays just one 
antibody of one antigen specificity. Interaction with the target antigen leads to selection of 
the relevant B cell clone, which may either proliferate to make short-lived plasma cells 
secreting the antibody or long-lived memory cells, capable of making antibodies of 
improved binding affinity through hypermutation on repeated stimulus with the antigen.
41
In the process of phage display, rearranged variable region sequences are amplified 
by PCR from B cells. Heavy and light chain variable region sequences are then randomly 
joined together in a further PCR to produce a repertoire of DNA molecules encoding 
antibody fragments analogous to the original antibody repertoire. The repertoire of 
antibody fragment-encoding DNA is inserted into a filamentous bacteriophage or phagemid 
vector to produce a fusion of the antibody fragment with the phage coat protein. In this 
way, each antibody fragment is displayed on the surface of a filamentous phage in a manner 
analogous to the display of antibody on the surface of a B cell. The antibody fragments 
displayed on phage are selected by binding to the relevant antigen, and can proliferate by 
replication in E. coli. Just as B cells may secrete antibody as short-lived plasma cells, so 
the E. coli can be induced to produce soluble antibody fragments. Likewise, just as B cells 
may become memory cells, their antibodies undergoing affinity maturation upon repeated 
exposure to antigen, so antibody fragments displayed on phage may undergo affinity 
maturation by repeated rounds of selection on antigen, or by the deliberate introduction of 
random mutations followed by re-selection (Winter, Griffiths et al. 1994).
Antibodies can be displayed on phage either as single polypeptide chains or as
non-covalently bound heterodimers. To be displayed as single chains the heavy and light
chain variable domains are linked together by a polypeptide spacer, to produce a single
chain variable fragment (scFv) which preserves the binding characteristics of the original
antibody binding site (McCafferty, Griffiths et al. 1990). To be displayed as
non-covalently associated heavy and light chains, which are essentially Fab fragments, one
chain is exported into the bacterial periplasm linked to the pill phage protein and the other
chain is co-expressed into the periplasm. There the two chains pair as they would during
natural antibody expression (Hoogenboom, Griffiths et al. 1991). In general the scFv
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format is favoured over the Fab format for antibody libraries because Fabs do not express 
as reliably, which results in reduced selection efficiency (Vaughan, Williams et al. 1996). 
Figure 1.5 illustrates how the structure of scFv relates to that of whole antibody.
1.3.2 Filamentous phage and the display of antibody fragments
Different types of bacteriophage have been employed to construct phage libraries, 
but the first and the most common type to be used is filamentous phage. Both fd 
filamentous phage and M13 filamentous phage have been used. Both are members of the 
Ff filamentous single stranded DNA phages that infect E. coli cells. The phage binds to 
the sex pili of E. coli and this binding is mediated by the gene 3-encoded minor coat protein 
pill, also known as g3p (Hoogenboom, Griffiths et al. 1991).
Filamentous phage is unique in that of its five virion proteins, three can tolerate the 
insertion of foreign peptides. The manner in which the inserted peptide is displayed on the 
phage surface varies according to the phage protein with which it is fused. An intact 
filamentous phage is 930 nm long and contains a single stranded DNA genome of 6400 
base pairs. The filamentous phage is covered throughout its length with 2800 copies of the 
major coat protein, pVIII. Peptides fused with this protein are therefore displayed in 
hundreds of copies over the surface of the phage virion. There are five copies of pill and 
five copies of pVI on each phage, and these proteins are located at one end of the virion. 
Peptides fused to pVI are displayed with the carboxy terminus oriented outward. Peptides 
fused to pill may be displayed in one to five copies per virion (Cabilly 1999). The crystal 
structure of the N-terminal domains of pill have been determined (Lubkowski, Hennecke et
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al. 1998). It appears that proteins displayed fused to pill do not interfere with the infection 
of E. coli because they are fused far from the central part of the molecule which probably 
constitutes the binding site for the E. coli pilus. The pill protein is the protein most 
commonly chosen to display peptides and proteins such as antibody fragments because it 
allows just one peptide or protein to be displayed per phage particle. If more than one 
antibody fragment is displayed, selection will be dominated by avidity rather than affinity, 
and high affinity antibodies cannot be so easily isolated (Marks, Hoogenboom et al. 1991).
The pill fusion with scFv can be encoded with the other phage proteins within the 
same phage replicon (McCafferty, Griffiths et al. 1990) or it can be encoded separately on a 
phagemid, a plasmid containing a phage origin of replication (Hoogenboom, Griffiths et al. 
1991). As phagemids do not carry the genes for the other phage proteins, they can only be 
packaged into phage particles if the other phage proteins are provided from another source. 
This is achieved by “rescue” through the addition of a helper phage such as M13K07. This 
helper phage contains the genes for all the phage proteins, including pill, but due to a 
defective origin of replication it is poorly packaged in competition with the phagemids 
(Vieira and Messing 1987).
In selecting displayed antibody fragments for high affinity binding to antigen it is 
optimal for just one antibody fragment to be displayed per phage particle. If every pill 
incorporated were fused with an antibody fragment each phage would display five such 
fragments. However, the average valency is reduced by the use of helper phage, as the 
wild-type helper pill competes with the pill fusion proteins for incorporation into the phage 
particle. The average valency is further reduced because the pill fusion is often
proteolysed, removing the antibody fragment before the phagemid pill is incorporated.
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The result of these two processes is that the phage are estimated on average to display less 
than a single fusion protein per phage particle, creating “monovalent” phage suitable for 
high affinity antibody selection (Winter, Griffiths et al. 1994). The use of phagemid 
vectors has an added advantage over the use of whole phage vectors, in that the phagemid 
vector has a transfection efficiency two or three orders of magnitude higher than the phage 
vector, allowing larger phage display libraries to be constructed (Hoogenboom, Griffiths et 
al. 1991).
1.3.3 Phagemid pHENl for the display of antibody fragments
The phagemid vector pHENl was constructed specifically for the purpose of 
displaying antibody fragments on phage (Hoogenboom, Griffiths et al. 1991). The pHENl 
phagemid, modified by the addition of a hexahistidine tag to give pHENlH6 , is illustrated 
in Figure 2.3 in Materials & Methods.
pHENl is a derivative of pUC119 (Vieira and Messing 1987), adapted by the
inclusion of the coding region of pill from the fd filamentous phage. The pill signal
sequence has been replaced by a pelB signal sequence. Between the signal sequence and
the gene for pill is an internal Sfil site and a Notl site, allowing antibody fragments to be
cloned as Sfil/Notl fragments. Directly after the Notl site is a c-myc tag, enabling
expressed antibody fragments to be detected with the anti-c-myc mAb 9E10. An amber
stop codon (TAG) has been introduced between the tag and the region encoding the
N-terminus of pill. This amber codon enables the antibody fragment to be expressed
either as a fusion with pill to be displayed on phage, or as a soluble fragment without the
pill fusion. Growth of this phagemid in suppresser (supE) strains of E. coli such as TGI E
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coli, in which the amber codon is read as glutamine, results in the ribosome translating 
through the amber codon on to the pill gene. This results in the antibody fragment being 
expressed as a fusion with the pill protein. Growth of the same phagemid in a 
non-suppresser strain of E. coli such as HB2151, which reads the amber codon as a stop 
codon, results in the translation ending at the end of the antibody fragment, which is 
therefore expressed as a soluble fragment without the pill protein (Hoogenboom, Griffiths 
et al. 1991).
Transcription of antibody-pIII fusions in pHENl is driven from the inducible lacZ 
promoter and the expressed protein is targeted to the bacterial periplasm by means of the 
pelB leader. The phagemid can be rescued with helper phage in medium without IPTG 
because the natural leakiness of the promoter provides sufficient expression of 
antibody-pIII. Increased expression by IPTG induction may lead to cell death due to the 
toxicity of the fusion protein (Hoogenboom, Griffiths et al. 1991). One further refinement 
to the phagemid is the addition of a hexahistidine tag to allow rapid purification of antibody 
fragments by nickel chelation (Vaughan, Williams et al. 1996).
1.3.4 Selection of specific high affinity antibodies
The ability to select high affinity antibodies of a desired specificity from a phage 
display library depends on a number of factors. Phage must be subjected to repeated 
rounds of selection by binding to antigen before rare and specific high affinity antibodies 
can be isolated. This process is known as panning the library. It is estimated after one 
round of panning rare binders are enriched by one in 1 0 3 and after two rounds they are
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enriched by one in 106 (McCafferty, Griffiths et al. 1990). The representation of rare 
antibodies in the library should be enhanced by amplifying variable region sequences 
initially using PCR primers based on each of the heavy and light chain gene families to 
maximise the diversity of library members (Marks, Hoogenboom et al. 1991). The size of 
the library is also important. The larger and more diverse the library, the greater the 
chance of isolating high affinity antibodies (Perelson 1989). A medium size library of 107 
members is similar in size to the B-cell repertoire of a mouse at any one moment (Marks, 
Hoogenboom et al. 1991). A larger library containing 1.4 x 1010 scFv fragments permitted 
the isolation of antibodies with sub-nanomolar affinities to a range of antigens (Vaughan, 
Williams et al. 1996).
Diversity is also increased by the fact that the original heavy and light chain 
pairings are scrambled in the process of creating the library, resulting in the association of a 
given heavy chain with any number of different light chains and vice versa (Marks, 
Hoogenboom et al. 1991).
With sufficiently large and diverse libraries, even the need for immunisation of the 
donor is bypassed. Such libraries are sufficiently diverse that high affinity antibodies can 
be isolated to any given antigen, even if the library is derived from naive donors (Vaughan, 
Williams et al. 1996).
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1.3.5 Applications of antibody phage display to clinical problems
Phage display technology has now yielded a considerable number of scFvs or mAbs 
with biological activity of clinical and potentially therapeutic relevance. A number of 
phage library-derived antibodies have been isolated which have been shown to neutralise 
viruses of clinical importance. These include rabies virus (Ray, Embleton et al. 2001), 
hepatitis E virus (Schofield, Glamann et al. 2000), respiratory syncytial virus (Nguyen, Hay 
et al. 2000), Ebola virus (Maruyama, Rodriguez et al. 1999), herpes simplex viruses 1 and 2 
(Burioni, Williamson et al. 1994), human cytomegalovirus (Takekoshi, Maeda et al. 1998), 
and HIV-1 (Burton, Barbas et al. 1991). Antibodies with therapeutic potential have also 
been isolated against other, non-viral, infections. Phage-derived antibodies against 
bacterial toxins, such as the tetanus toxin (Lang, Vogel et al. 1995) and the pertussis toxin 
(Williamson and Matthews 1999) have the potential to replace plasma-derived 
immunoglobulins currently used for passive immunisation. Other infectious targets to 
which antibodies have been derived include the protozoan Cryptosporidium parvum 
(Baecher-Allan, Santora et al. 1999) and the pathogenic isoform of the prion protein 
(Williamson, Peretz et al. 1998). Antibodies have also been isolated with a potential role 
in autoimmune diseases, such as myasthenia gravis (Graus, de Baets et al. 1997) and 
haemolytic disease of the newborn (Miescher, Zahn-Zabal et al. 2000), and in specific 
malignancies such as Hodgkin’s Disease (Klimka, Barth et al. 1999), or in tumour 
angiogenesis (Vitaliti, Wittmer et al. 2000).
Virus-neutralising or other biological activity in some instances is present in the 
scFv molecule alone. In other instances, the desired biological activity is obtained only
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when the scFv is turned back into a whole antibody or otherwise engineered. Respiratory 
syncytial virus can be neutralised by scFv alone, and Fab fragments derived from libraries 
of Fab can neutralise Ebola virus (Maruyama, Rodriguez et al. 1999) and herpes simplex 
viruses 1 and 2 (Burioni, Williamson et al. 1994). To neutralise rabies virus in a standard 
in vivo assay, however, it was necessary to clone anti-rabies scFv into a mammalian 
expression vector carrying the human IgGl Fc region (Ray, Embleton et al. 2001).
1.3.6 Applications of antibody phage display to malaria
Since the advent of phage display, the technology has been applied to studies of 
malaria on a number of occasions. The technology has been used in three main ways. 
Firstly, it has been used to display malaria proteins as immunogens. Secondly, it has been 
used to display random peptides to identify epitopes recognised by anti-malarial antibodies. 
Thirdly, it has been used to display antibody-fragments to obtain mAbs to given malaria 
antigens.
The first studies to apply phage display techniques to malaria examined ways in 
which malaria-derived peptides (rather than antibody fragments) displayed on phage could 
be used as immunogens, either to provide anti-malarial mAbs as reagents, or to serve as 
potential malaria vaccines. In the earliest study to apply phage display techniques to 
malaria, repeat regions of the circumsporozoite protein (CSP) of P. falciparum were cloned 
into the pill coat protein gene and displayed on filamentous phage and shown to be 
antigenic and immunogenic in rabbits (de la Cruz, Lai et al. 1988). Regions of CSP were 
also displayed on the gpVIII major coat protein of bacteriophage Fd and shown to be
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immunogenic in mice without the use of external adjuvants (Willis, Perham et al. 1993) 
(Greenwood, Willis et al. 1991). A putatively protective epitope of P. falciparum liver 
stage antigen-1 (LSA-1) was displayed on the coat protein of RNA bacteriophage MS2 and 
shown to be immunogenic in mice (Heal, Hill et al. 1999).
In later studies, libraries of random peptides displayed on phage were used to 
identify important malaria antigen B cell and T cell epitopes recognised by anti-malarial 
mAbs. Random peptide libraries were used to identify T cell epitopes recognised by 
malaria-protective MHC molecules (Davenport, Quinn et al. 1996), to identify mimotopes 
recognised by antibodies to P. vivax MSP-142 (Demangel, Rouyre et al. 1998), to identify 
mimotopes recognised by a mAb against P. falciparum ring-infected erythrocyte surface 
antigen (RES A) (Adda, Tilley et al. 1999) and to map epitopes of the glutamate-rich protein 
(GLURP) of P. falciparum using anti-GLURP IgG (Theisen, Soe et al. 2000).
Three studies have been published in which monoclonal antibodies recognising
malaria antigens were isolated from libraries of antibody fragments (scFvs) displayed on
phage. The first of these studies described the construction of a library of murine antibody
fragments derived from mice protected from malaria challenge by immunisation with
recombinant P. chabaudi DS apical membrane antigen (AMA-1). The library was panned
with AMA-1 and yielded a population of scFvs which recognised AMA-1 from the P.
chabaudi DS strain but not from the 556KA strain, although a subset of these scFv also
recognised AMA-1 from P. falciparum (Fu, Shearing et al. 1997). Recently, two studies
have been published describing the isolation of scFv from antibody libraries derived from
malaria-exposed human donors. A monoclonal scFv recognising the block 2 region of
Plasmodium falciparum was isolated from a library of scFv derived from ten patients with
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clinical malaria from Cameroon (Sowa, Cavanagh et al. 2001). Another library derived 
from malaria-exposed individuals from Cameroon was used to select scFv against 
Pfs48/45, a P. falciparum gamete surface protein (Roeffen, Raats et al. 2001).
1.4 Chimeric and humanised antibodies
As discussed in section 1.2.6 above, it is important to determine whether 
invasion-inhibitory antibodies are generated in response to P. falciparum infection, but it is 
also important to determine whether such antibodies, if generated, can make an important 
contribution to protection. This question could be answered in part by determining 
whether the invasion-inhibitory mAbs 12.8 and 12.10 can protect against P. falciparum in 
vivo, in a primate model. Murine antibodies produced from hybridoma cell lines are not 
ideal reagents for such an experiment because they are difficult to produce in a form which 
is standardised and sufficiently pure, and because they will be recognised as foreign by the 
primate immune system. Recombinant versions of these mAbs would be easier to produce 
to the necessary quality, and could be engineered to be less immunogenic in primates. 
Chimeric versions of these mAbs, engineered to contain human instead of murine Fc 
regions, would be more suitable reagents for this purpose provided they retain their 
invasion-inhibitory activity. If recombinant chimeric versions of mAb 12.8 or mAb 12.10 
can modify or control P. falciparum infections in primates, it is possible that they may have 
a potential therapeutic application in humans.
Murine monoclonal antibodies have been made to a wide range of therapeutic 
targets since the advent of hybridoma technology in the 1970s. Making human hybridoma
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mAbs has proved much more difficult. Hybrids of human cells with mouse myeloma cells 
are unstable, with preferential loss of human chromosomes. Humans can rarely be 
hyperimmunised to order, and human cells from spleen or lymph nodes are not readily 
obtained. The alternative to hybridoma fusions, immortalisation of human B-cells with 
Epstein-Barr virus, leads to cell lines which are unstable and poor producers of antibody 
(Winter and Milstein 1991). Because of these difficulties, mAbs to targets of therapeutic 
importance have predominantly been derived from murine hybridomas.
As therapeutic agents in humans, however, murine mAbs have three serious 
disadvantages. Firstly they are recognised as foreign and induce an immune response in 
human patients. This human anti-mouse antibody (HAMA) response leads to rapid 
clearance of the murine mAb from the plasma. Secondly murine mAbs may sensitise the 
patient so that repeated administration may lead to allergic and even anaphylactic reactions. 
Thirdly, murine mAbs cannot efficiently recruit the human immune effector mechanisms 
that involve recognition of the Fc part of the molecule and lead to complement-dependent 
cytotoxicity or antibody-dependent cell-mediated cytotoxicity (Bendig 1995). Techniques 
have therefore been developed to attempt to overcome these difficulties by engineering 
murine antibodies to become more human.
The are two basic methods by which a murine antibody may be rendered more 
human. One is to create a chimeric antibody and the other is to engineer a “humanised” 
antibody. The relationship between a murine, chimeric and humanised (CDR-grafted) 
antibody is shown in Figure 1.6.
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The simpler of these two methods is that of creating a chimeric antibody. This 
involves taking only the variable domains from the murine antibody and joining these to 
the constant regions of a human antibody. This technique has the advantage of being 
relatively easy technically, and murine antibodies thus engineered may have considerably 
reduced immunogenicity in man (LoBuglio, Wheeler et al. 1989). However, 
approximately 35% of the final chimeric antibody sequence remains derived from the 
mouse antibody (Bendig 1995). Thus while single doses of such mAbs may not generate a 
major immune response in man, repeated dosing may cause a HAMA response in over 50% 
of patients (Elliott, Maini et al. 1994).
A more elaborate method of rendering murine mAbs more human is to take only the
antigen-binding loops or complementarity determining regions (CDRs) from the murine
hybridoma mAb and to graft these into the framework regions of human variable domains.
These reshaped variable regions are then joined to human constant domains to yield an
antibody which is fully “humanised” (Jones, Dear et al. 1986). Humanised antibodies are
less immunogenic because only about 9% of the final antibody sequence is derived from
the murine mAb (Bendig 1995). However, the process of humanisation is much more time
consuming than that of creating a chimeric antibody. The transfer of murine CDRs alone
onto human framework regions may often lead to a loss of affinity, which may only be
restored by reintroducing some foreign framework residues. The number and identity of
these residues has to be determined empirically, working with homologous human variable
antibody domains and computer models of the variable domain structure (Bendig 1995). A
recent approach to humanisation bypasses much of the empirical work described above by
making use of phage display techniques. In this approach, only the third CDRs of the
original murine heavy and light chains are preserved, and the rest of the variable domains
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are replaced with human sequences selected from phage-displayed antibody libraries 
(Rader, Cheresh et al. 1998).
More than a decade elapsed from the development of hybridoma techniques to the 
first use of monoclonal antibodies as therapeutic agents in man. Until recently very few 
monoclonal antibodies were in routine clinical use, but the number of therapeutic mAbs 
available on the market has increased sharply in the past few years. The first murine mAb 
used therapeutically was OKTC, a murine hybridoma IgG2a mAb which targets CD3 on 
the surface of T lymphocytes. OKTC is a potent immunosuppressant, and has proved 
useful in the prevention of rejection of kidney and liver transplants (Wilde and Goa 1996). 
Half the patients who receive this murine mAb however, generate OKTC-neutralising 
anti-idiotypic antibodies, which limit re-use of this therapy, and first administration can 
produce a dangerous acute clinical syndrome due to massive cytokine release (Chatenoud 
1993). The murine/human chimeric mAbs in clinical use appear to be less immunogenic. 
Rituximab, an anti-CD20 chimeric antibody, is useful in the treatment of non-Hodgkin’s 
lymphoma, and causes relatively mild immune response-mediated side effects (Grillo- 
Lopez, White et al. 1999). Infliximab, an anti-tumour necrosis factor (TNFa) chimeric 
mAb, is effective against the inflammatory bowel condition Crohn’s disease (Hyams, 
Markowitz et al. 2000) and rheumatoid arthritis, and causes few side effects although about 
10% of treated patients develop a HAMA response (Markham and Lamb 2000). Another 
chimeric mAb has been developed as a therapeutic agent in the form of a Fab fragment. 
Abciximab, which is directed against the glycoprotein Ilb/IIIa receptor on platelets and 
inhibits platelet aggregation, is now a mainstream therapy in widespread use for unstable 
angina (van den Brand, Laarman et al. 1999). Antimurine antibodies have been
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demonstrated in patients receiving abciximab, but these HAMA responses do not seem to 
limit its use.
Most of the therapeutic mAbs currently on the market are fully humanised. 
CAMPATH-1H is a humanised anti-CD52 IgGl that binds to the lymphocyte surface 
antigen CD52 and is an effective treatment for various lymphomas and leukaemias (Flynn 
and Byrd 2000). Daclizumab (Zenapax) is a humanised mAb against the interleukin-2 
receptor on T lymphocytes and is effective in preventing acute rejection of kidney 
transplants (Eckhoff, McGuire et al. 2000) and trastuzumab (Herceptin) is a humanised 
mAb against the human epidermal growth factor receptor-2 and has proven useful in 
treating women with metastatic breast cancer (Baselga 2001). Accumulating evidence 
from clinical use appears to confirm the expectation that humanised antibodies will prove 
less immunogenic than murine or chimeric mAbs. In a phase II study of 46 patients 
receiving weekly intravenous trastuzumab, no antibodies against trastuzumab could be 
detected in any of the subjects (Baselga, Tripathy et al. 1999).
While monoclonal antibodies alone can be therapeutically useful, their therapeutic 
potential may be greatly enhanced if they are used to selectively target drugs or toxins to 
specific target cells. Two such immunoconjugates are already available clinically. 
Rituximab has been linked to yttrium 90 to create a tumour-targeted 
radioimmunoconjugate, which appears more effective against non-Hodgkin’s lymphoma 
than rituximab alone (Witzig 2000). Mylotarg is a humanised anti-CD33 mAb linked to a 
cytotoxic antibiotic, and can induce complete remission of acute myeloid leukaemia 
(Sievers, Larson et al. 2001).
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Only one therapeutic mAb is available so far against an infectious disease. 
Palivizumab (Synagis) is a humanised IgGl directed against respiratory syncytial virus 
(RSV), a major pathogen of children and premature infants. Palivizumab is very effective; 
used prophylactically in 1502 high-risk children, palivizumab reduced hospitalisation due 
to RSV by 55% (1998).
No mAbs derived from phage display libraries are yet on the market, although a 
number are undergoing trials. The most advanced of these, D2E7, is a fully human 
anti-tumour necrosis factor mAb which has been shown to be effective in the control of 
rheumatoid arthritis (Taylor 2001).
-In the last few years the number of monoclonal antibodies in use or in development 
as therapeutic agents has increased dramatically. Much of this increase so far is due to 
improved techniques for engineering safe, effective and non-immunogenic agents from 
murine mAbs. Agents derived from human phage display libraries are almost certain to 
come into similarly widespread use in the near future. Against this background, it is 
pssible that mAbs against the malaria parasite, as well as having a role in basic research, 
may potentially have a therapeutic role in the future.
15 The aims of this project
This project has two main aims. One aim is to isolate and characterise naturally 
occurring human monoclonal antibodies to MSP-119 in the form of single chain variable 
fngments (scFvs) obtained from phage display libraries derived from malaria-exposed
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donors. By examining the sequence diversity and binding characteristics of a variety of 
MSP-119-specific antibody fragments derived in this way, it should be possible to dissect 
the natural human immune response at the molecular level. To detect any 
invasion-inhibitory activity in these antibody fragments it will probably be necessary to 
engineer them back to a format approaching that of a whole antibody. If this can be done, 
it should then be possible to use the techniques and materials developed in this project to 
isolate natural human mAbs with invasion-inhibitory activity. This would provide a very 
useful insight into the mechanism of natural immunity to malaria.
The other aim of this project is to clone and sequence the antigen-binding variable 
regions of two murine hybridoma monoclonal antibodies which are known to inhibit 
erythrocyte invasion by P. falciparum, and to use those sequences to create and characterise 
scFv and murine/human chimeric versions of those mAbs. The scFv versions of these 
mAbs should serve as a useful model with which to develop techniques for restoring 
invasion-inhibitory activity to scFvs, which may then be applied to human scFvs derived 
from the phage libraries. The recombinant chimeric mAbs can, by being shown to retain 
invasion-inhibitory activity, confirm the identity of the sequences obtained from the parent 
murine hybridomas. The chimeric versions of these mAbs can be produced in a 
standardised high quality form which should be less immunogenic in primates than murine 
hybridoma mAbs would be. The chimeric mAbs will therefore also be appropriate agents 
to test in a primate model of P. falciparum in order to determine whether these mAbs can 
modify or prevent clinical malaria. This would provide useful insights into the biological 
relevance of invasion-inhibitory mAbs to naturally acquired malaria immunity. It is also 
possible that these invasion-inhibitory recombinant mAbs may be developed as therapeutic 
agents for clinical malaria in the future.
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Figure 1.1 
The primary and secondary processing of Plasmodium falciparum  
Merozoite Surface Protein-1
After primary processing, MSP-1 exists as a complex attached to the merozoite 
surface by a GPI anchor. Secondary processing occurs at the time of erythrocyte invasion. 
During secondary processing, a parasite-encoded protease cleaves MSP-142 to produce 
MSP-119 and MSP-1 3 3 . MSP-I33 is shed along with the rest of the protein complex. MSP- 
119 remains on the surface of the merozoite and is carried into the erythrocyte.
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Figure 1.2
The structure of MSP-119
The solution structure of P. falciparum MSP-119 has been determined by nuclear 
magnetic resonance (Morgan, Birdsall et al. 1999) and the crystal structure of the 
homologous molecule from P. cynomolgi has also been determined (Chitarra, Holm et al. 
1999). Both studies confirm that the protein structure has two domains with epidermal 
growth factor (EGF)-like folds. The protein has a U-shaped overall structure with the 
N-terminal proteolytic processing site close to the C-terminal GPI membrane anchor site, 
consistent with the involvement of a membrane bound protease in secondary processing.
Here MSP-119 is shown in four different orientations. The N-terminus (pink) and 
the C-terminus (dark grey) are identified, and can be seen to be close to each other. The 
first EGF-like fold is shown in lighter grey and the second EGF-like fold is shown in darker 
grey.
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Figure 1.3
MSP-1 secondary processing and erythrocyte invasion
Merozoite Surface Antigen-1 (MSP-1) covers the surface of the merozoite. MSP-1 
exists as a protein complex, and at the time of erythrocyte invasion, the MSP-142 
component of the complex is cleaved by a parasite-encoded protease. Most of the MSP-1 
complex is shed, including a 33 kDa fragment of MSP-I42. A 19 kDa fragment, MSP-119, 
remains on the surface of the invading merozoite and is carried into the erythrocyte. 
Antibodies which prevent this cleavage also prevent erythrocyte invasion.
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Figure 1.4
Natural and phage display-based antibody selection
The successive steps of the phage display technique mimic the natural processes of 
immune selection (Winter, Griffiths et al. 1994). The two processes of natural and 
phage-display based antibody selection are compared schematically here.
In the natural immune system, a finite number of V-genes encode sections of the 
variable regions of the heavy and light chains of antibodies. As stem cells mature to B 
cells, these V-genes are rearranged in many different permutations, yielding an immense 
repertoire of different antibody antigen-binding sites. Each B cell displays just one 
antibody of one antigen specificity. Interaction with the target antigen leads to selection of 
the relevant B cell clone, which may either proliferate to make short-lived plasma cells 
secreting the antibody or long-lived memory cells, capable of making antibodies of 
improved binding affinity through hypermutation on repeated stimulus with the antigen.
In the process of phage display, rearranged V-genes are amplified by PCR from B 
cells. Heavy and light chain V-genes are then randomly joined together in a further PCR 
to produce a repertoire of DNA encoding antibody fragments analogous to the original 
antibody repertoire. Each antibody fragment is displayed on the surface of a filamentous 
phage in a manner analogous to the display of antibody on the surface of a B cell. The 
antibody fragments displayed on phage are selected by binding to the relevant antigen, and 
can proliferate by replication in E. coli. Just as B cells may become plasma cells and 
secrete antibody or become memory cells developing affinity matured antibody, so 
antibody fragments displayed on phage may be secreted or undergo affinity maturation by 
repeated rounds of selection on antigen or by the introduction of random mutations.
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Single chain variable fragment (scFv) and antibody
The whole IgG molecule is made up of two heavy chains and two light chains, 
providing two antigen-binding sites. Antigen specificity is determined by the variable 
regions of both the heavy chain (Vh, shown in red) and the light chain (V l, shown in 
green). The remainder of the IgG molecule consists of constant regions (C l and Chi-Ch3, 
shown in pink) whose sequences are conserved.
The antigen-binding site of an IgG molecule can be reconfigured as a single chain 
molecule (scFv) which retains the antigen specificity of the parent antibody. The scFv 
consists of the Vh and Vl regions, joined together by a flexible linker (shown in blue).
The scFv molecule differs from the whole IgG molecule in avidity, having only one 
antigen-binding site, and in size, having a molecular mass of approximately 30 kDa, 
compared with a mass of approximately 150 kDa for the whole IgG.
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Figure 1.6
Murine, chimeric and humanised antibodies
A rodent antibody may be adapted to reduce potential immunogenicity prior to any 
therapeutic application in man. An antibody may be “partially humanised” by grafting the 
rodent variable regions of the antibody onto human constant regions to make a chimeric 
antibody. To reduce potential immunogenicity still further, an antibody may be “fully 
humanised” by grafting only the rodent complementarity-determining regions (CDRs) into 
an otherwise human antibody. This is achieved by changing the framework residues (FRs) 
between the CDRs to residues commonly found in human antibody sequences. The 
humanised variable regions are then grafted onto human constant regions as before.
In this figure, the rodent CDRs are shown in pink, rodent framework and constant 
regions are shown in blue, and human framework and constant regions are shown in white.
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CHAPTER 2
MATERIALS AND METHODS
2.1 mAb 12.8 and mAb 12.10 variable region cloning and sequencing
2.1.1 Preparation of whole RNA and cDNA from 12.8 and 12.10 murine 
hybridoma cells
Murine hybridoma cell lines 12.8 and 12.10 (McBride, Newbold et al. 1985) (kindly 
supplied by Dr Jana McBride of the University of Edinburgh) were grown up, and total 
RNA extracted and purified on a caesium chloride gradient as follows. 107 cells were 
pelleted and resuspended in 7.7 ml filter sterilised GIT buffer (4M guanidine thiocyanate, 4 
mM sodium acetate pH 6.0, in 100 ml RNAse-free H2O, to which 64 pi mercaptoethanol 
was added), and lysed by vortex. The lysate was stored on ice for 5 min, layered onto 4 ml 
of 5.7 M caesium chloride in diethylpyrocarbonate (DEPC)-treated H2O and centrifuged at 
174,000 x g in a swing out rotor overnight at 20°C. The RNA pellet was resuspended in 
300 pi H2O, visualised by electrophoresis on a 1% agarose gel with ethidium bromide 
staining, and the RNA concentration was measured by absorbance at 260 nm. The RNA 
was stored in 75% ethanol at -70°C.
Alternatively total RNA was extracted using the RNA Stat-60 kit (Biogenesis Ltd).
First strand cDNA was produced for amplification using the First-Strand cDNA 
Synthesis Kit (Pharmacia Biotech) with the Afo/l-d(T)i8 primer according to the 
manufacturer’s instructions.
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2.1.2 PCR amplification of mAb 12.8 and mAb 12.10 heavy and light 
chain variable region sequences from cDNA
The DNA encoding the variable regions of the antibody heavy and light chains was 
amplified from hybridoma cDNA using 12 different sets of degenerate primers designed to 
anneal to the different possible leader sequences of the variable region (MHV and MKV 
primers for mouse IgG heavy and light (kappa) chains respectively), and a single primer or 
primer mix designed to anneal to the 5’ end of the constant region (MHC and MKC primer 
for mouse IgG heavy and light chains respectively). The MHC primer was an equimolar 
mix of four primers, MHCG1, MHCG2a, MHCG2b and MHCG3, designed to anneal to the 
constant regions of mouse IgGl, IgG2a, IgG2b and IgG3 respectively. The primer 
sequences are shown in Table 2.1.
The PCR reaction was carried out in a total volume of 50 pi, constituted as follows;
cDNA/mRNA hybrid 1 pi
lOx PCR Buffer II 5 pi
25 mM MgCl2 3 pi
lOmMdNTPs 4 pi
10 pM MHV or MKV primer 1.25 pi
10 pM MHC or MKC primer 1.25 pi
H20  32 pi
AmpliTaq polymerase 1 unit 2.5 pi
PCR was carried out using a hot start, with 25 cycles melting at 94°C for 1 minute, 
annealing at 55°C for 1 minute, extending at 72°C for 2 minutes, followed by extension at 
72°C for 10 minutes. PCR products were run on a 1% low melting point agarose 
electrophoresis gel, and extracted using the Wizard Prep kit (Promega).
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2.1.3 Cloning of mAb 12.8 and mAb 12.10 variable region DNA 
sequences
PCR products were ligated into the pCR™2.1 vector (Invitrogen) and then used to 
transform E. coli XL-1 Blue cells by heat shock according to the Invitrogen protocol. 
Transformants with inserts were identified by PCR screen using the same MHV/MKV and 
MHC/MKC primers as were used for the initial amplification of the IgG variable region 
DNA. The same PCR conditions were used. Cycling was carried out for 20 cycles, 
melting at 94°C for 1 minute, annealing at 60°C for 1 minute, extending at 72°C for 2 
minutes, finally extending at 72°C for 10 minutes. The products were analysed by gel 
electrophoresis. Positive clones identified by PCR screening were stored as glycerol 
stocks at -80°C. The mAb 12.8 and mAb 12.10 variable region sequence inserts in the
T W
pCR 2.1 vector were sequenced using TA Forward and TA Reverse primers, cycling with 
an annealing temperature of 40°C.
TA Forward Primer: CG AGCTCGT ACGT AG A 
TA Reverse Primer: TACCGAGCTCGGATCCACTA
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2.1.4 Attempted N-terminal amino acid sequencing of mAb 12.8 and 
mAb 12.10 heavy and light chains
Using 2 pg of each mAb, 12.8 and 12.10, the heavy and light chains were resolved 
by SDS-PAGE using CAPS buffer (100 mM 3-[cyclohexylamino]-l-propanesulphonic acid 
[CAPS] pH 11.0). The resolved proteins were transferred onto an immobilon membrane. 
Electroblotting buffer was 10 mM CAPS and 10% (v/v) methanol in H2O. After transfer 
the membrane was saturated with 100% methanol for 5 seconds then stained with 0.1% 
Coomassie Blue in 40% (v/v) methanol, 10% (v/v) acetic acid in H2O for 1 min. The 
membrane was destained with 50% methanol (v/v) in H2O. The transferred stained protein 
was sent to Dr Arthur Moir of the Department of Molecular Biology and Biotechnology at 
the University of Sheffield for N-terminal sequencing based on the Edman degradation 
reaction.
To overcome N-terminal blocking of the proteins, the mAbs were incubated with 
pyroglutamate aminopeptidase to remove putative N-terminal pyrrolidone carboxylic acid 
residues prior to SDS-PAGE. Incubation with pyroglutamate aminopeptidase was carried 
out using 10 pg of mAb in 0.1 M sodium phosphate pH 8.0 containing 5 mM dithiothreitol 
(DTT) and 10 mM EDTA. Approximately 0.2 pg of pyroglutamate aminopeptidase was 
added and the reaction was allowed to proceed at room temperature overnight.
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2.1.5 Amino acid sequencing of hybridoma antibodies by nanospray 
tandem mass spectrometry
The mAb 12.8 and mAb 12.10 IgG heavy and light chains were fractionated by 
electrophoresis using a 12% polyacrylamide gel under reducing conditions. The 
fractionated proteins were stained for 5 minutes with 50% (v/v) MeOH, 10% (v/v) acetic 
acid, 0.1% (w/v) Coomassie Blue, and destained with 12% (v/v) MeOH, 7% (v/v) acetic 
acid. The stained bands were excised and SDS extracted by incubating with 200 mM 
ammonium bicarbonate (ABC)/50% acetonitrile (ACN) buffer for 30 minutes at 30°C. 
The protein was then reduced with excess 20 mM dithiothreitol in 200 mM ABC for l hr at 
30°C, and then washed with 200 mM ABC buffer. Cysteines were alkylated with freshly 
prepared 50 mM iodoacetamide in 200 mM ABC in the dark for 20 min at room 
temperature, and the bands were then washed extensively with 50 mM ABC to remove 
excess iodoacetamide. The gel containing the protein was then cut in small pieces and 
covered in 100% ACN for 15 min, and dried in a vacuum centrifuge.
The protein was digested with trypsin. A sufficient volume of 2 ng/pl trypsin 
(modified sequencing grade Promega, Madison,WI) in 5 mM NH4HCO3 was added to 
cover the gel pieces and digestion performed overnight at 32°C in an incubator. The digests 
were then acidified by the addition of a 1 / 1 0  volume of 2 % trifluoroacetic acid prior to 
analysis.
Digestion supernatant was loaded onto a 2mm x 0.8mm C l8  microcolumn (LC 
Packings, Amsterdam, Netherlands), washed and step eluted with 60% methanol, 0.1% 
formic acid directly into an Econo 12 nanospray needle (New Objective Inc, Cambridge, 
MA). Nanospray (Wilm and Mann 1996) tandem mass spectra were acquired on an LCQ 
“classic” quadrupole ion trap mass spectrometer (ThermoQuest Corporation, Austin, TX)
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equipped with a nanospray source (Protana, Odense, Denmark) operated at a spray voltage 
of 800V and a capillary temperature of 150°C. Tandem (MS2) mass spectra were acquired 
at a collision energy of 30% and a parent ion isolation width of 3 Da. Masses of all tryptic 
fragments, charged and uncharged, were computer-predicted from candidate sequences 
derived from DNA sequencing. Fragments corresponding to predicted masses were 
isolated, and the daughter ion spectrum determined to confirm amino acid sequences.
2.2 Murine/Human chimeric mAbs 12.8 and 12.10
2.2.1 Transient expression of chimeric mAbs 12.8 and 12.10 in cos cells
Cos-7 cells (American Type Culture Collection CRL 1651) were grown until 
confluent in Dulbecco’s Modified Eagles Medium (DMEM) (Life Technologies 
41966-029) supplemented with 10% (v/v) foetal calf serum (Hyclone A 1101-L), 580 
pg/ml L-glutamine, 50 units/ml penicillin and 50 pg/ml streptomycin in a 150 cm flask. 
The cells were then trypsinised, centrifuged at 250g for 5 min then resuspended in 6  ml of 
medium as above. They were then divided equally between three 150 cm2 flasks each 
containing 25 ml of fresh pre-warmed medium as above. The cells were incubated 
overnight at 37°C in 5% CO2 in air and then harvested while growing exponentially. The 
cells were trypsinised, centrifuged again as above, and then washed in 20 ml PBS and 
resuspended in PBS to a concentration of lx l0 7 cells/ml. Seven hundred microlitres of 
these cells were then pipetted into a Gene Pulser cuvette (Bio-Rad 165-2088). Ten 
micrograms of both the heavy chain and light chain expression vector DNA for either 
chimeric mAb 12.8 or 12.10 was added and electroporated with a 1900 Volt 25 pFarad 
capacitance pulse using the Bio-Rad Gene Pulser (165-2078). The electroporated cos cells
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were left at room temperature for 1 0  minutes then gently added to a 1 0  cm diameter tissue 
culture dish containing 8  ml of pre-warmed DMEM supplemented with 5% (v/v) y-globulin 
free foetal calf serum plus L-glutamine, penicillin and streptomycin as above. The cells 
were incubated in 5% CO2 at 37°C for 72 hours and then the supernatant containing 
expressed chimeric antibody was harvested for analysis.
2.2.2 Purification of chimeric mAbs 12.8 and 12.10 using Protein A
Expressed chimeric mAbs 12.8 and 12.10 were purified from cos cell supernatants 
using the ImmunoPure IgG (Protein A) Purification Kit (Pierce, 44667). The Protein A 
column was equilibrated with 5 ml of PBS pH 8.0 or the Immunopure IgG Binding Buffer. 
The cos cell supernatant was diluted with an equal volume of PBS and added to the 
column. The column was then washed with 15 ml PBS. The bound IgG was eluted with 
5 ml ImmunoPure IgG Elution Buffer.
2.2.3 Quantification of expressed chimeric mAbs 12.8 and 12.10 by 
ELISA
A 96-well Nunc-Immuno MaxiSorp plate was coated with 100 pl/well of 0.4 pg/ml 
goat anti-human IgG antibody, Fey fragment-specific (Jackson ImmunoResearch Labs, 
109-005-098) in PBS. This was left to incubate at 4°C overnight. The excess coating 
solution was removed and the plate was washed 3 times with 200 pl/well washing buffer 
(lx PBS with 0.1% [v/v] Tween). 100 pi SEC buffer (lx PBS with 0.02% [v/v] Tween 
20, 0.2% (w/v) BSA) was added to each well. 200 pi of a solution of the chimeric mAb at 
a known concentration of 1 pg/ml in SEC buffer was added to two of the wells to serve as a 
standard. 2 0 0  pi of experimental cos cell supernatants under test were added to the
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appropriate wells in serial 2-fold dilutions in SEC buffer. The plate was incubated at 37°C 
for 1 hour. The wells were rinsed 6  times with 200 pi wash buffer. 100 pi 
peroxidase-conjugated goat anti-human kappa light chain (Sigma, A-7164), diluted 1:5000 
in SEC buffer, was added to each well. The incubation and wash were repeated as above. 
Colour was developed by adding 150 pi K-BLUE substrate (Sky Bio, KB 176) to each well 
and leaving in darkness for 10 minutes then adding 50 pi RED STOP (Sky Bio, RS20) 
solution to each well. The absorbance was read at 655 nm.
2.3 Construction and expression of scFv fragments from mAb 12.8 and 
mAb 12.10 DNA
2.3.1 Construction of single-chain variable fragments (scFvs) from mAb 
12.8 and mAb 12.10
The amplified heavy chain and light chain variable (Vh and V l)  D N A  sequences were 
assembled into a construct encoding a single-chain Fv by means of a three-step PCR 
reaction, illustrated in Figure 2.1. The oligonucleotide primers used are shown in Table 
2 .2 .
In the first step, the Vh DNA was amplified with a 5’ primer, 12.8Vn.BackSfi or 
12.10VH.BackSfi, (designed to anneal to the 5’ end of the gene just after the leader 
sequence) which introduced an Sfil and Ncol site, and a 3’ primer, 12.8VH.For or 12.10 
VH-For. The VlDNA was amplified with a 5’ primer, 12.8VL.Back or 12.10VL.Back, and 
a 3’ primer, 12.8VL.ForNotl or 12.10VL.ForNotI, which added a Notl site. DNA encoding 
an 18 amino acid flexible linker was amplified with a 5’ primer, 12.8Linker218.Back or 
12.10Linker218.Back, designed to overlap with the 3’ end of the V h, and a 3’ primer,
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12.8Linker218.For or 12.10Linker218.For, designed to overlap with the 5’ end of the Vl. 
The sequence of the flexible linker is shown in Table 2.2.
In the second step, the Vh PCR product from step 1 was combined with the linker DNA 
using 12.8VH.BackSfi or 12.10VH.BackSfi and 12.8Linker218.For or 12.10Linker218.For. 
The Vl PCR product from step 1 was also combined with the linker DNA, using 
12.8Linker218.Back or 12.10Linker218.Back and 12.8VL.ForNotI or 12.10VL.ForNotI.
In the third and final step, the PCR products from step 2 were united into a single chain 
Fv using 12.8VH.BackSfi or 12.10VH.BackSfi and 12.8VL.ForNotI or 12.10VL.ForNotI.
PCR reactions were carried out as before, but in a volume of 100 pi, using 20 
nanograms of template DNA, and amplifying with Deep Vent polymerase. An annealing 
temperature of 65°C was used for steps 1 and 2, and an annealing temperature of 55°C was 
used for step 3.
The scFvs were cloned in E. coli XL 1-Blue and sequenced as before.
2.3.2 Repair of scFv 12.10 DNA sequence by site-directed mutagenesis
On sequencing the DNA encoding scFv 12.10, an unwanted single base pair mutation 
was found encoding the substitution of proline for serine at position 17 of the first 
framework region of the heavy chain. A primer, N12 lOVnFrl .rev, was designed to enable 
correction of the sequence using PCR to produce a site-directed mutagenesis. The method 
is illustrated diagrammatically in Figure 2.2. N12lOVnFrl.rev was designed to anneal to 
the framework 1 region of the heavy chain, and this primer incorporated the correct DNA 
sequence without the unwanted mutation. The sequence of N12lOVnFrl.rev is shown 
below with the nucleotide correction underlined.
N1210VHFrl.rev:GACAGCTTCACTGAAGCCCCAGGCTTC.
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Using the mutated scFv DNA as a template, this primer was used with 
1210VH.BackSfi to amplify a 5' portion of scFv 12.10 approximately 75 base pairs long, 
which incorporated the corrected sequence rather than the unwanted mutation. The 75 
base pair product from this PCR was then used as a primer in conjunction with the primer 
1210.VLForNotI, to amplify the whole of scFv 12.10 (again using the DNA with the 
unwanted mutation as a template). This second PCR was intended to yield a full-length 
scFv product in which the mutation had reverted back to the desired sequence.
The first step PCR in the site-directed mutagenesis was set up as follows:
DNA template* 5 ng/pl 10 pi
lOx Pfu buffer 5 pi
25 mM MgCl2 2  pi
10 mM dNTP 4 pi
10 pM N 121 OscFv.VnFr 1 .rev 1.25 pi
10 pM 1210VH.BackSfi 1.25 pi
H20  25.5 pi
Pfu 1 pi
*The DNA template was the DNA encoding the scFv 12.10 with the unwanted mutation
The reaction was cycled at 94°C 5 min, then 94°C 1 min, 55°C 1 min, 72°C 2 min 
for 25 cycles, then 72°C 10 min.
Pfu was used in preference to AmpliTaq polymerase because AmpliTaq would add 
A overhangs which would introduce further mutations. The product of the first PCR above 
was gel-purified using the Wizard Prep kit (Promega) to a volume of 50 pi and 1 pi of this 
was used as Primer 2 in the second PCR reaction below. The DNA template was the same 
as that used in the first PCR, above. The second PCR was set up as follows:
DNA template 5 ng/pl 10 pi
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1 Ox Pfu buffer 5 pi
25 mM MgCl2 2  pi
10 mM dNTP 4 pi
10 pM N 121 OscFv.VLForNotI 1.25 pi
Primer 2 (3 ng/pl) 2  pi
H20 24.75 pi
Pfu 1 pi
The reaction was cycled as before.
2.3.3 Subcloning of scFv 12.8 and scFv 12.10 sequences into expression 
plasmid and phagemid vectors
Plasmids with the scFv 12.8 and scFv 12.10 inserts were digested with Sfll and Notl, 
and the DNA was extracted with phenol/chloroform. The scFv sequences were ligated as 
SfiVNotl fragments into Sfil/Notl-cut expression vectors. Two vectors were used. Initially 
the scFvs were ligated into pXJC/c-mycfH.6, a pUC-derived expression vector with 
C-terminal c-myc and hexahistidine tag sequences (obtained from Dr Olivier Leger, MRC 
Collaborative Centre) and, subsequently, the scFvs were ligated into pHENlH6 . pHENl 
is a phagemid vector designed for the expression of scFvs either on the surface of M13 
filamentous phage (as a fusion with the phage gene III structural protein), or as a soluble 
free protein with a C-terminal c-myc tag (Hoogenboom, Griffiths et al. 1991). pHENlH6  
is adapted from pHENl by the addition of a C-terminal hexahistidine tag in front of the 
C-terminal c-myc tag. Ligations were performed in a volume of 10 pi using approximately 
50 ng vector DNA, 100 ng insert DNA, 1 pi (4 Weiss units) T4 DNA Ligase (Invitrogen) 
and 1 pi lOx Ligation Buffer (Invitrogen), overnight at 16°C. Forty microlitres of E. coli
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TGI or HB21/51 competent cells were transformed using 1 pi of the ligation reactions 
(approximately 10 ng of DNA) by electroporation (1.7kV), resuspended in 1 ml SOC buffer 
(2% [w/v] bacto-tryptone, 0.5% [w/v] bacto-yeast extract, 8.5 mM NaCl, 2.5 mM KC1, 10 
mM MgCh, 20 mM glucose pH 7.0) at 37°C, shaken in an Innova 4000 incubator shaker 
(New Brunswick Scientific) at 30 rpm for 1 hour at 37°C and then plated onto agar.
The phagemid vector pHENlH6  is illustrated in Figure 2.3.
scFv 12.10 was also subcloned into the phagemid vector pHENlH6ABD2. The vector 
pHENlH6ABD2 was constructed by Dr Jonathan Chappel and is adapted from pHENlH6  
ty the addition of two albumin-binding domains (ABDs) positioned immediately after the 
Noil site and immediately before the hexahistidine tag. Expression in this vector results in a 
cFv expressed as a fusion with the two albumin-binding domains and the hexahistidine 
aid c-myc tags. The purpose of creating such a fusion is to express scFv which, in the 
presence of albumin, will bind two albumin molecules (molecular weight 6 8  kDa) and 
tlereby acquire a total mass approximating to that of a whole antibody.
The albumin-binding domains are flanked with 3 additional glycine residues in order to 
ftcilitate flexibility in the fusion protein and to preserve the binding of the scFv, ABDs and 
bxahistidine and c-myc tags. The albumin-binding domain sequence was obtained from 
tie plasmid pASK90-abd-D1.3 supplied by Arne Skerra (Technische Universitat 
Mmchen).
The vector pHENlH6ABD2, with the sequence of the albumin-binding domain, is 
slown in Figure 2.4.
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2.4 Sequencing, expressing, purifying and detecting scFvs
2.4.1 DNA sequencing
To prepare DNA for sequencing, glycerol stocks were inoculated into either 15 ml or 50
ml of 2TY medium (16 g tryptone, 10 g yeast extract, 5 g NaCl per litre) +100 pg/ml 
ampicillin, and grown with shaking in an Innova 4000 incubator shaker at 300 rpm 
overnight at 37°C. Plasmid DNA was then purified using the Qiagen Mini/Midiprep 
Plasmid Purification Protocol. DNA to be sequenced was prepared using the ABI PRISM 
dRhodamine terminator cycle sequencing ready reaction kit (Applied Biosystems). For 
each sequencing reaction, 200-500 ng of the template DNA to be sequenced and 3.2 pmol 
of primer DNA were added to 8.0 pi of Terminator Ready Reaction Mix and made up with 
H2O to a volume of 20 pi. Reactions were cycled at 96°C for 45 seconds, 50°C for 30 
seconds, 60°C for 4 minutes, for 25 cycles, with rapid thermal ramping. The resulting 
extension products were purified by adding them to 2.0 pi 3 M sodium acetate pH 4.6 with 
50 pi 95% (v/v) ethanol. The tubes were vortexed and placed on ice for 10 minutes to 
precipitate the extension products. The tubes were then spun in an Eppendorf 
microcentrifuge 5415 C at 13,000 rpm (11,340 g) for 30 minutes. The supernatant was 
aspirated and discarded and the pellet was rinsed with 250 pi 70% (v/v) ethanol. The tubes 
were centrifuged again as above for 5 minutes and the supernatant was discarded and the 
pellets were air-dried. Pellets were resuspended in loading buffer (deionised formamide in 
a 5:1 ratio with 25 mM EDTA [pH 8.0] with blue dextran [50 mg/ml]). The samples were 
vortexed and centrifuged and heated at 95°C for 2 minutes to denature and then loaded onto 
the sequencing gel. Sequencing was carried out using the Perkin Elmer ABI Prism 377 
DNA Sequencer.
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2.4.2 Expression of scFvs in E. coli
An agar plate was streaked from a glycerol stock of the scFv clone, and incubated at 
37°C overnight. A fresh colony was inoculated into 25 ml 2TYAG (16g tryptone, lOg 
yeast extract, 5g NaCl per litre + lOOpg/ml ampicillin, supplemented with 2% w/v 
glucose), and grown overnight at 30°C in an Innova 4000 incubator shaker at 300 rpm. 
The culture was then added to 1 litre of pre-warmed 2TYAG and grown in an Innova 4000 
incubator shaker at 300 rpm for 4 hours at 30°C in a baffled flask. The cells were then 
pelleted by centrifugation at 3000 rpm (1240 g) for 15 minutes in a pre-cooled Beckman 
centrifuge with a JA-17 rotor, and resuspended in 1 litre 2TY containing 100 pg/ml 
ampicillin and 1 mM isopropylthiogalactopyranoside (IPTG), pre-warmed to 30°C, and 
grown in an Innova 4000 incubator shaker at 300 rpm in a baffled flask for 4 hours. The 
cells were then pelleted as before and frozen at -80°C for later periplasmic extraction.
. Periplasmic extracts were made by thawing the cell pellet into 20 ml periplasmic buffer 
(25 mM Tris-HCl pH 7.5, 20% sucrose, 200 mM NaCl, 1 mM EDTA) and shaking at 4°C 
for 1 hour. If proteolytic breakdown was known to occur, phenyl methyl sulphonyl 
fluoride (PMSF) was added to the periplasmic buffer to 0.1 mM before use. The 
suspension was then centrifuged at 14,000 rpm (27,000 g) in a Beckman centrifuge with a 
JA-17 rotor at 4°C for 15 min to pellet the cell debris, and the supernatant containing the 
periplasmic fraction was retained.
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2.4.3 Purification of expressed scFvs using hexahistidine tag
MgCh was added to the periplasmic fraction to a concentration of 2  mM, and then 100 
pg DNasel was added. One millilitre of 50% Ni-NTA agarose slurry (Qiagen), 
pre-washed 3 times in wash buffer (50 mM Na phosphate, 300 mM NaCl, 10 mM 
imidazole, pH 8.0), was added to the periplasmic fraction and incubated on a rotating 
platform at 4°C for 1 hour. The resin was then pelleted in an Eppendorf microcentrifuge 
5415C at 1000 rpm (70 g) for 1 minute and, after removal of 90% of the supernatant, the 
slurry was added to a Qiagen 1 ml column (#34024) which was allowed to drain under 
gravity. Two x 4 ml wash buffer was applied, and then the bound scFv was eluted with 4x 
0.5 ml elution buffer (50 mM Na phosphate, 300 mM NaCl, 250 mM imidazole, pH 8.0). 
Eluted scFv was dialysed in 3 changes of PBS at 4°C over 24 hr using Pierce Slide-A-Lyzer 
10 kDa cut-off dialysis cassettes, and stored at 4°C.
2.4.4 Detection of expressed scFvs by Western blot using c-myc or 
hexahistidine tag
The scFv was resolved by SDS-PAGE on a 12% polyacrylamide gel under 
non-reducing conditions, and transferred to an Immobilon nitrocellulose membrane. The 
scFv was detected using Qiagen Anti-PentaHis antibody according to the Qiagen protocol, 
using horseradish peroxidase conjugated goat anti-mouse IgG (H+L) (Sigma) and ECL 
chemiluminescent detection (Amersham Life Science). Alternatively, anti-c-myc 9E10 
hybridoma supernatant was used in place of the Anti-PentaHis antibody.
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2.5 Construction of the phage display libraries
2.5.1 Selection of malaria-exposed donors
Blood donors were selected from among adult men and women resident in the 
village of Brefet and its environs, in The Gambia, West Africa. Of 20 donors selected, 10 
were selected on the basis of previously noted high levels of anti-MSP-1 IgG as detected by 
ELISA in a previous study (Egan, Waterfall et al. 1997). The remainder was chosen at 
random from among volunteers in the village. Equal numbers of male and female donors 
were selected, and the majority of female donors had had one or more pregnancies. Details 
of donors are shown in Table 2.3.
Blood was collected for one library in March 1997 (dry season; low prevalence of 
clinical malaria) and for the other library in October 1997 (end of wet season; high 
prevalence of clinical malaria).
2.5.2 Isolation of donor peripheral blood mononuclear leucocytes 
(PBMLs)
Twenty millilitres of venous blood was taken from each donor and added to a 25 ml 
universal container containing 5 ml RPMI 1640 with 50 units/ml penicillin, 50 pg/ml 
streptomycin and 250 units of heparin. The universal containers were filled to the top with 
medium, and samples were transported from the field to the laboratory (approximately 2  
hours) at 4°C and then allowed to return to room temperature in the laboratory. The blood 
was then further diluted 1:1 with RPMI 1640 plus penicillin and streptomycin as above and 
20 ml of diluted blood was layered carefully onto 15 ml Ficoll-Paque PLUS (Pharmacia 
Biotech 17-1440-02) and centrifuged in a Sigma 4-10 centrifuge at 3500 rpm (2340 g) for
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25 minutes at room temperature with the brake off. The plasma was then removed, 
aliquoted and frozen at -20°C. The layer containing PBMLs was diluted in 10 ml RPMI 
1640 plus 5% foetal calf serum and centrifuged at 3500 rpm (2340 g) for 15 minutes at 
room temperature. The pellet was then resuspended in 6  ml RPMI 1640 plus 5% foetal 
calf serum. This wash was repeated twice, spinning once at 3500 rpm (2340 g) and then at 
1700 rpm (510 g) and the cells were then resuspended in 3 ml RPMI 1640 plus 5% foetal 
calf serum, and stored briefly at 37°C. Cell counts and viability tests were performed with 
a haemocytometer using 25 pi of cell suspension mixed with 25 pi of trypan blue.
2.5.3 Extraction of total RNA from donor PBMLs
RNA extractions were performed using the Qiagen RNeasy Midiprep kit. Cells 
from 5-6 separate blood donations were pooled for RNA extraction. One millilitre of cell 
suspension in RPMI 1640 was taken from each processed donation. The cells were spun at 
300 g for 5 minutes and the supernatant aspirated. The pellet was loosened and 3.8 ml 
Qiagen Buffer RLT plus P-mercaptoethanol was added to lyse the cells. The cell lysate 
was vortexed for 10 seconds and then passed 10 times through a 20-gauge needle. An 
equal volume of 70% ethanol was added and the cell lysate was vortexed again. The lysate 
was then added to a Qiagen RNeasy midi spin column and centrifuged at 4000 g for 5 
minutes. The column was washed with 3.8 ml Qiagen buffer RW1 and spun at 4000 g for 
5 minutes. The column was then washed again with 2.5 ml Qiagen buffer RPE diluted 
with 100% ethanol 1:4 v/v and centrifuged at 4000 g for 2 minutes. Finally 2.5 ml Qiagen 
buffer RPE was added and the column was spun at 4000 g to dry the spin column 
membrane, and the total RNA was eluted from the column by adding 150 pi RNAse-free 
H2O for 1 minute, then centrifuging at 4000 g for 3 minutes. This step was then repeated
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with a further 150 pi RNAse-free H2O. RNA was quantified by measuring the absorbance 
at 260 nm.
2.5.4 Separation of MSP-119-specific PBMLs using Dynabeads
An attempt was made to separate out PBMLs expressing MSP-119-specific antibody
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on the cell surface for subsequent RNA extraction. 8x10 tosyl-activated Dynabeads 450 
(Dynal) were coated with MSP-119-GST according to the Dynal protocol. PBMLs were 
pooled (from 5-6 separate donations) using 1 ml of cells suspended in RPMI 1640 from 
each donation, in a 15 ml falcon tube. The coated Dynabeads were added to a 
concentration of 2 x l0 7 beads/ml and the cells and beads were shaken together on a shaker 
at 30 rpm for 1 hour at 4°C. The cell/bead mix was then placed on a Dynal magnet for 60 
seconds, the medium was removed, and the cells and beads were resuspended in a further 
5-6 ml RPMI 1640 plus 5% foetal calf serum. This wash was repeated three times. The 
cell/bead mix was then resuspended in 1 ml RPMI 1640 plus 5% foetal calf serum. Cell 
count and cell viability was assessed as above, counting only those cells visibly attached to 
a bead. RNA extraction was then attempted as described above.
2.5.5 Synthesis of cDNA from total RNA
The steps involved in constructing the scFv libraries, from cDNA synthesis to the 
construction of 5/zI/AM-digested scFv inserts ready for cloning, are shown 
diagrammatically in Figure 2.5. cDNA was made from total RNA using the First-Strand 
cDNA Synthesis Kit (Pharmacia Biotech XY-028-00-15). This step is shown in Figure 2.5 
Step 1. Reactions were set up as follows:
Bulk First-Strand Reaction Mix 77 pi
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Oligonucleotide Primer (20 pmol/pl) 7 pi
DTT Solution 7 pi
RNA 140 pi
Four reactions were carried out using four different oligonucleotide primers. The 
primers used were:
3 HuIgl-4 (20 pmol/pl) to amplify the variable regions of the immunoglobulin heavy 
chains
3 HuIgK (20 pmol/pl) to amplify the variable regions of the immunoglobulin light k  chains 
3 HuIgX, (20 pmol/pl) to amplify the variable regions of the immunoglobulin light X chains 
NotI-d(T)i8 (Pharmacia Biotech) (0.2 pg/pl) to non-specifically amplify mRNA 
3 HuIgl-4 GTCCACCTTGGTGTTGCTGGGCTT 
3 HuIgK ACACTCTCCCCTGTTGAAGCTCTT 
3 HuIgX TGAAGATTCTGTAGGGGCCACTGTCTT 
RNA was heated to 65°C for 10 minutes then chilled on ice prior to the reactions. The 
reactions were carried out at 37°C for 1 hour. The cDNA was then flown back from The 
Gambia to the UK at 4°C and then stored at -20°C.
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2.5.6 Amplification of antibody variable region sequences from human 
donor PBML cDNA
The DNA sequences encoding the variable regions of the human heavy chains, 
kappa light chains and lambda light chains were amplified separately from the cDNA. 
This step is shown diagrammatically in Figure 2.5 Step 2. The multiple primers used were 
based on each of the human heavy and light chain gene families in order to maximise the 
diversity of the libraries (Marks, Tristem et al. 1991). The primers were designed to 
anneal to the 5’ and 3’ ends of the DNA encoding the rearranged variable region sequences. 
Back primers (denoted by “BACK” in the primer name) anneal to the 5’ end and forward 
primers (denoted by “FOR” in the primer name) anneal to the 3’ end of the variable region 
sequence. Most of the primers have already been described (Marks, Hoogenboom et al. 
1991) but some were newly designed by Dr Jonathan Chappel at the MRC Collaborative 
Centre, Mill Hill, London. Primers for the different gene families were only used if a 
functionally rearranged gene from that family was listed in the V-BASE GOLD database 
(which lists only functionally rearranged sequences) on 27 September 1996. The primer 
sequences are shown in Table 2.4. The PCR reactions carried out to amplify variable 
region sequences from the different heavy and light chain gene families are shown in Table 
2.5.
PCR reactions were set up in a final volume of 50 pi as follows:
Perkin Elmer buffer II 5 pi
25 mM MgCl2 3 pi
10 mM dNTPs 4 pi
H20 32 pi
Primer 1 (10 pmol/pl) 2  pi
Primer 2 (10 pmol/pl) 2  pi
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cDNA 1 pi
AmpliTaq (5u/pl) 1 pi
Reactions were carried out under oil with a hot start at 94°C for 5 minutes and then 
94°C for 1 minute, 55°C for 1 minute, 72°C for 1 minute, for 30 cycles.
Five microlitres of PCR product was visualised after electrophoresis on a 2.5% 
agarose gel with ethidium bromide. PCRs giving only a weak band were repeated using 
Deep Vent DNA polymerase (NEB). These reactions were set up as follows:
lOx Deep Vent Buffer 5 pi
dNTPs (10 mM) 4 pi
H20 35 pi
Primer 1(10 pmol/pl) 2  pi
Primer 2(10 pmol/pi) 2  pi
cDNA 1 pi
Deep Vent (2 u/pl) 1 pi
Reactions were cycled as above with a hot start and oil overlay, and products were
visualised as above. PCRs still giving only weak bands were repeated using 5 times more 
cDNA and PCR was carried out under a hot lid rather than under oil overlay.
PCR products were resolved on a 2.5% low melting point agarose gel containing 
ethidium bromide, and 1 mM guanosine was added to the gel and buffer as an ultraviolet 
protectant (Grundemann and Schomig 1996) when constructing the second (October 97) 
library. Forty-five microlitres of PCR reaction was added to each well.
Bands containing amplified variable region sequences were excised from the gel 
and purified using the phenol/lithium chloride melt procedure (Faison 1992). DNA pellets 
were resuspended in 2 0  pi H2O and 2  pi of each purification was used to quantify the 
recovery.
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Purified variable region sequence mixes were prepared containing 10 ng of each 
variable region PCR product. Three mixes were made, Vh mix, containing the PCR 
products from the 10 Vh PCR reactions, VK mix, containing the PCR products from the 9 
VK PCR reactions, and V*., mix, containing the PCR products from the 13 Vx PCR 
reactions. Each mix was diluted to a concentration of 5 ng/pl to prepare for the first stage 
of scFv assembly.
2.5.7 Preparation of linker DNA
To assemble VhDNA with VKor V*, DNA to make scFv, it is necessary to join them 
together with DNA encoding a flexible 15 amino acid linker. The linker has the amino 
acid sequence (Gly-Gly-Gly-Gly-Ser)3, and the DNA sequence 
GGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCT.
In order to be able to join the linker DNA to the Vh DNA and the VK or DNA, the 
linker was amplified using primers designed to add extensions to the linker DNA which 
would overlap with the Vh DNA and the VK or V*. DNA. This step is shown 
diagrammatically in Figure 2.5 Step 2. The primers were designed so that the 5’ end of the 
linker would overlap with the 3’ end of the Vh DNA, and the 3’ end of the linker would 
overlap with the 5’ end of the VK or V\ DNA. This arrangement enables the creation of 
scFv of the form VH-linker-VK or Vn-linker-Vx.
Four different primers were used to produce overlaps between the 5’ end of the 
linker and the 3’ end of the different families of Vh genes. Nine different primers were 
used to produce overlaps between the 3’end of the linker and the 5’ end of the different 
families of VK genes. Thirteen different primers were used to produce overlaps between 
the 3’end of the linker and the 5’ end of the different families of V*. genes. Each of the 4
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Vh primers were used with each of the 9 VK or 13 primers in 8 8  different PCR reactions. 
The primer sequences are shown in Table 2.6. The PCR reactions are shown in Table 2.7.
PCR reactions were set up as follows:
lOx PCR Buffer II 5 pi
MgCl2 (25 mM) 3 pi
dNTPs (10 mM) 4 pi
Primer 1 (10 pmol/pl) 2  pi
Primer 2(10 pmol/pl) 2  pi
Linker template (10 ng/pl) 1 pi
H20 32.5 pi
AmpliTaq 0.5 pi
The reactions were set up in a 96 well plate format and cycled on a 
TRIO-Thermoblock (Biometra) thermal cycler at 94°C for 5 minutes, then at 94°C for 1 
minute, 45°C for 1 minute, 72°C for 1 minute for 30 cycles. Each reaction was set up both 
with template linker DNA and, as a negative control, without template linker DNA.
The PCR products were resolved on a 2.5% agarose gel, and bands containing the 
amplified linker were excised and gel purified using a phenol/gel melt procedure previously 
described (Faison 1992). The final washed pellets were resuspended in 20 pi H2O and 
frozen at -20°C until use in the scFv assembly PCR.
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2.5.8 scFv assembly stage 1: attaching VH heavy chain sequences and VK 
and Vx light chain sequences to scFv linkers
The amplified Vh, Vk and Vx sequences were attached to the scFv linker by PCR. 
This step is shown diagrammatically in Figure 2.5 Step 3. Reactions were set up as shown 
in Table 2.8. Ten different PCR reactions were set up.
Two PCR reactions attached the Vh sequences to either the linker with a 3’ end 
designed to overlap with the 5’ end of the V K sequences, or to the linker with a 3’ end 
designed to overlap with the 5’ end of the V x  sequences. These are reactions 1 and 2 in 
Table 2.8. In these reactions, two template DNA mixes were used. One template was a 
mix of all the amplified Vh sequences as described in section 2.5.6. The other template 
was a mix of all the linkers amplified with regions overlapping both the 3’ end of the Vh 
sequences and the 5’ end of the V K sequences or the V x  sequences, as described in section 
2.5.7. An equimolar mix of all 10 of the HuVHBACK primers (see Table 2.4 a) was used 
to anneal to the 5’ end of the Vh sequences and a single primer, HuLINKFOR, was used to 
anneal to the 3’ end of the linker.
HuLINKFOR AGATCCGCCGCCACCCGACCC
Five PCR reactions attached the linker to the VK sequences. These are reactions 3-7 
in Table 2.8. Again two template DNA mixes were used. One template was a mix of all 
the amplified VK sequences as described in section 2.5.6. The other template was a mix of 
all the linkers amplified with regions overlapping both the 3’ end of the Vh sequences and 
the 5’ end of the VK sequences, as described in section 2.5.7. In all 5 reactions, a single 
primer, HuLINKBACK, was used to anneal to the 5’ end of the linker. Five different 
primers were used in the 5 reactions to anneal to the 3’ end of the VK sequences. These 
primers were the 5 HuJkFOR primers used in section 2.5.6 and shown in Table 2.4 b).
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HuLINKBACK GGTGGCGGTGGCTCGGGCGGT
Three PCR reactions attached the linker to the Vx sequences. These are reactions 
8-10 in Table 2.8. Again two template DNA mixes were used. One template was a mix 
of all the amplified Vx sequences as described in section 2.5.6. The other template was a 
mix of all the linkers amplified with regions overlapping both the 3’ end of the Vh 
sequences and the 5’ end of the Vx sequences, as described in section 2.5.7. As before, in 
all 3 reactions a single primer, HuLINKBACK, was used to anneal to the 5’ end of the 
linker. Three different primers were used in the 3 reactions to anneal to the 3’ end of the 
Vx sequences. These primers were the 3 HuRFOR primers used in section 2.5.6 and 
shown in Table 2.4 b). Reactions were set up in a volume of 100 pi as follows:
lOx PE Buffer II 10 pi
25 mM MgCl2 6  pi
10 mM dNTPs 8  pi
Template 1: Vh (5 ng/pl) or VK or Vx (2 ng/pl) PCR mix 1 pi
Template 2: Linkers with k  or X overlaps (2 ng/pl) 1 pi
Primer 1(10 pmol/pl) 4 pi
Primer 2(10 pmol/pi) 4 pi
H20  65 pi
AmpliTaq 1 pi
PCR reactions were performed with a hot start at 94°C for 3 minutes and cycled at 
94°C for 90 seconds, 55°C for 1 minute, 72°C for 2 minutes, for 25 cycles, then 72°C for 10 
minutes.
To provide sufficient product, multiple PCRs were performed. Reactions using Vh
or VK sequences (reactions 1-7 in Table 2.8) were set up in duplicate and reactions using Vx
sequences (reactions 8-10 in Table 2.8) were each set up in 4 tubes.
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PCR products were precipitated with ethanol and resolved on a 1.4% agarose gel 
with 1 mM guanosine. The appropriate bands were excised from the gel and purified using 
the Wizard Prep Kit (Promega) and eluted with 50 pi H2O. The DNA was quantified by 
comparison to standard DNA concentrations. The purified DNA eluates were diluted to 2.5 
ng/pl in H2O for the second and final stage scFv assembly PCR. The purified DNA from 
PCR reactions 1 and 2 above (V h joined to the linker with k overlaps and V h joined to the 
linker with X overlaps) were pooled for the second stage assembly PCR.
2.5.9 scFv assembly stage 2: attaching VH-linker to linker-VK or linker-V*, 
to make complete scFvs with restriction sites
Reactions were set up to combine Vh genes with either VK genes or V\ genes, via 
the linkers attached to them in the previous PCR, to make full-length scFvs. Sfil and Notl 
restriction sites were also incorporated at either end of the scFvs in this PCR step. This 
stage in the scFv construction is shown diagrammatically in Figure 2.5 Step 4. The 
primers used in these reactions are shown in Table 2.9.
Three reactions were performed.
One reaction was designed to join the VH-linker sequences to the linker-VK 
sequences to make V h-V k scF v . In this reaction, one DNA template was the mix of 
VH-linker sequences described in section 2.5.8 and the other DNA template was the mix of 
linker-VK sequences described in the same section. Ten primers (designated 
HuVH...BACKSfi) were designed to anneal to the 5’ ends of the 10 families of Vh 
sequences and to incorporate a Sfil restriction site, and these primers were used in an 
equimolar mix. Five primers were designed to anneal to the 3’ end of the VK sequences
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and to incorporate a Notl restriction site. Again, these 5 primers were used in an equimolar 
mix.
Another reaction was designed to join the VH-linker sequences to the linker-Vx 
sequences to make V h-V x scFv . In this reaction, one DNA template was the mix of 
VH-linker sequences described in section 2.5.8 and the other DNA template was the mix of 
linker-Vx sequences described in the same section. Again, the 10 HuVH...BACKSfi 
primers were used in equimolar mix as described above. Three primers were designed to 
anneal to the 3’ end of the VK sequences and to incorporate a Notl restriction site. Two of 
these primers, HuJMFORNot and HuJ^2-3FORNot, were used in this reaction to anneal to 
the 3’ ends of the different families of Vx sequences. Again, these 2 primers were used in 
an equimolar mix.
One extra reaction was set up using the HuVH.. .BACKSfi primer mix as above and 
using HuV7xFORNot as the other primer. This reaction was done separately because it 
was found that the HuV7xFORNot primer worked better in the final assembly PCR if an 
annealing temperature of 72°C was used instead of 69°C.
Reactions were set up in a volume of 100 pi as follows:
Perkin Elmer lOx Buffer 
25 mM MgCl2 
10 mM dNTPs 
H20
Template 1: VH-linker (2.5 ng/pL)
Template 2: linker-Vx or linker-V?l (2.5 ng/ pi)
Primer 1: HuVHBACKSfi mix
1 0  pi 
6  pi 
8  pi 
69 pi 
1 pi
1 pi
2  pi
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Primer 2: HiJicFORNot mix or HuJAFORNot mix or Xlx alone) 2 pi
AmpliTaq Gold 1 pi
All reactions except those using primer Xlx were cycled as follows:
94°C for 90 seconds, 69°C for 1 minute, 72°C for 2 minutes, for 30 cycles, then 72°C for 10 
minutes.
Reactions using primer Xlx were cycled as follows:
94°C for 90 seconds, 72°C for 2 minutes, for 30 cycles, then 72°C for 10 minutes.
Reactions were carried out under oil. To provide sufficient DNA, each reaction 
using VK-linker was set up in duplicate and each reaction using V x-linker was set up in 4 
tubes.
The PCR products were precipitated and resuspended in TE buffer (40 pi for VK and 
80 pi for Vx PCRs). The PCR products were then resolved on a 1.4% agarose gel (40 pi 
per well) and the appropriate bands were excised and purified using the Wizard Prep kit 
(Promega) and eluted with 3x 50 pi H2O. The purified PCR product was quantified and 
stored at -20°C.
2.5.10 Reamplification of assembled scFvs with long primers
The library scFvs were reamplified with primers designed to give an extension of 
1 0 0  bases beyond the restriction sites in order to improve the efficiency of the restriction 
digestion of the PCR products prior to ligation. This is illustrated diagrammatically in 
Figure 2.5 Step 5.
BACKSfi was designed to anneal to the 5 ’ ( V h )  end of the scFv and FORNot was 
designed to anneal to the 3’ ( V K or V x )  end of the scFv. The sequences of BACKSfi and 
FORNot are shown in Table 2.10.
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The PCR was set up as follows:
Perkin Elmer lOx Buffer II 10 pi
MgCl2 (25 mM) 6  pi
dNTPs (10 mM) 8  pi
BACKSfi (10 pM) 2 pi
FORNot (10 pM) 2 pi
VhVk scFv or VhVx scFv (5 ng/pl) 2 pi
H20  69 pi
AmpliTaq 1 pi
Each of the two PCRs (amplifying either VhVk scF v  or YuVx scFv) was set up in 10 
separate identical reactions. Reactions were carried out with a hot start at 94°C for 4 
minutes and then cycled at 94°C for 1 minute, 72°C for 2 minutes, for 15 cycles, followed 
by an extension at 72°C for 10 minutes.
2.5.11 SfW Notl restriction digestion of scFvs
This step is illustrated diagrammatically in Figure 2.5 Step 6 . After reamplification 
of the library scFvs with long primers, the 10 PCR products from each reaction were 
combined and extracted once with phenol/chloroform, then again with chloroform, then 
ethanol precipitated and resuspended in 100 pi H20. The V hV k scF v and V h W  scFv DNA 
were each digested with 250 u Sfil (Boehringer). Restriction digests were set up in a
volume of 500 pi as follows:
1 Ox Buffer M 50 pi
V hV k scF v  or V hV*. scF v  DNA 100 pi
H20  325 pi
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-S/zI (10 u/|j.l) 25 |il
The digest was carried out at 50°C overnight.
The DNA was extracted and precipitated as above and the AM digestion was set up as 
follows:
1 Ox Buffer M 50 pi
VhVk scF v  or VHVx scF v  DNA 1 0 0  pi
H20  325 pi
AM (10 u/pl) 25 pi
This digest was carried out at 37°C for 4 hours. The DNA was extracted and precipitated 
as above (March library) or gel-purified from 1.4% gels as above (October library) in 
preparation for ligation.
2.5.12 Ligation of scFvs into pHENlH 6  vector
The VhVk scF v  or YhVx scF v DNA inserts were ligated into the phagemid vector 
PHEN1H6.
Prior to the ligation, 30 pg of caesium chloride-purified pHENlH6  vector was 
digested with SfWNotVPstl (Boehringer). Successive digestions were each carried out in a 
volume of 500 pi with 50 pi lOx Buffer M. Sfil digestion was carried out at 50°C for 4 
hours, AM  digestion at 37°C for 4 hours and Pstl digestion at 37°C for 2 hours. The DNA 
was phenol/chloroform extracted and ethanol precipitated after each digest. The digested 
vector was resuspended in 100 pi H20 , passed over a chromaspin 1000 column and 
quantified.
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The ligations were carried out in a volume of 500 pi using 400 ng of vector, 100 ng 
of V hV k scF v  or V hV x scF v , IOx  ligation buffer and T4 ligase (New England Biolabs). 
The ligations were set up as follows:
pHENlH6  8  pi
V hV k scF v or V hV*. scF v  10 pi 
IOx ligation buffer 50 pi
H20  382 pi
T4 Ligase (400 u/ml) 50 pi
The ligations were each split into 5 aliquots of 100 pi and purified using the QIAEX II kit 
(Qiagen) and eluted at 50°C with 20 pi 10 mM Tris pH 8.5.
2.5.13 Transformation of E. coli with scFv in pHENlH 6
Fresh electrocompetent E. coli TG1-TR cells were prepared. Fifty cuvettes were 
prepared on ice and 2 pi aliquots of ligated DNA were placed in each cuvette. Fifty 
microlitres of E. coli cells were added to the cuvettes, using 10 at a time, and the cells were 
electroporated with 1.7 kV. After electroporation, 1 ml 2TYG was added to the cuvette 
and removed, and the cuvette was rinsed with a further 1 ml 2TYG and the transformed 
cells were pooled and shaken at 220 rpm for 1 hour. An aliquot of cells was removed for 
titration and the remainder was centrifuged at 2340 g for 10 minutes then resuspended in 3 
ml 2TYG. Five lots of 600 pi of these cells were plated on each of 5 large plates of 2TY 
agar with 100 pg/ml ampicillin and 2% glucose, and incubated overnight at 30°C. The 
colonies were then scraped and resuspended in 10 ml 2TY plus 15% (v/v) glycerol and 
stored as 48 x 1ml aliquots of VhVk scFv  and 48 x 1ml of VhV*. scFv  at -70°C.
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2.6 Panning the libraries
2.6.1 Preparation of phage from library glycerol stocks
An aliquot of 1 ml of each library glycerol stock (i.e. March library V hV k, March 
library VhVx, October library VhVk and October library VhVx) was added to 500 ml 
2TYAG and grown at 37°C in a baffled flask in an Innova 4000 incubator shaker at 300 
rpm until the A6oo was 0.5 (80 minutes). M13K07 helper phage (Gibco BRL) 0.5 ml (= 
2.5 x 1011 phage) was added to give a final concentration of 5 x 108 phage/ml. The cells 
were incubated at 37°C for 30 minutes without shaking and then for 30 minutes shaking at 
200 rpm to allow infection. The cells were then centrifuged at in a Beckman J-6 B 
centrifuge at 5000 rpm (2380 g) for 10 minutes and resuspended in 500 ml 2TYA (without 
glucose) plus kanamycin 50 pg/ml and grown at 30°C for 16 hours shaking at 300 rpm.
The phage was concentrated by precipitation with polyethylene glycol. The culture 
was centrifuged in a Beckman JA-17 centrifuge at 8000 rpm (8820 g) in 10 x 50 ml 
Oakridge tubes for 15 minutes. The phage-containing supernatant was transferred to a 
sterile flask and 150 ml of 20% polyethylene glycol/2.5 M NaCl was added and mixed. 
The mix was left on ice for 90 minutes to precipitate the phage, and then centrifuged at 
8820 g for 15 minutes at 4°C to pellet the phage. The supernatant was removed, and the 
remaining phage was centrifuged again as above and the residual supernatant removed with 
a pipette. Each pellet of precipitated phage was then resuspended in 1 ml of TE buffer (10 
mM Tris pH 8.0, 0.1 mM EDTA) and the ten 1 ml phage suspensions were pooled. 
Residual bacterial debris was removed from the 10 ml suspension of phage in TE buffer by 
centrifuging at 8820 g for 5 minutes, and the phage-containing supernatant was transferred 
to a fresh tube.
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Further purification of the phage was carried out as follows. Five grams of caesium 
chloride (CsCl) were added to the 10 ml of phage stock in TE buffer to give a final CsCl 
concentration of 0.5 g/ml and mixed to dissolve. The phage was then placed in a 13.5 ml 
16 x 76 mm polyallomer tube (Beckman, Cat #342413) and ultracentrifuged at 42,000 rpm 
in a Beckman XL-90 Ultracentrifuge with a 70.1 TI rotor for 24 hours. The ultracentrifuge 
was stopped with the brake off. Three distinct bands were seen; a clear band at the top of 
the tube, an opaque band below it and another clear band below that. Each band was 
carefully removed separately with a 19 G needle and dialysed against 1L TE buffer in a 
Slide-A-Lyzer 10K dialysis cassette at 4°C overnight to remove the CsCl.
To determine which band contained the greatest quantity of phage, the quantity of 
phage was titrated from each band as follows. The dialysed phage-containing material 
from each Slide-A-Lyzer cassette was made up to 2 ml with TE buffer to create purified 
library phage stocks. Aliquots from each of these stocks were diluted into successive 
tenfold dilutions in 2TY on a 96 well plate. TG1-TR E. coli cells were grown in 50 ml of 
medium at 37°C for approximately 4 hours until they reached A6oo 0.5-1.0. Duplicates of 
10 pi of the phage stock dilutions were added to 1 ml of the TG1-TR cells and allowed to 
infect for 30 minutes at 37°C without shaking. One hundred microlitres from each of these 
dilutions of phage culture were then plated in duplicate onto TYAG plates and left 
overnight at 30°C. The colonies were counted to estimate the original concentration of 
phage.
Library phage stocks were stored as above in TE buffer at 4°C until used for 
panning.
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2.6.2 Panning for MSP-1 ^ -specific scFvs
A plastic Nunc Immuno tube (Maxisorp 75 x 12 mm, Cat. No. 4-44202) was coated 
with recombinant MSP-I19-GST (Burghaus and Holder 1994) as follows. One millilitre of 
MSP-I19-GST (10 pg/ml in PBS) was added to the Immuno tube and kept at 4°C for 16 
hours. The coated Immuno tube was then rinsed three times with PBS, and then blocked 
by filling to the brim with 3% (w/v) skimmed milk powder in PBS for 2 hours at room 
temperature, then rinsed 3 times with PBS. Concentrated library phage was pre-blocked as 
follows. Approximately lxlO14 phage from each of the two libraries (03/97 and 10/97) 
were pooled together in a volume of 1 ml in a 1.5 ml Eppendorf tube. Eighteen percent 
(w/v) skimmed milk powder in 200 pi of 6 x PBS was added and left at room temperature 
for 1 hour. GST was then added to the phage at a concentration of 100 pg/ml for 1 hour to 
prevent selection of anti-GST scFvs during panning. 1 millilitre of pre-blocked phage was 
then added to the MSP-li9-GST-coated Immuno tube and incubated (stationary) at 37°C for 
1 hour. The Immuno tube was then rinsed with PBS/0.1% Tween 20 (PBS/Tween) 5 times 
(10 times for panning rounds 2, 3 and 4) and then rinsed 20 times with PBS. Bound phage 
was then eluted by adding 1 ml freshly made 100 mM triethylamine (pH 11.0) to the 
Immuno-tube and incubating at room temperature for 10 minutes. Eluted phage was then 
transferred to a fresh 1.5 ml Eppendorf tube, neutralised by adding 500 pi 1M Tris-HCl pH 
7.4 and stored on ice.
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2.6.3 Re-infection of E. coli TGI cells with eluted phage
Exponentially growing E. coli TGI cells were prepared as follows. A 50 ml 2TY 
broth (16g tryptone, lOg yeast extract, 5g NaCl, in 1L) was inoculated with a single colony 
of E. coli TGI taken from a streaked minimal agar plate, and incubated with shaking 
(Innova 4000) at 37°C for 4 hours (until A6oo was 0.5-1.0). Five millilitres of the TGI 
culture was added to a 50 ml universal tube, and 1.4 ml of the eluted phage was added (the 
remaining 100 pi of eluted phage was stored at 4°C). The eluted phage was left to infect 
the is. coli at 37°C for 30 minutes stationary and then at 37°C for 30 minutes shaking at 100 
rpm. Two hundred microlitres of culture was removed to make serial dilutions for plating 
and counting as follows. A 2TYAG agar plate was plated with 100 pi of phage-infected E. 
coli and 3 more 2TYAG agar plates were plated with 100 pi of three serial ten-fold 
dilutions (made on ice) of infected E. coli, and incubated overnight. Colonies on these 
plates were then counted to estimate the number of phage retrieved by panning. The 
remaining 6.2 ml of phage-infected E. coli culture was centrifuged (Beckman JA-17) at 
3500 rpm (690 g) for 10 minutes and the pellet was resuspended in 0.6 ml 2TY broth and 
spread on a large (243 x 243 mm) 2TYAG agar plate and incubated at 30°C for 16 hours.
2.64 Storage and rescue of phagemid scFvs after selection
The colonies from each round of panning were scraped from the large 2TYAG agar 
platt into 10 ml of 2TY broth in a 50 ml universal tube. Fifty microlitres of this broth 
wasthen used to inoculate 25 ml of 2TYAG and shaken at 37°C for 90 minutes (until A6oo 
was 0.5-1.0). The remainder of the broth was mixed with 5 ml 50% v/v glycerol, rotated 
for 10 minutes at room temperature and then stored in 1 ml aliquots at -70°C. The 
iniocftated 25 ml 2TYAG culture was infected with helper phage as follows. M13K07
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Qhelper phage was added to a final concentration of 5x10 pfu/ml. The cells were left 
stationary at 37°C for 30 minutes, shaken in an Innova 4000 incubator shaker at 100 rpm at 
37°C for 30 minutes, then transferred to a 50 ml universal tube and centrifuged (Beckman 
JA-17) at 3500 rpm (1690 g) for 10 minutes. The bacterial pellet was then resuspended in 
25 ml prewarmed 2TY with 50 pg/ml kanamycin and 100 pg/ml ampicillin. The cell 
suspension was then transferred to a 250 ml flask and shaken at 300 rpm at 30°C for 16 
hours to produce phage particles. One millilitre of culture was then transferred to a 1.5 ml 
Eppendorf tube and centrifuged at 13000 rpm (11,340 g) for 5 minutes. The 
phage-containing supernatant (containing about lx l0 12/ml) was transferred to a fresh tube 
and used to perform the next round of panning as described above in section 2 .6 .2 .
2.6.5 Assessment of diversity of M SP-li9-GST-binding scFvs by BstNI 
digest
To give an indication of the sequence diversity of MSP-lig-GST-binding scFv 
clones, BstNl restriction digest patterns were obtained as follows. scFvs were amplified by 
PCR in a volume of 20 pi containing:
Perkin Elmer II IOx buffer 2 pi
25 mM MgCl2 1 . 2  pi
lOmMdNTPs 1.6 pi
RSP 48 primer (10 pmol/pl) 1 pi
fdTET primer (10 pmol/pl) 1 pi
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Sterile H20  12.7 pi
AmpliTaq DNA polymerase 0.5 pi
A small amount of an ELISA-positive MSP-119-GST-binding clone was transferred 
from the glycerol stock of the master plate into the PCR tube using a sterile pipette tip, and 
the PCR mix was overlaid with mineral oil. The PCR product was amplified using a 
Biometra thermal cycler using 30 cycles of 94°C for 1 minute, 55°C for 1 minute, 72°C for 
2 minutes followed by extension at 72°C for 10 minutes. Three microlitres of PCR product 
was analysed by electrophoresis on a 1.5% agarose gel, to confirm the presence of a band 
of approximately 1 kb. The remaining PCR products were made up to lx NEB2 Buffer 
with 100 mg/ml BSA, and 2 units of BstNl were added. After mixing, digests were 
incubated at 60°C for 2 hours under oil. Digests were resolved by electrophoresis on a 4% 
NuSeive agarose gel with ethidium bromide.
2.6.6 DNA sequencing of selected MSP-119-binding scFv clones
Sequencing was carried out using the Perkin Elmer ABI Prism 377 DNA 
Sequencer, using Perkin Elmer Terminator Ready Reaction Mix.
scFv inserts in the phagemid vector pHENlH6  were amplified for DNA sequencing 
using the following primers:
FdTET 5' GTCGTCTTTCCAGACGTTAGT 3'
RSP 48 5' AGCGGATAACAATTTCACACAGGA 3'
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2.7 Assessment of binding of mAbs and scFvs to target antigen
2.7.1 Binding of scFvs and mAbs to acetone-fixed P. falciparum  by 
indirect immunofluorescence (IFA)
Binding of scFvs and chimeric mAbs to parasites was assessed by IFA on acetone-fixed 
blood stage P. falciparum (FCB-1 and T9/96 lines). Multiwell glass slides of 
acetone-fixed P. falciparum smears were dried, then 5 pi of Ni-NTA-purified scFv was 
added to each well in concentrations of 30 pg/ml, 3 pg/ml, 0.3 pg/ml, and 0.03 pg/ml in 
PBS, and incubated in a humid chamber at 37°C for 30 minutes. Polyclonal scFv was 
tested at 20 pg/ml. The slides were then washed in PBS, and 15 pi of 9E10 (anti-c-myc) 
mouse hybridoma supernatant was added to each well, and incubated as above. Slides 
were then washed again as described and a 1:100 dilution of stock FITC-labelled 
anti-mouse antibody in PBS/1 % bovine serum albumin (BSA) was added to each well, 
incubating again as above. The slides were then washed again and covered, and then 
examined under the fluorescence microscope.
Chimeric mAbs, made by transient expression in cos cells and protein A-purified, were 
tested at the same concentrations as above, and revealed with a 1 : 1 0 0  dilution of stock 
FITC-labelled anti-human antibody in PBS/1% BSA.
Murine hybridoma mAbs 12.8 and 12.10 at 30 pg/ml were used as positive controls and 
revealed with FITC-labelled anti-mouse antibody. An anti-hen’s egg lysozyme scFv, scFv 
D1.3, was used at 30 pg/ml as a negative control for IFA with scFv, and mAb BX version 2 
(an unrelated non-P. falciparum-specific humanised mAb, directed against a 
cancer-specific antigen), donated by Susan Potts, MRC Collaborative Centre, was used at 
30 pg/ml as a negative control for IFA with chimeric mAbs.
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2.7.2 Binding of scFvs and chimeric mAbs to recombinant M S P - I 1 9  by 
ELISA
A Nunc Maxisorb 96-well ELISA plate was coated with 100 pi 1 pg/ml 
recombinant MSP-I19-GST fusion protein in PBS and left at 4°C overnight to coat. The 
plate was rinsed 3 times with PBS and then blocked with 280 pi per well of 3% 
Marvel/PBS for 1 hour at 37°C. The plate was then washed again 3 times with PBS and 50 
pi scFv was added at 100 pg/ml, and allowed to bind for 1 hour at 37°C. mAb 12.8 and 
mAb 12.10 were used as positive controls, and an anti-hen’s egg lysozyme scFv, scFv 
D1.3, was used as a negative control. The plate was then washed 3 times with PBS/Tween 
and then PBS, and to each well containing scFv was added 100 pi of 9E10 anti-c-myc 
mouse hybridoma cell culture supernatant, and the plate was incubated at 37°C for 1 hour. 
The plate was washed 3 times with PBS/Tween and then PBS, and then to each well was 
added 100 pi of a 1/5000 dilution in 3% marvel/PBS of peroxidase-conjugated anti-mouse 
kappa antibody (Harlan Sera-Lab). The plate was incubated again at 37°C for 1 hour, and 
then washed 3 times in PBS/Tween then PBS. The colour was developed by adding 150 pi 
Neogen K-BLUE substrate (Sky Bio) to each well and leaving in darkness for 10 minutes 
then adding 50 pi Neogen RED STOP solution (Sky Bio). The plate was read on a 
BIO-RAD 3550 Microplate reader at 655 nm.
For ELISA using chimeric mAbs 12.8 and 12.10, negative control wells were 
coated with hen’s egg lysozyme (1 pg/ml in PBS). One hundred microlitres of mAb was 
added to each well, in serial 1:1 dilutions, starting with a concentration of 50 pg/ml, and 
murine hybridoma mAbs 12.8 and 12.10 were used as positive controls and humanised 
mAb BX version 2 (see above) was used as a negative control mAb. Bound chimeric
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antibodies were detected with 100 pi of a 1/5000 dilution in 3% marvel/PBS of 
peroxidase-conjugated goat anti-human kappa light chain antibody (Sigma).
2.7.3 Identification of MSP-119-binding scFvs by ELISA
In order to isolate MSP-119-binding scFvs from the polyclonal scFv obtained in 
successive rounds of library panning, a soluble ELISA of 80 clones was carried out. 
Individual colonies were picked at random from the third and fourth rounds of library 
panning using a sterile pipette tip and transferred into 100 pi 2TYAG medium in a 96 well 
master plate and grown with shaking in an Innova 4000 incubator shaker at 100 rpm for 16 
hours at 30°C. A replica 96 well microtitre plate was prepared and inoculated from the 
master plate. The master plate was then stored at -70°C after adding 50 pi 50% glycerol to 
each well. The replica plate was shaken at 100 rpm for 6  hours at 37°C. The plate was then 
centrifuged in a Centaur 2 MSE centrifuge at 2000 rpm for 10 min and the supernatant was 
removed. The pellets were resuspended in 100 pi 2TY with 50 pg/ml kanamycin, 100 
pg/ml ampicillin, and 1 mM IPTG and shaken at 100 rpm at 30°C for 16 hours to produce 
scFv for ELISA.
A 96-well Nunc Maxisorb microtitre plate was coated with MSP-119-GST using 100 
pi per well of MSP-119-GST 1 pg/ml in PBS. Positive control wells were coated with 
hen’s egg lysozyme 100 pg/ml in 100 mM sodium bicarbonate pH 9.6. Negative control 
wells were left uncoated. The plate was left to coat at 4°C for 16 hours. The coating 
solution was then flicked out, the plates were rinsed three times with PBS, and then blocked 
with 280 pl/well of 3% dried milk powder in PBS for 2 hr at 37°C. The coated and 
blocked plates were then washed 3 times with PBS.
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The scFvs were blocked as follows. The scFv-containing culture plate was 
centrifuged at 2000 rpm for 10 min. One hundred microlitres of each scFv-containing 
supernatant was transferred to the corresponding well of a microtitre plate containing 2 0  pi 
of 6 x PBS with 18% dried milk powder and mixed. The plate was left for 1 hour at room 
temperature to block the scFv. Fifty microlitres of pre-blocked scFv was then transferred 
from each well of the blocking plate into the corresponding well of the antigen-coated 
plate. Blocked anti-hen’s egg lysozyme scFv D1.3 was added to the positive control wells. 
The scFv was allowed to bind for 1 hour at 37°C. The plate was then washed 3 times with 
PBS/Tween and 3 times with PBS using a Sanofi LP35 plate-washer (Pasteur Diagnostics). 
One hundred microlitres of 9E10 anti-c-myc hybridoma supernatant was added to each well 
and the plate was incubated for 1 hour at 37°C. The plate was washed again as above and 
100 pi of a 1/5000 dilution peroxidase-conjugated goat anti-mouse antibody (Jackson ) in 
3% Marvel/PBS was added and the plate was incubated for 1 hour at 37°C. The plate was 
washed again as above and then washed once with saline. The colour was developed by 
adding 150 pi Neogen K-BLUE substrate (Sky Bio) to each well and leaving in darkness 
for 10 minutes then adding 50 pi Neogen RED STOP solution (Sky Bio) and read at 655 
nm on a BIO-RAD 3550 Microplate reader.
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2.7.4 Competition ELISA with MSP-119-binding scFvs and mAbs 12.8 
and 1 2 . 1 0
A competition ELISA was designed to determine whether the phage library scFvs 
could compete with mAbs 12.8 and 12.10 for binding sites on the MSP-119 molecule. 
Competition ELISA plates were coated with MSP-119-GST at 0.5 pg/ml for competition 
with mAb 12.8 and at 0.05 pg/ml for competition with mAb 12.10. The scFvs were 
expressed in a 96-well replica plate inoculated from the master plate, as above, and the 
pre-blocked scFv-containing supernatants were transferred to the ELISA plate and allowed 
to bind. The plates were washed and then mAb 12.8 (at 0.5 pg/ml) or mAb 12.10 (at 0.05 
pg/ml) were allowed to bind also. Bound mAb was then revealed as described previously.
2.7.5 Binding of polyclonal scFv to P. falciparum  by Western blot
Ten microlitres each of T9/96 and FCB-1 P. falciparum merozoites were incubated 
for 1 hour at 37°C with 1 mM MgCh, 1 mM CaCh, Leupeptin, Antipain, Aprotinin & 
TLCK (Tos-Lys-chloromethylketone.HCl) in 200 pi PBS. The merozoites were then 
boiled for 10 minutes with 200 pi of non-reducing buffer, and 5 pi was loaded into each 
well of a 15% SDS polyacrylamide gel, and the gel was run and transferred onto a 
nitrocellulose membrane. The membrane was blocked with PBS/3%Marvel on a rotating 
platform at room temp for 2 hours, then the polyclonal scFv was added to the blocking 
solution at a final concentration of 1 pg/ml for 1 hour. The membrane was washed with 
PBS/Tween 3 times for 5 minutes and then incubated with 9E10 supernatant for 1 hour at 
room temperature. Peroxidase-conjugated goat anti-mouse IgG/lgM was added (diluted 1 
in 25,000 in PBS/3%Marvel) for 1 hour at room temp. The membrane was then washed
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three times as above and developed using the ECL chemiluminescent detection system 
(Amersham Life Science).
2.8 Assessing invasion-inhibitory activity of mAbs and scFvs
2.8.1 In vitro culture of P. falciparum
P. falciparum parasites were cultured in RPMI-1640 supplemented with 25 mM 
HEPES, 25 mM NaHCCb, 0.2% (w/v) glucose, 25 pg/ml gentamicin, 20 pg/ml 
hypoxanthine, plus either 10% (v/v) ABO-compatible human serum or 0.5% Albumax™ 
(Gibco BRL) and 2 mM glutamine with fresh washed human erythrocytes at a haematocrit 
of 1-2%. Cultures were maintained at 37°C in 1L Nunclon™ flasks (NUNC) gassed to 
contain an atmosphere of 7% CO2, 5% O2, 8 8 % N2. The medium was changed every 48 
hours. To replace the medium, cultures were centrifuged in a Beckman J-6 B centrifuge at 
2200 rpm (460 g) for 5 minutes and resuspended in fresh medium and recultured as above. 
Fresh human erythrocytes were added approximately twice weekly to maintain a 
parasitaemia of approximately 10-20%. Parasitaemias were measured every 48 hours 
using blood smears. Blood smears were air-dried, fixed in 100% methanol and stained for 
20 minutes with 10% (v/v) Giemsa stain in phosphate buffer pH 7.2.
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2.8.2 Synchronisation of P. falciparum  cultures and purification of 
schizonts
The P. falciparum culture was centrifuged for 5 minutes in a Beckman J-6 B 
centrifuge at 2400 rpm (550 g). The pellet was resuspended in 30 ml RPMI-1640 
supplemented as above plus 10% (v/v) ABO-compatible human serum, and centrifuged 
again in a Sigma 4-10 centrifuge at 1800 rpm (570 g) for 5 minutes. The supernatant was 
removed and the volume of the pellet was estimated. RPMI-1640 plus 10% serum, 
pre-warmed to 37°C, was added at a volume of 2.4 times the pellet volume. An equal 
volume of Plasmagel (Laboratoire Roger Bellon), pre-warmed to 37°C, was added, and the 
pellet was gently resuspended and left undisturbed for 30 minutes in an incubator at 37°C. 
The top layer, containing the schizonts, was carefully removed to a fresh tube, and an equal 
vohme of pre-warmed RPMI-1640 was added. The cells were centrifuged in a Sigma 4- 
10 centrifuge at 1700 rpm (510 g) and resuspended in fresh pre-warmed RPMI-1640 plus 
10°/i serum. To provide purified schizonts for invasion assays, schizonts from this stage of 
the procedure were used. To synchronise ongoing P. falciparum cultures, 6  ml of fresh 
ABO-compatible red cells, washed in RPMI-1640, were added to the schizonts and 
resiBpended to a final haematocrit of 10%. The culture was then left in a gassed flask at 
37°C for 2 hours.
The culture was then centrifuged in a Sigma 4-10 centrifuge at 2000 rpm (770 g) for 
5 mnutes. The supernatant was removed and the pellet was resuspended in 10 volumes of 
5% (w/v) sorbitol in water, to neutralise all but the ring forms of P. falciparum. The 
cultire was left in sorbitol at room temperature for 1 0  minutes, then centrifuged as above 
and washed once in RPMI-1640. The P. falciparum ring-forms thus isolated were then 
recutured in fresh pre-warmed RPMI-1640 plus 10% serum plus 2 mM glutamine at a
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haematocrit of 1-2% in a gassed flask. This process was repeated weekly to maintain 
synchrony.
2.8.3 Quantification of antibody/scFv mediated inhibition of erythrocyte 
invasion
Invasion assays were carried out essentially as previously described (Blackman, 
Heidrich et al. 1990). Specifically, purified antibodies/scFv were prepared by dialysis in 
RPMI 1640 (without Albumax) (Sigma) overnight at 4°C using a Slide-a-lyser dialysis 
cassette (50 kDa cut-off). Test antibodies/scFvs in RPMI 1640 (without Albumax) were 
placed in a flat-bottomed Costar 3596 96-well polystyrene plate. Each well was 
supplemented with 5 pi ABO-compatible human serum (i.e. 10% by final volume) or 
bovine serum albumin in the form of 0.5% (w/v) Albumax™ (Gibco BRL) (again at 10% 
by final volume) and with glutamine (final concentration 2 mM). 3D7 or FCB-1 
P. falciparum schizonts, collected and purified at 40 hours post invasion, were added with 
fresh erythrocytes (blood group O Rhesus Negative) to give a final parasitaemia of 2% and 
a final haematocrit of 3-5% in a total volume of 50 pi in each well. Final concentration of 
test antibody in each well was 0.5-1 mg/ml. scFvs were tested at a final concentration of 
approximately 2 0 0  pg/ml.
Positive control assays (“no invasion”) were carried out using mouse mAbs 12.8 
and 12.10 at 0.5-1 mg/ml, and using EGTA (0.4 mM final concentration). Negative 
control assays (“full invasion”) were carried out using 0.5-1 mg/ml mAb BC1, a murine 
mAb not directed against any P. falciparum antigen, or the anti-hen’s egg lysozyme scFv 
D1.3, and also using medium alone.
108
scFv 12.10-ABD2 was tested in the presence of 0.05% (w/v) human albumin. 
Human scFvs were also tested in the presence of 25-50 pg/ml anti-PentaHIS antibody 
(Qiagen) or a 1:8 dilution of hybridoma 9E10 supernatant.
The plates were placed in a gassed box containing an atmosphere of 7% CO2, 5% 
O2, 88% N2, and incubated at 37°C for 20 hours.
Each antibody was tested in two identical wells. The percentage of erythrocytes 
invaded after 20 hours was determined separately from two Giemsa-stained thin-film slides 
from each well. One thousand erythrocytes were counted on each slide, and slides were 
examined blind. The mean of these four independent counts was taken to be the final 
parasitaemia.
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Figure 2.1
PCR construction of a single chain variable fragment (scFv) from mAb
12.10
This figure shows the construction of scFv 12.10 from DNA encoding the variable 
regions of the mAb 12.10 heavy chain (V h, shown in blue) and light chain (V l, shown in 
red) and a flexible 18 amino acid linker, linker 218 (shown in green). The Vh and Vl 
sequences were assembled into a construct encoding a scFv by means of a three-step PCR 
reaction.
In Step 1, the Vh DNA was amplified with a 5’ primer, 12.10VH.BackSfi, (designed 
to anneal to the 5’ end of the gene just after the leader sequence) which introduced an Sfil 
and Ncol site, and a 3’ primer, 12.10VH.For. The VlDNA was amplified with a 5’ primer, 
12.10VL.Back, and a 3’ primer, 12.10VL.ForNotI, which added a Notl site. DNA encoding 
an 18 amino acid flexible linker was amplified with a 5’ primer, 12.101inker218.Back, 
designed to overlap with the 3’ end of the Vh, and a 3’ primer, 12.101inker218.For, 
designed to overlap with the 5’ end of the Vl.
In Step 2, the Vh PCR product from step 1 was combined with the linker using 
12.10VH.BackSfi and 12.101inker218.For. The Vl PCR product from step 1 was also 
combined with the linker, using 12.101inker218.Back and 12.10VL.ForNotI.
In Step 3, the PCR products from step 2 were united into a single chain variable 
fragment (scFv) using 12.10Vn.BackSfi and 12.10VL.ForNotI.
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Figure 2.1
PCR Step 1 (3 reactions)
12.10VH .BackSfi 12.10VL .Back
 ^  V h  V l
12.10VH.For 12.10VL.ForNotI
12.10 linker218.Back 
 ^  Linker 218
\ ------
12.10 linker 218.For
PCR Step 2 (2 reactions) i
12.10VH.BackSfi 12.10 linker218.Back
 \  \
\ --------------------------------  x-
12.10 linker 218.For 12.10VL.ForNotI
i
PCR Step 3 (1 reaction)
12.10VH.BackSfi SCFv Notl
__l_
Sfii Vh Linker 218 V L v
12.10VL.ForNotI
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Figure 2.2
PCR site-directed mutagenesis to correct the DNA sequence of scFv 12.10
On sequencing the DNA encoding scFv 12.10, an unwanted single base pair 
mutation was found encoding the substitution of proline for serine at position 17 of the first 
framework region of the heavy chain (marked here in blue). A primer, N1210VHFrl.rev, 
was designed to enable correction of the sequence using PCR to produce a site-directed 
mutagenesis. The method is illustrated here. N1210VHFrl.rev was designed to anneal to 
the framework 1 region of the heavy chain, and this primer incorporated the correct DNA 
sequence (marked here in black) without the unwanted mutation.
Using the mutated scFv DNA as a template, this primer was used with 
1210VH.BackSfi to amplify a 51 portion of scFv 12.10 approximately 75 base pairs long 
(shown here in pink), which incorporated the corrected sequence rather than the unwanted 
mutation. The 75 base pair product from this PCR was then used as a primer in 
conjunction with the primer 1210.VLForNotI, to amplify the whole of scFv 12.10 (again 
using the DNA with the unwanted mutation as a template). This second PCR was 
designed to yield a full-length scFv product in which the mutation had reverted back to the 
desired sequence.
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Figure 2.2
PCR Step 1
1210VH .BackSfi 
__________x
Single base pair mutation
V H LINKER V L
N1210V|_)Fr1.Rev
I Corrected sequence
Corrected sequence
Product of PCR Step 1
I
PCR Step 2
Product of PCR Step 1 
used as primer
Corrected sequence
- A  V H LINKER VL
\
Single base pair mutation N1210V, .ForNotl
VH LINKER VL
Corrected full length scFv
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Figure 2.3
Phagemid vector pHENlH 6
The phagemid vector pHENl was constructed specifically for the purpose of 
displaying antibody fragments on phage (Hoogenboom, Griffiths et al. 1991). The pHENl 
phagemid, modified by the addition of a hexahistidine tag to give pHENlH6, is illustrated 
here.
pHENlH6 is a derivative, via pHENl, of pUC119 (Vieira and Messing 1987), 
adapted by the inclusion of the coding region of pill from the fd filamentous phage. The 
pill signal sequence has been replaced by a pelB signal sequence which targets the 
expressed scFv to the bacterial periplasm. Between the signal sequence and the gene for 
pill are an internal Sfil site and a Notl site, allowing antibody fragments to be cloned as 
SfiVNotl fragments. Directly after the Notl site is a hexahistidine tag followed by a c-myc 
tag, both for immunodetection of antibody fragments. An amber stop codon (TAG) has 
been introduced between the tag and the region encoding the N-terminus of pill. Growth 
of this phagemid in suppresser (supE) strains of E. coli such as TGI E coli, in which the 
amber codon is read as glutamine, results in the ribosome translating through the amber 
codon on to the pill gene. This results in the antibody fragment being expressed as a 
fusion with the pill protein. Growth of the same phagemid in a non-suppresser strain of E. 
coli such as HB2151, which reads the amber codon as a stop codon, results in the 
translation ending at the end of the antibody fragment, which is therefore expressed as a 
soluble fragment without the pill protein (Hoogenboom, Griffiths et al. 1991). 
Transcription is driven from the inducible lacZ promoter.
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Figure 2.4
Phagemid vector pHEN!H6ABD2
pHENlH6ABD2 is modified from pHENlH6 by the insertion of two albumin- 
binding domains (ABDs) positioned immediately after the Notl site and immediately before 
the hexahistidine tag. Expression in this vector results in a scFv expressed as a fusion with 
the two albumin-binding domains followed by the hexahistidine and c-myc tags. The 
purpose of creating such a fusion is to express scFv which, in the presence of albumin, will 
bind two albumin molecules (molecular weight 68 kDa) and thereby acquire a total mass 
approximating to that of a whole antibody.
The albumin-binding domains are flanked with 3 additional glycine residues in 
order to facilitate flexibility in the fusion protein and to preserve the binding of the scFv, 
ABDs and hexahistidine and c-myc tags.
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Figure 2.5
Construction of the phage display libraries
This figure illustrates the steps involved in constructing the phage display libraries.
Step 1
Total RNA, extracted from the PBMLs of malaria-exposed donors, is used as a template for 
first-strand cDNA synthesis using specific primers.
Step 2
The variable regions of the antibody heavy chains and k  and X light chains are amplified 
from cDNA using PCR primers specific for each of the different gene families. DNA 
encoding the linker is amplified with primers designed to create overlaps with the 
sequences of the heavy and light chains.
Step 3
The linker sequences are joined to either the heavy chain sequence or the k or X light chain 
sequences.
Step 4
The products from step 3 are joined to make full-length scFv sequences, and the primers 
used to do this also insert Sfil and Notl restriction sites for cloning.
Step 5
Long PCR primers are used to introduce long extensions to the scFv sequences to facilitate 
efficient Sfil/Notl restriction digestion.
Step 6
The products from step 5 are digested with Sfil/Notl to yield scFv inserts ready for cloning 
into pHENlH6.
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Table 2.1 a)
PCR primers for cloning mouse heavy chain variable regions
Name
MHVlfl (27mer)
MHV2 (26mer)
MHV3 (27mer)
MHV4 (25mer)
MHV5 (30mer) 
MHV6 (27mer)
MHV7 (26mer)
MHV8 (23mer) 
MHV9 (30mer)
MHV10 (27mer) 
MHV11 (28mer) 
MHV12 (27mer)
MHCG1 (21mer)
MHCG2a (21mer)
MHCG2b (21mer)
MHCG3 (21mer)
Sequence
AT G A A A TG CA G CT G G G G CA T CT T CT TC
G
AT GGGAT GGAGC T GT AT C AT GT T C T T
A CC
AT GA AGTT GT G G TT AAAC T G G G TT T T T 
A
AT GAACT T T GGGCT CA G CT  T GAT T T 
G T G
A T G G A C T C C A G G C T C A A T T T A G T T T T C C T T
A T G G C T G T C C T A G G G C T A C T C T T C T G C  
T G C G
AT GGGAT GGAGC GGGAT C T T T C T C T T  
A T G A
A T G A G A G T G C T G A T T C T T T T G T G
AT GGATT GGGT GT G G A C C T T G C T A T T C C T G  
C A
A T G G G C A G A C T T A C A T T C T C A T T C C T G
A T G G A T T T T G G G C T G A T T T T T T T T A T T G
AT GAT GGT GT TA AG T CT T CT GT AC CT  G
CAGT GGAT AGACAGAT GGGGG
C A G T G G A T A G A C C G A T  GGGGG
C A G T G G A T G A G C T G A T G G G G G
CAAGGGAT AGACAGAT GGGGC
a MHV indicates primers that hybridise to leader sequences of mouse heavy chain 
variable region genes.
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Table 2.1 b)
PCR primers for cloning mouse kappa light chain variable regions
Name
MKVlfl (30mer) 
MKV2 (30mer)
MKV3 (30mer)
MKV4 (33mer)
MKV5 (30mer)
MKV6 (27mer)
MKV7 (31mer)
MKV8 (31mer)
MKV9 (25mer)
MKV10 (27mer) 
MKV11 (28mer)
MKV13 (26mer)
MKC (20mer)
Sequence
AT GA A GT T GC C T GT T AGGC T GT T GGT GC T G
AT GG AG A CA GA CAC AC T C CT GCT ATGG GT G 
T T
AT GAGTGT GCT CACT CAGGT CCT GGCGT T G
G
A T G A G G G C C C C T G C T C A G T T T T T T G G C T T C  T T G  
A A C AA
AT GGAT T T T C AG G T G C A G A T  T AT CAGCT T C 
A T
AT GAGGT G C C C T G T T C A G T T C C T G G G G  
T TT  C G C T A
AT GGGCAT C A A G A T G G A G T C A C A G A C C  CAG
G
A T G T G G G G A C C T T T T T T C C C T T T T T C A A T T  G 
T G C AA
A T G G T A T C C A C A C C T C A G T T C C T T G  
G T G
A T G T A T A T A T G T T T G T T G T C T  A T T T C T
A T G G A A G C C C C A G C T C A G C T T C T C T T C C
AT GGAT T C A C A G G C C C A G G T  T CT T AT
A C T G G A T G G T G G G A A G A T G G
a MKV indicates primers that hybridise to leader sequences of mouse kappa light 
chain variable region genes.
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Table 2.2 PCR primers and linker for construction of scFvs 12.8 and
12.10
12.8VH.BackSfi
GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG ATC CAC TTG GTG CAG TCT 
GG
12.8Vh.For
TGA GGA GAC TGT GAG AGT G 
12.8VL.Back
CAA ATT GTT CTC ACC CAG TCT CC 
12.8Vl .ForNotl
GAG TCA TTC TCG ACT TGC GGC CGC TCG TTT TAT TTC CAA CTT TGT CCC 
12.8Linker218.For
GGA GAC TGG GTG AGA ACA ATT TGA CCT TTA GTG GAA CCT TCA CCG G 
12.8Linker218.Back
CAC TCT CAC AGT CTC CTC AGG CTC TAC CTC TGG 
1210VH.BackSfi
GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTC CAA CTG CAG CA 
12.10 VH.For
TGA GGA GAC GGT GAC CGT G 
12.10VL.Back
GAC ATT GTG ATG ACC CAG TCT CA 
12.10VL.ForNotl
GAG TCA TTC TCG ACT TGC GGC CGC TCG TTT CAG CTC CAG CTT GGT CCC 
12.10Linker218.Back
CAG GGT CAC CGT CTC CTC AGG CTC TAC CTC TGG 
12.10Linker218.For
GAG ACT GGG TCA TCA CAA TGT CAC CTT TAG TGG AAC CTT CAC CGG 
Linker218
GGC TCT ACC TCT GGC TCT GGT AAA CCG GGT TCC GGT GAA GGT CCA CTA A
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Table 2.3
Adult Gambian blood donors from whom the libraries were derived
ID number Age Sex Location Donated to 
1st library
Donated to 
2nd library
Z999 68 M Bundung Y N
Z157 24 F Brefet Y Y
Z165 25 F Brefet Y N
Z152 40 F Brefet Y N
Z149 44 M Brefet Y Y
Z151 30 M Brefet Y Y
Z142 30 M Brefet Y Y
Z144 23 M Bundung Y N
Z49 35 M Brefet Y Y
Z168 31 F Brefet Y Y
Z88 44 F Brefet Y Y
Z71 32 F Sukuta Y Y
Z141 54 F Brefet Y Y
Z158 24 F Somita Y Y
Z176 44 F Somita Y Y
Z16 44 F Tubakuta Y Y
Z15 52 F Brefet Y Y
Z5 71 M Brefet Y N
Z21 34 M Mandinaring Y Y
Z143 25 M Bundung Y N
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Table 2.4 a)
PCR primers to amplify human VH heavy chain sequences
HuVHBACK primers anneal to the 5’ end of the Vh sequences. 
HuJHFOR primers anneal to the 3’ end of the Vh sequences.
Sources of linkers are noted as follows
Marks
JAC
VB
Primer
HuVHlaBACK
HuVH2xBACK
HuVH3aBACK
HuVH3xBACK
HuVH4aBACK
HuVH4xBACK
HuVH4yBACK
HuVH5xBACK
HuVH6aBACK
HuVH7xBACK
As previously described (Marks, Hoogenboom et al 
Dr Jonathan Chappel, MRC Collaborative Centre
V BASE GOLD database
Source(s) Sequence
Marks CAGGTGCAGCTGGTGCAGTCTGG
V BASE/JAC CAGGTCACCTTGAAGGAGTCTGG 
Marks GAGGTGCAGCTGGTGGAGTCTGG
V BASE/JAC GAGGTGCAGCTGGTGGAG 
Marks CAGGTGCAGCTGCAGGAGTCGGG
V BASE/JAC CAGCTGCAGCTGCAGGAGTC
V BASE/JAC CAGGTGCAGCTACAGCAGTG
V BASE/JAC GAGGTGCAGCTGGTGCAGTCTGG 
Marks CAGGTACAGCTGCAGCAGTCAGG
V BASE/JAC CAGGTGCAGCTGGTGCAATCTGG
1991)
HuJHl-2FOR
HuJH3FOR
HuJH4-5FOR
HuJH6FOR
Marks
Marks
Marks
Marks
TGAGGAGACGGTGACCAGGGTGCC
TGAAGAGACGGTGACCATTGTCCC
TGAGGAGACGGTGACCAGGGTTCC
TGAGGAGACGGTGACCGTGGTCCC
119
Table 2.4 b) 
PCR primers to amplify human VK and V* light chain sequences
HuVkBACK and HuXBACK primers anneal to the 5’ end of the VK and V*. sequences 
respectively.
HuJkFOR and HuJXFOR primers anneal to the 3’ end of the VK and Vx sequences 
respectively.
HuVKlaBACK Marks GACATCCAGATGACCCAGTCTCC
HuVK2aBACK Marks GATGTTGTGATGACTCAGTCTCC
HuVk2xBACK V BASE/JAC GATATTGTGATGACCCAGACTCC
HuVic3aBACK Marks GAAATTGTGTTGACGCAGTCTCC
HuVk3xBACK V BASE/JAC GAAATTGTAATGACACAGT CTC C
HuVK4aBACK Marks GACATCGTGATGACCCAGTCTCC
HuVK5aBACK Marks GAAACGACACTCACGCAGTCTCC
HuVK6aBACK Marks GAAATTGTGCTGACTCAGTCTCC
HuVk6xBACK V BASE/JAC GATGTTGTGATGACACAGTCTCC
HuJk IFOR Marks ACGTTTGATTTCCACCTTGGTCCC
HuJk2FOR Marks ACGTTTGATCTCCAGCTTGGTCCC
HuJk3FOR Marks ACGTTTGATATCCACTTTGGTCCC
HuJk4FOR Marks ACGTTTGATCTCCACCTTGGTCCC
HuJk5FOR Marks ACGTTTAATCTCCAGTCGTGTCCC
HuXIBACK Marks CAGTCTGTGTTGACGCAGCCGCC
HuA.lxBACK V BASE/JAC CAGTCTGTGCTGACTCAGCCACC
HuX2xBACK V BASE/JAC CAGTCTGCCCTGACTCAGCCT
HuX3aBACK Marks TCCTATGTGCTGACTCAGCCACC
HuA,3bBACK Marks TCTTCTGAGCTGACTCAGGACCC
HuX3xBACK V BASE/JAC TCCTATGAGCTGACTCAGCCAC
HuA,4xBACK V BASE/JAC CTGCCTGTGCTGACTCAGCCCCC
HuA,4yBACK V BASE/JAC CAGCCTGTGCTGACTCAATC
HuX5xBACK V BASE/JAC CAGCCTGTGCTGACTCAGCC
H11X6BACK Marks AATTTTATGCTGACTCAGCCCCA
HuX7xBACK V BASE/JAC CAGACTGTGGTGACTCAGGAGCC
HuA,8xBACK V BASE/JAC CAGACTGTGGTGACCCAGGAGCC
HuXlOxBACK V BASE/JAC CAGGCAGGGCTGACTCAGCCACC
HuJX,lFOR Marks ACCTAGGACGGTGACCTTGGTCCC
HuJX2-3FOR Marks ACCTAGGACGGTCAGCTTGGTCCC
HuJX7xFOR V BASE/JAC ACCGAGGACGGTCAGCTGGGTGCC
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Table 2.5 PCR reactions to amplify human VH, VK and Vx sequences
PCRs TO AMPLIFY HEAVY CHAIN VARIABLE REGION (VH)
5’ PRIMER 3’ PRIMER cDNA Polymerase 03/97 Polymerase 10/97
HuVHlaBACK JHFOR mix VH Deep Vent Deep Vent
HuVH2xBACK JHFOR mix Vh Deep Vent AmpliTaq
HuVH3aBACK JHFOR mix Vh AmpliTaq Deep Vent
HuVH3xBACK JHFOR mix Vh Deep Vent Deep Vent
HuVH4aBACK JHFOR mix Vh AmpliTaq AmpliTaq
HuVH4xBACK JHFOR mix Vh AmpliTaq Deep Vent
HuVH4yBACK JHFOR mix Vh Deep Vent Deep Vent
HuVH5xBACK JHFOR mix Vh Deep Vent AmpliTaq
HuVH6aBACK JHFOR mix Vh Deep Vent Deep Vent
HuVH7xBACK JHFOR mix Vh AmpliTaq Deep Vent
PCRs TO AMPLIFY KAPPA LIGHT CHAIN VARIABLE REGION (Vic)
5’ PRIMER 3’ PRIMER cDNA Polymerase 03/97 Polymerase 10/97
HuViclaBACK JkFOR mix V k Deep Vent AmpliTaq
HuVic2aBACK JkFOR mix V k AmpliTaq AmpliTaq
HuV k2xB A C K JkFOR mix V k Deep Vent AmpliTaq
HuVK3aBACK JkFOR mix Vk AmpliTaq AmpliTaq
HuV k3xB A C K JkFOR mix V k AmpliTaq AmpliTaq
HuVK4aBACK JkFOR mix Vk AmpliTaq AmpliTaq
HuVic5aBACK JkFOR mix V k AmpliTaq AmpliTaq
HuVK6aBACK JkFOR mix V k AmpliTaq AmpliTaq
H uV k6 xBACK JkFOR mix V k AmpliTaq AmpliTaq
PCRs TO AMPLIFY LAMBDA LIGHT CHAIN VARIABLE REGION (VA,)
5’ PRIMER 3’ PRIMER cDNA Polymerase 03/97 Polymerase 10/97
HuMBACK JA.FOR mix VA AmpliTaq AmpliTaq
HuMxBACK JAJFOR mix VA AmpliTaq AmpliTaq
HuX2xBACK JA.FOR mix VA AmpliTaq Deep Vent
HuA,3aBACK JA.FOR mix VA AmpliTaq Deep Vent
HuA,3bBACK JAPOR mix VA AmpliTaq Deep Vent
HuA,3xBACK JAJFOR mix VA AmpliTaq AmpliTaq
HuX4xBACK JAJFOR mix VA AmpliTaq AmpliTaq
HuA,4yBACK JAFOR mix VA AmpliTaq AmpliTaq
HuA.5xBACK JA.FOR mix VA AmpliTaq AmpliTaq
HuA,6BACK JAJFOR mix VA Deep Vent Deep Vent
HuA,7xBACK JAJFOR mix VA Deep Vent AmpliTaq
HuX8xBACK JAFOR mix VA AmpliTaq AmpliTaq
HuAJOxBACK JAFOR mix VA AmpliTaq AmpliTaq
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Table 2.6
PCR primers to amplify the library (GGGGS) 3 scFv linker
Regions which should hybridise to the linker are shown in bold type. 
Sources of linkers are noted as follows:
Marks
JAC
KK
VB
Primer
R H uJH l-2
RHuJH3
RHuJH4-5
RH 11JH 6
As previously described (Marks, Hoogenboom et al. 1991) 
Dr Jonathan Chappel, MRC Collaborative Centre 
Dr Katy Kettleborough, MRC Collaborative Centre 
V BASE GOLD database
Source(s) Sequence
Marks
Marks
Marks
Marks
GCACCCTGGTCACCGTCTCCTCAGGTGG
GGACAATGGTCACCGTCTCTTCAGGTGG
GAACCCTGGTCACCGTCTCCTCAGGTGG
GGACCACGGTCACCGTCTCCTCAGGTGG
RHuVklaB ACKFv 
RHuVic2aBACKFv 
RH uV k2xB A C K Fv 
RHuVK3aBACKFv 
R H uV k3xB A C K Fv 
RHuVK4aBACKFv 
RHuVK5aBACKFv 
RHuVK6aBACKFv 
R H uV k6 xB A C K Fv
Marks/KK GGAGACTGGGTCATCTGGATGTCAGATCCGCC 
Marks/KK GGAGACTGAGTCATCACAACATCAGATCCGCC
V B/JAC/KK GGAGTCTGGGTCATCACAATATCAGATCCGCC 
Marks/KK GGAGACTGCGTCAACACAATTTCAGATCCGCC
V B/JAC/KK GGAGACTGTGTCATTACAATTTCAGATCCGCC 
Marks/KK GGAGACTGGGTCATCACGATGTCAGATCCGCC 
Marks/KK GGAGACTGCGTGAGTGTCGTTTCAGATCCGCC 
Marks/KK GGAGACTGAGTCAGCACAATTTCAGATCCGCC
V B/JAC/KK GGAGACTGTGTCATCACAACATCAGATCCGCC
RHuMBACKFv
RHuX 1 xB ACKFv
RHuA2xBACKFv
RHuX3aBACKFv
RHuX,3bBACKFv
RHuX,3xBACKFv
RHuX4xBACKFv
RHuX4yBACKFv
RHuA,5xBACKFv
RHuX6BACKFv
RHuAJxBACKFv
RHuA,8xBACKFv
RHuA,10xB ACKFv
Marks/KK GGCGGCTGCGTCAACACAGACTGAGATCCGCCGCCACCCGAC
V B/JAC/KK GGTGGCTGAGTCAGCACAGACTGAGATCCGCCGCCACCCGAC
V B/JAC/KK AGGCTGAGTCAGGGCAGACTGAGATCCGCCGCCACCCGAC 
Marks/KK GGTGGCTGAGTCAGCACATAGGAAGATCCGCCGCCACCCGAC 
Marks/KK GGGTCCTGAGTCAGCTCAGAAGAAGATCCGCCGCCACCCGAC
V B/JAC/KK GTGGCTGAGTCAGCTCATAGGAAGATCCGCCGCCACCCGAC
V B/JAC/KK GGGGGCTGAGTCAGCACAGGCAGAGATCCGCCGCCACCCGAC
V B/JAC/KK GATTGAGTCAGCACAGGCTGAGATCCGCCGCCACCCGAC
V B/JAC/KK GGCTGAGTCAGCACAGGCTGAGATCCGCCGCCACCCGAC 
Marks/KK TGGGGCTGAGTCAGCATAAAATTAGATCCGCCGCCACCCGAC
V B/JAC/KK GGCTCCTGAGTCACCACAGTCTGAGATCCGCCGCCACCCGAC
V B/JAC/KK GGCTCCTGGGTCACCACAGTCTGAGATCCGCCGCCACCCGAC
V B/JAC/KK GGTGGCTGAGTCAGCCCTGCCTGAGATCCGCCGCCACCCGAC
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Table 2.7 a)
PCR reactions to amplify the linker for incorporation in Vh-Vk scFv
PR IM E R  1
RHuVKlaB ACKFv 
RHuV ic2aBACKFv 
RHuVk2 xBACKFv 
RHuV ic3aBACKFv 
RHuVk3xB ACKFv 
RHuVK4aBACKFv 
RHuVic5aBACKFv 
RHuVic6aBACKFv 
RHuV k6xB  ACKFv
RHuVKlaB ACKFv 
RHuVx2aB ACKFv 
RHuVk2xB  ACKFv 
RHuVtc3aBACKFv 
RHuV k3xBACKFv 
RHuVK4aBACKFv 
RHuVK5aBACKFv 
RHuV ic6aB ACKFv 
RHuV k6xBACKFv
RHuVKlaB ACKFv 
RHuVic2aBACKFv 
RHuVk2xBACKFv 
RHuVx3aB ACKFv 
RHuVk3xBACKFv 
RHuV x4aB ACKFv 
RHuVic5aB ACKFv 
RHuVic6aBACKFv 
RHuVk6xBACKFv
RHuVKlaB ACKFv 
RHuVic2aBACKFv 
RHuVk2xBACKFv 
RHuVK3aB ACKFv 
RH uV k3xBACKFv 
RHuV K4aB ACKFv 
RHuVic5aBACKFv 
RHuVK6aBACKFv 
RHuV k6xB  ACKFv
PR IM E R  2
+ RHuJHl-2
+ RH uJH l-2
+ RHuJHl-2
+ RHuJH 1 -2
+ RHuJH 1-2
+ RHuJH 1-2
+ RHuJH 1-2
+ RHuJH 1-2
+ RHuJH 1-2
+ RHuJH3
+ RHuJH3
+ RHuJH3
+ RHuJH3
+ RHuJH3
+ RHuJH3
+ RHuJH3
+ RHuJH3
+ RHuJH3
+ RHuJH4-5
+ RHuJH4-5
+  RHuJH4-5
+ RHuJH4-5
+ RHuJH4-5
+ RHuJH4-5
+ RHuJH4-5
+ RHuJH4-5
+ RHuJH4-5
+ RHuJH6
+ RHuJH6
+ RHuJH6
+ RHuJH6
+ RHuJH6
+ RHuJH6
+ RHuJH6
+ RHuJH6
+ RHuJH6
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Table 2.7 b)
PCR reactions to amplify the linker for incorporation in V r-Vj, scFv
PRIMER 1 P R IM ER  2
RHuA. IB ACKFv + RHuJH 1-2
RHuMxB ACKFv + RHuJH 1-2
RHuA»2xB ACKFv + RHuJH 1-2
RHuA.3aBACKFv + RHuJH 1-2
RHuA3bBACKFv + RHuJH 1-2
RHuA.3xBACKFv + RHuJH 1-2
RHuMxBACKFv + RHuJH 1-2
RHuA.4yBACKFv + RHuJH 1-2
RHuA.5xBACKFv + RHuJH 1-2
RHuA.6BACKFv + RHuJH 1-2
RHuA.7xBACKFv + RHuJH 1-2
RHuA.8xBACKFv + RHuJH 1-2
RHuA. 1 OxBACKFv + RHuJH 1-2
RHuA.lBACKFv + RHuJH3
RHuAJxBACKFv + RHuJH3
RHu5i2xBACKFv + RHuJH3
RHuA.3aBACKFv + RHuJH3
RHuA3bBACKFv + RHuJH3
RHuA3xBACKFv + RHuJH3
RHu/.4xBACKFv + RHuJH3
RHuA4yBACKFv + RHuJH3
RHu/.5xBACKFv + RHuJH3
RHu/.6BACKFv + RHuJH3
RHu/.7xBACKFv + RHuJH3
RHu/.8xBACKFv + RHuJH3
RHu/.l OxBACKFv +- RHuJH3
RHuA IB ACKFv + RHuJH4-5
RHu/.l xB ACKFv + RHuJH4-5
RHu/.2xBACKFv + RHuJH4-5
RHu/.3aBACKFv + RHuJH4-5
RHuA3bB ACKFv + RHuJH4-5
RHuA3xBACKFv + RHuJH4-5
RHuA4xBACKFv + RHuJH4-5
RHuA4yBACKFv + RHuJH4-5
RHuA5xBACKFv + RHuJH4-5
RHuA6BACKFv + RHuJH4-5
RHuA7xBACKFv + RHuJH4-5
RHuA8xBACKFv + RHuJH4-5
RHuA 1 OxBACKFv + RHuJH4-5
RHuA IB ACKFv + RHuJH6
RHuA lxB ACKFv + RHuJH6
RHuA2xBACKFv + RHuJH6
RHuA3aBACKFv + RHuJH6
RHuA3bBACKFv + RHuJH6
RHuA3xBACKFv + RHuJH6
RHuA4xBACKFv + RHuJH6
RHuA4yBACKFv + RHuJH6
RHuASxBACKFv + RHuJH6
RHuA5BACKFv + RHuJH6
RHuAJxBACKFv + RHuJH6
RHuASxBACKFv + RHuJH6
RHuAl OxBACKFv + RHuJH6
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Table 2.8
PCR reactions to attach VH and VK and V*. sequences to linker DNA
PCR Reaction 1 2 3 4 5 6 7 8 9 10
10xPEBufferII/MgCl2/dNTPs 24 24 24 24 24 24 24 24 24 24
DNA template:
Vh PCR product mix (5 ng/pl)
1 1 0 0 0 0 0 0 0 0
DNA template: 
K linkers 2 ng/pl
1 0 1 1 1 1 1 0 0 0
DNA template: 
A linkers 2 ng/pl
0 1 0 0 0 0 0 1 1 1
Primer VHback mix 4 4 0 0 0 0 0 0 0 0
Primer HulinkFOR 4 4 0 0 0 0 0 0 0 0
Primer HulinkBACK 0 0 4 4 4 4 4 4 4 4
DNA template:
Vk PCR product mix (5 ng/pl)
0 0 1 1 1 1 1 0 0 0
DNA template:
VA, PCR product mix (5 ng/pl)
0 0 0 0 0 0 0 1 1 1
Primer HuJkFOR 0 0 4
K1
4
K2
4
K3
4
K4
4
K5
0 0 0
Primer HuJA-FOR 0 0 0 0 0 0 0 4
A1
4
A2-3
4
A7x
H20 65 65 65 65 65 65 65 65 65 65
AmpliTaq 1 1 1 1 1 1 1 1 1 1
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Table 2.9 a)
5’ Prim ers used to assemble whole scFv and introduce Sfil restriction 
enzyme sites
HuBACKSfi primers anneal to the 5 ’ end of the Vh sequence and introduce a Sfil 
restriction site to the 5’ end o f the scFv
(Sfil, bold type; Ncol,  underlined)
Primer Source(s) Sequence
HuVH 1 aBACKSfi Marks
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGGTGCAGTCTGG
HuVH2xBACKSfi V BASE/JAC
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTCACCTTGAAGGAGTCTGG
HuVH3aBACKSfi Marks
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAGTCTGG
HuVH3xBACKSfi V BASE/JAC
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAG
HuVH4aBACKSfi Marks
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGCAGGAGTCGGG
HuVH4xBACKSfi V BASE/JAC
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGCTGCAGCTGCAGGAGTC
HuVH4yBACKSfi V BASE/JAC
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTACAGCAGTG
HuVH5xBACKSfi V BASE/JAC
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGGTGCAGTCTGG
HuVH6aBACKSfi Marks
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTACAGCTGCAGCAGTCAGG
HuVH7xBACKSfi V BASE/JAC
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGGTGCAATCTGG
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Table 2.9 b)
3’ Primers used to assemble whole scFv and introduce Notl restriction 
enzyme sites
HuFORNot primers anneal to the 3’ end of the VK or sequence and introduce a Sfil 
restriction site to the 5 ’ end o f the scFv
(Notl, bold type)
Primer
HuJk 1 FORNot
GAGTCATTCTCGACTTGCGGCCGCACGTTTGATTTCCACCTTGGTCCC
Source(s) Sequence
Marks
HuJK2FORNot
HuJK3FORNot
HuJK4FORNot
HuJK5FORNot
HuJMFORNot
HuR2-3FORNot
Marks
GAGTCATTCTCGACTTGCGGCCGCACGTTTGATCTCCAGCTTGGTCCC
Marks
GAGTCATTCTCGACTTGCGGCCGCACGTTTGATATCCACTTTGGTCCC
Marks
GAGTCATTCTCGACTTGCGGCCGCACGTTTGATCTCCACCTTGGTCCC
Marks
GAGTCATTCTCGACTTGCGGCCGCACGTTTAATCTCCAGTCGTGTCCC
Marks
GAGTCATTCTCGACTTGCGGCCGCACCTAGGACGGTGACCTTGGTCCC
Marks
GAGTCATTCTCGACTTGCGGCCGCACCTAGGACGGTCAGCTTGGTCCC
HuJ?JxFORNot V BASE/JAC
GAGTCATTCTCGACTTGCGGCCGCACCGAGGACGGTCAGCTGGGTGCC
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Table 2.10
PCR primers designed to anneal to the 5’ and 3’ ends of the library scFv 
to produce long extensions
These primers were designed to hybridise to either the HuVHBACKSfi primer 
series, or the HuJic/^FORNot primer series, giving an extension of 100 bases outside the 
restriction sites. The extended sequences of these primers match the sequences of the 
corresponding flanking sequences of the pHENlH6  phagemid, and are added to the scFv to 
improve the cutting efficiency of the restriction enzymes Sfil and Notl. Restriction sites 
are shown in bold type.
BACKSfi Marks/JAC
ACCATGATTACGCCAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAATACCTATTGCCTAC
GGCAGCCGCTGGAGTCCTCGCAACTGCGGCCCAGCCGGCCATGGCC
FORNot Marks/JAC
GACGTTAGTAAATGAATTTTCTGTATGAGGTTTTGCTAAACAACTTTCAACAGTCTATGCGGCCCCATTCAGA
TCCTCTTCTGAGAGTCATTCTCGACTTGCGGCCGCAC
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CHAPTER 3
CLONING AND SEQUENCING OF MURINE INVASION- 
INHIBITORY MONOCLONAL ANTIBODIES
3.1 Introduction
Around the time of erythrocyte invasion, the MSP-1 polypeptide complex on the 
surface of the invading merozoite undergoes a proteolytic cleavage, leaving only a small 
fragment, MSP-119, remaining on the merozoite surface. Two murine hybridoma mAbs 
specific for MSP-119, mAh 12.8 and mAh 12.10, inhibit erythrocyte invasion (Blackman, 
Heidrich et al. 1990) by blocking the protease-mediated cleavage of MSP-1 (Blackman, 
Scott-Finnigan et al. 1994).
Two questions of major interest arise from these observations. The first question is 
whether such invasion-inhibitory antibodies are made as part of the natural human immune 
response to P. falciparum infection. This project aimed to investigate this question by 
isolating and characterising natural human monoclonal antibodies to MSP-119 from a phage 
display library made from malaria exposed human donors. A second question of particular 
interest is whether antibodies which are invasion-inhibitory in vitro have the capacity to 
modify or prevent P. falciparum infection in vivo. This project aimed to take a step closer 
to answering this question by characterising recombinant human/murine chimeric versions 
of these mAbs which are likely to be suitable for testing in a primate model of 
P. falciparum infection.
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An essential prelude to these studies was the identification, cloning and sequencing 
of the variable regions of the genes encoding the antigen binding sites of mAbs 12.8 and 
12.10, and this work is described in this chapter.
It proved to be difficult to identify all the DNA sequences encoding the variable 
portions of the light and heavy chains of these antibodies, because it was difficult to 
distinguish the mAh 12.10 light chain sequence from a non-functional light chain 
pseudogene also present in the hybridoma. Hybridoma heavy and light chain pseudogenes 
are transcribed and may be partially translated, but are not generally secreted, and so do not 
contribute to the secreted hybridoma antibody. One light chain pseudogene, the MOPC-21 
kappa light chain gene, has been identified in the myeloma cell line from which the 12.8 
and 12.10 hybridomas were derived (Cowan, Secher et al. 1974) and it has been shown to 
be non-functional due to a deletion of 4 nucleotides leading to a frameshift (Walfield, 
Seising et al. 1981). Its sequence has been described (Carroll, Mendel et al. 1988). 
However, another pseudogene was identified in the mAb 12.10 hybridoma, which had not 
been previously described. Misleadingly, this pseudogene in the 12.10 hybridoma was 
almost identical to the functional sequence encoding the mAb 12.8 light chain, and 
consequently the 12.10 pseudogene was initially thought to be the functional gene for the 
mAb 12.10 light chain. To resolve the uncertainty it became necessary to obtain the amino 
acid sequences of the mAb 12.8 and mAb 12.10 heavy and light chains. These sequences 
could not be obtained by N-terminal sequencing, presumably due to N-terminal blocking of 
the proteins, and were eventually obtained by mass spectrometry. In this way the identity 
and sequences of the antigen-specific variable regions of these invasion-inhibitory mAbs 
were finally confirmed.
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3.2 Results
3.2.1 Amplification of DNA encoding the variable regions of mAb 12.8 
and mAb 12.10
DNA encoding the variable regions of the heavy and light chains of mAbs 12.8 and
12.10 was amplified using a single primer (MHC or MKC for heavy and light chains 
respectively) designed to anneal to the constant region of the heavy or light chain, and 12 
different primers (MHV or MKV for heavy and light chains respectively) designed to 
anneal to the different possible leader sequences of the gene. 12 PCR reactions were 
therefore carried out to amplify each heavy and each light chain variable sequence. In 
each case more than one of the 12 reactions gave a product of the expected size. This is 
because the primers amplify not only the functional genes but also the two known 
non-functional pseudogenes (the light chain sequence described above and a heavy chain 
sequence) which are transcribed but not translated, and are derived from the parent 
myeloma cell line (Cowan, Secher et al. 1974). From previous experience, it is known that 
the MHV5 primer anneals to the known heavy chain pseudogene and MKV2 anneals to the 
known light chain pseudogene. After attempting PCR amplification with all the primers, 
the variable region sequences were amplified along with a number of pseudogenes. After 
further work to investigate these sequences (described below) it was possible to determine 
that the following variable region sequences had been amplified with the following primers: 
mAb 12.8 heavy chain MHV7
mAb 12.10 heavy chain MHV9
Parent myeloma heavy chain pseudogene MHV5
mAb 12.8 light chain MKV5
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mAb 12.10 light chain MKV7
Parent myeloma light chain pseudogene MKV2 & MKV7
Previously unknown 12.10 light chain pseudogene MKV5
Figure 3.1 shows the products of the 12 PCR reactions carried out to amplify the variable 
region of the heavy chain of mAb 12.10, in which both the functional gene DNA and the 
parent myeloma pseudogene DNA have been amplified.
3.2.2 Cloning and sequencing of DNA encoding variable regions of mAbs 
12.8 and 12.10
The mAb 12.8 and mAb 12.10 heavy and light chain variable region DNA products 
were cloned into the pCR™2.1 vector (Invitrogen) and sequenced using the Perkin Elmer 
ABI Prism 377 DNA Sequencer. The variable regions of both the heavy and the light 
chains differ significantly in DNA sequence between the two mAbs, which is consistent 
with the finding that they bind non-identical epitopes on the MSP-119 molecule (Chappel 
and Holder 1993).
Figure 3.2 shows the DNA and amino acid sequences of the variable regions of the 
heavy chains and light chains of mAb 12.8 and mAb 12.10, with the two mAbs compared.
3.2.3 A new non-functional light chain pseudogene found in the 
hybridoma 12.10
The myeloma cell line from which the hybridomas were made, P3/NS-l/l-Ag4-l 
(NS-1), is derived from the MOPC-21 plasmocytoma (McBride, Newbold et al. 1985), 
which is known to contain a light chain pseudogene, the MOPC-21 pseudogene, whose
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sequence is known (Carroll, Mendel et al. 1988). This pseudogene is transcribed, but is 
non-functional, having a frameshift in the third complementarity-determining region 
(CDR3). The MOPC-21 pseudogene is not secreted and so does not contribute to the 
secreted hybridoma antibody. The primers MKV2 and MKV7 are known from previous 
experience to anneal to the MOPC-21 pseudogene. However, the mAb 12.10 hybridoma 
was found to contain a further light chain pseudogene, which amplified with primer MKV5. 
This pseudogene also has a frameshift in CDR3. However, it bears a great similarity in 
sequence to the functional light chain of the mAb 12.8 hybridoma, which was derived from 
the same series of fusion experiments. Because of this similarity, it was initially assumed 
that this frameshifted gene was the functional gene, and that the frameshift represented 
either an artefact of the PCR amplification or of the DNA sequencing. Repeated 
amplifications and sequencing, however, showed a consistent frameshift in this gene. 
Sequencing of the PCR product obtained with primer MKV7 (and previously assumed to be 
the MOPC-21 pseudogene) showed it to be another completely different light chain gene in 
the 12.10 hybridoma, with an open reading frame throughout. With two candidate light 
chain DNA sequences to choose between, the functional DNA sequence was then identified 
by mass spectrometry of mAb 12.10 itself and mAb 12.10 Fab. There was no evidence on 
mass spectrometry of any expression of the mAb 12.10 pseudogene which amplified with 
primer MKV5, whereas the expressed product of the light chain region amplified with 
primer MKV7 was identified, confirming this as the variable region sequence of the 
functional gene.
Figure 3.3a) shows a comparison between the variable region DNA sequences of
the mAb 12.10 functional light chain gene and light chain pseudo gene, which are very
different from each other. Figure 3.3a) also shows the close similarity between the
functional mAb 12.8 light chain variable region and the mAb 12.10 non-functional
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pseudogene variable region. Figure 3.3b) shows the same comparisons, translated into 
amino acid sequences.
3.2.4 Attempted confirmation of mAb 12.8 and mAb 12.10 heavy and 
light chain amino acid sequences by N-terminal sequencing
Primarily because of the difficulty in distinguishing the mAb 12.10 light chain 
functional gene from the pseudogene, an attempt was made to determine the amino acid 
sequences of the variable regions of mAbs 12.8 and 12.10 by N-terminal sequencing. 
Approximately 2 pg of each of mAb 12.8 and mAb 12.10 was used and the heavy and light 
chains were resolved by SDS-PAGE using CAPS buffer as described in section 2.1.4, and 
then blotted onto an immobilon membrane and stained with Coomassie blue. The 
transferred protein was sent to Dr Arthur Moir of the Department of Molecular Biology and 
Biotechnology at the University of Sheffield for N-terminal sequencing based on the 
Edman degradation reaction. It did not prove possible to obtain any amino acid sequence 
information, and it was presumed that this was because of N-terminal blocking of the 
proteins. In case this blocking was due to the presence of N-terminal pyrrolidone 
carboxylic acid residues, an attempt was made to remove any such groups by incubating the 
proteins with pyroglutamate aminopeptidase. The treated proteins were then processed as 
before. Despite this measure, again no sequence information was obtained.
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3.2.5 Confirmation of mAb 12.8 and mAb 12.10 heavy and light chain
amino acid sequences by mass spectrometry
Since protein sequence information could not be obtained by N-terminal 
sequencing, it was decided to determine the amino acid sequences of the mAbs 12.8 and
12.10 by mass spectrometry. The proteins were processed as described in section 2.1.5, 
and mass spectrometry was carried out with Dr Steve Howell of the Division of Protein 
Structure at the National Institute for Medical Research. From candidate DNA sequences, 
predictions of expected tryptic fragments and their masses (as determined uncharged and 
charged) were made. Figure 3.4 shows such a prediction of the tryptic fragments 
anticipated from the mAb 12.10 light chain sequence amplified with the primer MKV7, 
which proved to be the functional gene. The figure also shows the actual mass 
spectrogram of the tryptic fragments obtained by digesting the light chain band of the mAb
12.10 Fab fragment. As an example, a peak is seen at mass 543.8 Da, corresponding to the 
predicted tryptic fragment T5, doubly charged ([M+2H] in Figure 3.4). This fragment was 
accordingly isolated in the mass spectrometer, and its constituent ions analysed to 
determine the amino acid sequence. Figure 3.5 shows the predicted masses of the 
fragment ions, or “daughter ions”, of tryptic fragment T5, and the same figure shows the 
actual “daughter ion” spectrum, whose peaks correspond almost precisely to the predicted 
sizes, thus confirming the amino acid sequence.
Other tryptic fragments from both mAbs were analysed in the same way. By this 
method it became possible to identify the functional gene for the 1 2 . 1 0  light chain, and also 
to confirm the other DNA sequences.
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Figure 3.6 shows the amino acid sequences as deduced from the DNA sequences, 
with underlining of those fragments which have been additionally confirmed at the protein 
level by mass spectrometry.
3.3 Discussion
The variable regions of the IgG heavy and light chains of the murine hybridoma 
mAbs 12.8 and 12.10 have now been cloned and sequenced. The amino acid sequences of 
the antigen-binding sites of these invasion-inhibitory IgGs are therefore now known. 
Although a non-functional light chain pseudogene has been identified in mAb 12.10 which 
is almost identical to the functional gene in mAb 12.8, the functional gene DNA sequences 
have been validated by mass spectrometry of the mAbs themselves. Much of the amino 
acid sequence of the mAb variable regions has been independently determined and 
confirmed in this way. The two invasion-inhibitory mAbs show marked differences in 
their amino acid sequences, both in the heavy and the light chains. This is consistent with 
previous observations that the two mAbs bind to non-identical epitopes in MSP-119, and 
demonstrates that two very different antibody variable region sequences can both have 
invasion-inhibitory properties.
It is assumed that the hybridoma 12.8 functional light chain gene and the hybridoma
1 2 . 1 0  light chain pseudogene are derived from the same original light chain gene, as the 
two hybridomas were made in the same series of fusion experiments (McBride, Newbold et 
al. 1985). Presumably the gene remained functional in hybridoma 12.8, but through a 
frameshift became non-functional in hybridoma 1 2 .1 0 , in which there was another 
functional light chain gene contributing to the secreted antibody instead. It is possible, 
however, that this pseudogene is was already present in some precursor cell lines from
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which these hybridomas were derived. If this is the case, this study’s identification of this 
pseudogene may prove useful in the future. Knowledge of the pseudogenes present in a 
hybridoma is very useful when trying to identify and amplify antibody variable region 
sequences for the purposes of engineering antibodies into chimeric or humanised form. 
Various methods have been described for neutralising any pseudogenes which may 
interfere with this process (Nicholls, Johnson et al. 1993) (Cochet, Martin et al. 1999).
This work also underlines the potential usefulness and efficiency of sequencing 
proteins by mass spectrometry when DNA sequencing and N-terminal protein sequencing 
fail to resolve ambiguities.
137
Figure 3.1
PCR amplification of mAb 12.10 heavy chain variable region sequence
One PCR primer was used to anneal to the constant region of the heavy chain 
(primer MHC) and 12 different primers were used to anneal to the different possible leader 
sequences (primers MHV1-MHV12). PCR reactions were run on a 1% agarose gel.
Lanes 1 to 12 contain PCR reactions carried out with primers MHV1 to MHV12 
respectively. Bands of the expected size (approximately 450 base pairs) are seen in lanes 5 
and 9. From previous experience, primer MHV5 is known to amplify the parent myeloma 
heavy chain pseudogene, which is transcribed but not translated. The product in lane 5 
was therefore disregarded, and the product in lane 9 was purified, cloned and sequenced, 
and found to be the variable region of the mAb 12.10 heavy chain as expected.
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Figure 3.2a)
DNA sequences of mAb 12.8 and mAb 12.10 heavy and light chain
variable region sequences
Above is shown a comparison between the heavy chain variable region DNA 
sequences of mAb 12.8 (12.8VH) and mAb 12.10 (12.10VH).
Below is shown a comparison between the light chain variable region DNA 
sequences of mAb 12.8 (12.8V k) and mAb 12.10 (12.10V k).
Identical nucleotides in the two heavy chains are highlighted in blue. Identical 
nucleotides in the two light chains are highlighted in green. There are significant 
differences between the two mAbs in both the heavy and light chain sequences.
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Figure 3.2a)
mAb 12.8 and mAb 12.10 heavy chain variable region DNA sequences
 1 0   2 0  3 0  4 0    5 0  6 0
1 2 .8 V H  C A G A TC CA C T TG G TG C A G TC TGGACCTGAG CTGAGGAAGC CTGGAGAGAC AGTCA A G A TC
1 2 .1 0 V H  CA G G TC CA A C TGCAGCAGCC TGGGGCTGAA CTG G TG A A G C CTG G G G C TTC  AGTGAAGCTG
7 0  8 0  9 0  1 0 0  1 1 0  1 2 0
1 2 .8 V H  TCCTG CA A G G  C T TC TG G G TA  TA C C T TC A C A  A A C TA TG G A A  TGAAGTG GGT GAAGCAGGAT
1 2 .1 0 V H  TCCTG CA A G G  C T TC TG G G TA  C A C C TTC A C C  A G C TA C TG G A  TA CA CTG G G T GAAGCAGAGG
1 3 0  1 4 0  1 5 0  1 6 0  1 7 0  1 8 0
1 2 .8 V H  A | a | H a I g |  GI P Gl 9 CTG§  | S Ct AGAi CT ijT C ljfflA G A  G C C A |C A p|g
1 2 .1 0 V H  C § t |@ 1 c |a $  | c c | t G ^ H  GATTffA G A j ^ i f T T C f T A  a J a A c H tC G  TAGTfATJAT
1 9 0  2 0 0  2 1 0  2 2 0  2 3 0  2 4 0
1 2 .8 V H  GCTGATGACT TCAAGGGACG GTTTGCCTTC TCTTTGGAAA CCTCTGCCAC CACTGCCTAT
1 2 . i o v h  a a O | g a | a |  ^ H J a J c a a  | g c c a | a c | g  a C tg T a < |a cA  a a H c t | H g
2 5 0  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
1 2 .8 V H  TTGCAGATCA ACAACCTCAA AAATGAGGAC ATGGCTACAT A T T T C T G T - -  - - G  TA-
1 2 .1 0 V H  ATGCAACTCA GCAGCCTGAC A : 'TGAGGAC TCTGCGGTCT ATTTCTGTGC AAGAAACTGG
3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
1 2 .8 V H  CAGTCGG---------- T 7. 71, CTGGGGCCAA G G C A CCA CTC T C A C A G TC TC  CTCA
1 2 .1 0 V H  G C cJ a c: 73: T 1TCGATGT CTGGGGCGCA GGGACCACGG TC A C C G TC TC  CTCA
mAb 12.8 and mAb 12.10 light chain variable region DNA sequences
1 0  2 0  3 0  4 0  5 0  6 0
1 2  . 8Vk 
1 2  . IOVk
AGATTGlTC |CACCCAGT§ fflCAG ClAfflj [ATGT|TGj||E |T C C ® g G M  GAA@GTC?)C'S
4 4 D B g ^  I c a c c c a g t c  1 | a c a a | t1H  |a t  g t c c a  c a t  I aa tO T a®
___________ 7 0  8 0  9 0  1 0 0  1 1 0  1 2 0
1 2  . 8Vk
1 2 . IOVk
ATGACCTGCi G T ^ @ « C «  | A l - | A | - g §  AfljTACAljHcffl —  CTGGTACi i G g g j A G f f l
ATCACCT<§C& A G G fe M -S I  I cJ aI gI gP  T jC T G c B lf l  G c f i S » l |
1 3 0  1 4 0  ____________ 1 5 0 ___________ 1 6 0  1 7 0  ___________ 1 8 0
fflBlCACCOTc CCCA&AAGAT gU | T G A  CAgfflfflAfflA i T l G C T T g i  GAGTCCCTGC
s^ A C A a B t  B B . f f l B c i f c  TGATTTACTC G q C A T c J lfc  | g | t a c a | H  g a g t c c c t g a
1 9 0  2 0 0  2 1 0  2 2 0  2 3 0  2 4 0
TCGCTTlAGffl mmmM  CTGGGACCTC p A T T g g c I g  ^/tATCAGCA GCATGGA^C
T C G C T y G cl S M I B I M aiE CTGGGACGGA B t CaB tO  I tgI gcS I ^
2 5 0  2 6 0  _________  2 7 0  2 8 0  2 9 0  3 0 0
1 2 . 8Vk TG AAGA7 ;CT G C C A -7 'T T A T  TA C T G C C A T C  AGCGGAGTAG T T A C C C A T T C  A C G TTC G G C Tg g g g T c g j c f f i - ' t t a t  ® £ g | c l g T j  I gS g g a g ta g  | A C |§ A T i§  a c g t t c g g
1 2 .  IOVk TG A A G iJ-cH  |G ® G T |rT A T  TACTG3CAg| JaIaTTC^TAG |aC T ® G C T C  ACGTTCGG
3 1 0  3 2 0
1 2  . 8Vk 
1 2 .  IOVk i i « «  n »  %
Figure 3.2b)
Amino acid sequences of mAb 12.8 and mAb 12.10 heavy and light chain
variable region sequences
Above is shown a comparison between the heavy chain variable region amino acid 
sequences of mAb 12.8 (12.8VH) and mAb 12.10 (12.10VH). Identical residues within the 
framework regions of the two heavy chains are highlighted in pink. Identical residues 
within the complementarity-determining regions (CDRs) of the two heavy chains are 
highlighted in blue.
Below is shown a comparison between the light chain variable region amino acid 
sequences of mAb 12.8 (12.8V k) and mAb 12.10 (12. IOVk). Identical residues within the 
framework regions of the two light chains are highlighted in green. Identical residues 
within the complementarity-determining regions (CDRs) of the two light chains are 
highlighted in yellow.
Marked differences are seen in all three CDRs of both the heavy and the light 
chains, which is consistent with the observation that they bind to different epitopes within 
MSP-I19.
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Figure 3.2b)
mAb 12.8 and mAb 12.10 heavy chain variable regions
10  2 0  3 0  40  50
1 2 .8 V H  QIHLV'QSGPE L KPG VK SCKASGYTFT NYGMNWVKQD rGKGLKWMGW 
1 2 .1 0 V H  | vq | q| p| a|  I vB a s I l  SCKASGYTf |  s | w i H f f e ^ R  P § qH e| i | e
70  80  90  1 0 0  1 1 0
1 2 .8 V H  ADDffigGRFAF SLETlATTAY lJ iN N I k n O T  —  S— V I | nB q
1 2 .1 0 V H  NEkJ B s KATL T V D K |S S p B  H ILSSI TSH  s ( \ ^ | | a RNW AYWFFIvH a
mAb 12.8 and mAb 12.10 light chain variable regions
10  2 0  3 0  40  50
1 2 .8 V K  Q M fL jM P A I ■ a | p | E K | T  R ff lS A S S S I -  D Y M H ffl® K | jTSggRW;§iD
1 2 .  IOVK dH r® ( hKF B l J l | D R g S  IQKASQDVS S A V A ^ Q | r|  I o f l H LIf l S
7 0  80  90 1 0 0
1 2 .8 V K  RF: GSGSGT3 YSLTISSK  
1 2 . IOVK RFAGSGSGTD FTFTISSV
E l  U PA lT l i g HQ R SSY PFTfflS  G T K L E lR
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Figure 3.3a)
DNA sequences of hybridoma 12.10 light chain pseudogene and mAb 12.8 
and mAb 12.10 functional light chain variable region sequences
Above is shown a comparison between the DNA sequence of the hybridoma 12.10 
light chain pseudogene (12.10V kT ) and the mAb 12.10 light chain variable region 
(12.IOVk). Identical nucleotides are highlighted in blue. The hybridoma 12.10 light 
chain pseudogene was found when the PCR product amplified with primer MKV5 was 
cloned and sequenced. This pseudogene is distinct from the known MOPC-21 kappa light 
chain pseudogene, also present in the hybridoma and derived from the parent 
plasmocytoma, which has already been described. The 12.IOVk pseudogene is 
transcribed, but there is a frameshift at base pair 282 (residue 95), where there is a single 
base pair deletion. This pseudogene is apparently not secreted, as mass spectrometry of 
mAb 12.10 showed no evidence of an expressed product. It is quite different in sequence 
from the functional mAb 12.10 light chain variable region, 12.IOVk.
Below is shown a comparison between the DNA sequence of the hybridoma 12.10 
light chain pseudogene variable region (12.10kvF) and the DNA sequence of the mAb 12.8 
light chain functional variable region (12.8V k). Identical nucleotides are highlighted in 
green. The two sequences are almost identical. The 12.8 and 12.10 hybridomas were 
made in the same series of fusion experiments, and presumably the two sequences derive 
ultimately from the same parent light chain gene.
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Figure 3.3a)
Hybridoma 12.10 V k  pseudogene and mAb 12.10 V k  variable region
1 2 . IOVkV 
1 2 .  IOVk
1 2 . IOVkV 
1 2 . 1 0 V k2
1 2 . IOVkV 
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120
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1 8 0
flj^f&CACCWC I p C l B A G C T  G G A T T llT G A  C A | g |g j A |A  J l l G C T T | f |  g
P I a c a a S s t  t d m J f l c T A C  t M t t ^ c t c  g g | B B | t | c  | g | t a c a ^ 9  p
1 9 0  __________2 0 0
G | pCAGTGGGT 
C f pGCAGTGGAT
A G T C C C T G T
G A G TCC CTG A
T C G C TTG A
T C G C T TC G
210 I
CTGGGACCTCJ
ctgggacggaI
2 3 0
p i A T T ® C | g  JG A A T C A G C A  GCATGC 
T l T T C A g T H  p C A T C A G d J  | t g TG(
2 5 0  2 6 0  2 7 0
TG A A G A T G I®  I t i g f t - C T T A T  U  S i
TGAAGA-CKS i G ^ G T f T A T  TA C T
3 1 0  __________ 3 2 0
AAGCTGGAAA TCAAA 
AAGCTGGAGC TGAAA
2 8 0  
iG G A G jg G  GTJ
Ia t t c M -  GTAC
2 4 0
3 0 012 9 0
:acgt ggacgttcgg 
:-cgc TcACGTTCGG
Hybridoma 12.10 Vk pseudogene and mAb 12.8 Vk
1 0  2 0  30
1 2 . IOVkV 
1 2  . 8Vk
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Figure 3.3b)
Amino acid sequences of the hybridoma 12.10 light chain pseudogene and 
mAb 12.8 and mAb 12.10 functional light chain variable regions
Above is shown a comparison between the amino acid sequences of the hybridoma
12.10 light chain pseudogene (12.10VkvF) and the mAb 12.10 light chain variable region 
(12. IOVk). Identical residues are highlighted in blue.
Below is shown a comparison between the amino acid sequence of the hybridoma
12.10 light chain pseudogene variable region (H.IOk'F) and the amino acid sequence of the 
mAb 12.8 light chain functional variable region (12.8Vk). Identical residues are 
highlighted in blue. The two sequences are almost identical. The frameshift at base pair 
282 (residue 95) in the hybridoma 12.10 pseudogene is represented in this translation by the 
letter X.
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Figure 3.3b)
Hybridoma 1 2 .1 0  pseudogene translation and mAb 1 2 .1 0  V k  variable region
10 20 30 ______40 50 60
1 2 .  IOVkV qW tB B p AT g A | P ^ K ® T  M f g S g T S S I -  S Y M H p p fK f  | T g g | S W l ] D  i j K L A s M j v
1 2 . IOVk d iv m t q s h k f  m s t s i g d r v s  i t c k a s q d v s  s a v a w y q q r p  g q s p k l l i y s  a s y r y t g v p d
7 0 80 90 100
1 2 . i o v k v  r f s g s g s g t I s  Y siJK g|fiM E j ■ a | t 9 B h S  r I r y B x w ^ I
1 2 . IOVk RFAGSGSGTD F T F T IS S V Q A  EDLAVYYCQQ H S S T P L -T F G
Hybridoma 1 2 .1 0  pseudogene translation and mAb 1 2 .8  V k  variable region
10 20 30 40
1 2 . IOVkV 
1 2  . 8 V k
QIVLTQSPAI MSASPGDKVT MTCSATSSIS JMHWYQQKPG TSPKSWIYDT SKLASGVI 
QIVLTQSPAI MSASPGEKVT MTCSASSSID |MHWYQQKPG TSPKRWIYDT SKLASGVI
70 80 90
1 2 . IO V kV  
1 2  . 8 V k
FSGSGSGTSY SLTISSMEAE 
FSGSGSGTSY SLTISSMEAE
DAATYYCHQR
DAATYYCHQR
100
?Rj i xwi H G
Is H f - t f J s
3IKXJ1 I  
3TKLEI K
Figure 3.4
Mass spectrometry of mAbs: Predicted tryptic fragments and mass 
spectrogram of 12.10 Fab light chain
Above are shown the predicted fragments from a tryptic digestion of the mAb
12.10 light chain variable region. Fragments are numbered T1 to T8 according to their 
position in the light chain, T1 being at the N-terminus. The predicted apparent masses for 
each fragment are given below as they would appear by mass spectrometry if the fragments 
had one, two or three positive charges ( [M+H], [M+2H] & [M+3H] respectively)
Below is shown the mass spectrogram of the Fab 12.10 light chain. As an example, 
a peak with apparent mass 543.8 Da is highlighted with an arrow. This peak corresponds 
to the predicted tryptic fragment T5 (LLIYSASYR) with two positive charges (T5 [M+2H], 
predicted mass 543.3).
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Figure 3.4
Fragment Residues Sequence
T8 104 - 107 LELK
T3 19 - 24 VSITB K.
T6 55 - 61 YTGVP DR
T2 10 - 18 FMSTS IGDR
T1 1 - 9 DIVMT QSHK
T5 46 - 54 LLIYS ASYR
f4 25 - 45 ASQDV SSAVA WYQQR PGQSP K
T7 62 - 103 FAGSG SGTDF TFT IS SVQAE DLAVY YBQQH SSTPL TFGAG TK
Fragment [M+H] [M+2H] [M+3H]
T8 502.32 251.67 168.11
T3 547.35 274.18 183.12
T6 807.40 404 .20 269.81
T2 1013.47 507.24 338.50
T1 1058.53 529.77 353 .52
T5 1085.60 543.30 362.54
T4 2290.12 1145.56 764.05
T7 4274.02 2137.51 1425.35
S #  1-40 RT 
T: + p m s
100-1
0 01-1.19 AV 40 SM: 7B NL 3.59E6
70-
ra 60-
400
981 0
<  50
1146.5
543
1316.7
1082.3
1244.2
1431.8
600
' I " " '  " I
800 1000 1200
J4S0.1 1640.4 17877
m/z
Tryptic fragment 5 
[M+2H] 543
N.I.M.R. London. NW7 1AA.
Jennings 2 3/9/01 NC
Figure 3.5
Mass spectrometry of mAbs: predicted “daughter ions” from tryptic 
fragment 5 of 12.10 Fab light chain, and mass spectrogram of fragment 5
Above are shown the predicted masses of every possible “daughter ion”, or 
fragment, of the tryptic peptide T5 as those “daughter ions” would appear if they had a 
single positive charge.
Below is the mass spectrogram of the tryptic peptide T5 after isolation of T5 from 
the other tryptic fragments, followed by breakdown of T5 into all possible constituent 
“daughter ions”. Peaks are seen with masses corresponding almost precisely to the 
predicted “daughter ion” masses, thus confirming the amino acid sequence of the peptide as 
predicted by the candidate DNA sequence.
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Tryptic fragment 5 Monoisotopic Mass -  1084.59 Residues 1 - 9
Fragment ions: Monoisotopic m/z ra tio s  with 1 p o s it iv e  charge
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Figure 3.6
Amino acid sequences of 12.8 & 12.10 heavy and light chains as 
determined by mass spectrometry
The amino acid sequences of the variable regions of the mAb 12.8 and mAb 12.10 
heavy and light chains, and the predicted amino acid sequence of the hybridoma 12.10 light 
chain pseudogene, are shown. Underlining denotes tryptic fragment peptide sequences 
confirmed by mass spectrometry. Tryptic fragments identified and sequenced by mass 
spectrometry are listed after each sequence. Red (heavy chains) or green (light chains) 
residues in the sequences denote residues in the complementarity-determining regions 
(CDRs). Asterisks (*) denote ends of tryptic fragments. J denotes pyroglutamic acid, 
with a mass 17 Da less than glutamine). B denotes cysteine residues which have been 
altered to carboxyamidomethyl-cysteine through treatment of the protein with 
iodoacetamide.
It can be seen that a substantial proportion of the DNA sequences of the variable 
regions of both mAbs 12.8 and 12.10 heavy and light chains have been independently 
confirmed by amino acid sequencing. In the case of the variable region of the light chain 
of mAb 12.10, mass spectrometry has identified all but one of the peptides predicted from 
the open reading frame DNA sequence obtained with the PCR primer MKV7. None of the 
peptides predicted from the frameshifted DNA sequence obtained with PCR primer MKV5 
are identified, thus clearly establishing that the sequence obtained with the PCR primer 
MKV7 is derived from the functional gene, whereas the frameshifted sequence obtained 
with PCR primer MKV5 is derived from a non-functional pseudogene which does not 
contribute the mAb 12.10.
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Figure 3.6
mAb 128 heavy chain variable region
JIHLV QSGPE L R *K PG  E T V K * I  SBK*AS GYTFT NYGMN WVK*QD T G K *G L  K*WMGW IN T F S  
GEPTY ADDFK* GR*FAF SLETS ATTAY LQINN LK*NED M A TYF BV Q SV  ID N W G  Q G T T L  T V S S  
Tryptic fragments identified are T1 (mass 1359 [M+H]) T4 (mass 1739 [M+H]) T7 (mass 2265 [M+H]) and 
T9 (mass 2232 [M+H])
mAb 12.8 light chain variable region
JIVLT QSPAI MS ASP GEK*VT M TB SA  S S S I D  YMHWY QQKPG TSPK*R* W IY D T  S K ’ L A S
GVPAR* FSGSG SGTSY SLTIS SMEAE DAATY YBHQR S S Y P F  TFGSG TK*LEI K 
Tryptic fragments identified are T1 (mass 1840 [M+H]), T2 (mass 2991 [M+H]) T4 (mass 912 [M+H]) T5 
(mass 770 [M+H]) T6 (mass 3264 [M+H]) T7 (mass 1279 [M+H]) and T8 (mass 502 [M+H])
mAb 1210 heavy chain variable region
JVQLQ QPGAE LVKPG ASVK*L SBK*AS GYTFT SY W IH  WVK*QR PG Q G L E W IG E  I I P N N
G R * S N Y  N E K * F K *  S K * A T L  T V D K *S  S S T A Y  M Q LSS L T S E D  SA V Y F  BAR*NW A YW FF DVWGA 
G T T V T  V S S
Tryptic fragments identified are T1 (mass 1960 [M+H]) and T3 (mass 1846 [M+H]) 
mAb 1210 light chain variable region (encoded by functional gene)
D IV M T  Q S H K * F  M S T S I  G D R *V S  I T B K A  SQ D V S SAVAW YQQRP GQSPK* LLIYS ASYR*Y
G V PD  R*FAGS GSGTD FTFTI SSVQA EDLAV YYBQQ H S S T P  LTFGA GTK*LE LK 
Tryptic fragments identified are T4 (mass 2290 [M+H], 1146 [M+2H]) T5 (mass 1086 [M+H], 543 [M+2H]) 
and T7 (mass 4274 [M+H])
Hybridoma 12.10 light chain variable region (encoded by pseudogene)
Q IV L T  Q S P A I  M S A S P  G D K *V T  M TBSA  TYMHSSIS WY QQK PG  T S P K * S  W IY D T S K * L A S
G V P V R * F S G S G  S G T S Y  S L T I S  SM EAE DAATY YBH QR* SR*YPX X X FG G  G IK * L E  I K *
No predicted tryptic fragments found
CHAPTER 4
SINGLE CHAIN VARIABLE FRAGMENTS AND CHIMERIC 
ANTIBODIES DERIVED FROM INVASION-INHIBITORY MURINE 
MONOCLONAL ANTIBODIES
4.1 Introduction
Once the DNA sequences of the variable regions of mAb 12.8 and mAb 12.10 were 
determined, a decision was made to construct single chain variable fragments (scFv) of 
these antibodies. This was done for a number of reasons.
Firstly, it was important to determine whether scFv versions of these 
invasion-inhibitory mAbs would retain the ability to inhibit erythrocyte invasion. One 
long-term aim of this project was to isolate novel human invasion-inhibitory anti-MSP-li9 
antibodies from the phage display libraries. Any such antibodies obtained from the phage 
display libraries would be obtained initially as scFv fragments. It was therefore important 
to know whether such scFv fragments could be expected to retain any invasion-inhibitory 
activity present in the parent antibodies. A previous study (Guevara Patino 1997) showed 
that Fab and F(ab')2 fragments of mAb 12.10 do not retain the ability of the parent antibody 
to inhibit both MSP-1 secondary processing and erythrocyte invasion. It was anticipated 
therefore that scFv 12.10 would be unlikely to retain invasion-inhibitory activity, but this 
was not certain. Nor was it possible to anticipate the likely activity of a scFv version of 
mAb 12.8, since at this time no Fab fragments of mAb 12.8 had ever been made or studied.
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Secondly, if antibodies in scFv format will not retain the invasion-inhibitory activity 
of the parent antibodies, then techniques will be required to restore invasion-inhibitory 
activity to scFvs. Such techniques will be needed if scFvs obtained by panning the 
libraries are to be screened for potential invasion-inhibitory activity. Any technique for 
restoring invasion-inhibitory activity would need to be tested on a scFv version of a known 
invasion-inhibitory antibody such as mAb 12.8 or mAb 12.10.
Preliminary experiments were done to test a possible method of restoring 
invasion-inhibitory activity to scFv 12.10. This method rests on the assumption that the Fc 
portion of the antibody, whose loss leads to loss of biological activity in the case of mAb
12.10, is essential because its size is required to contribute some steric effect required for 
the inhibition of secondary processing. Possible techniques to restore invasion-inhibitory 
activity might therefore depend on increasing the mass of the scFv molecule until it 
approximates to the mass of a whole antibody. Engineering scFv back into whole 
antibodies is time consuming and labour intensive, and so is not suitable for screening large 
numbers of scFv quickly. An alternative way of increasing the size of scFv 12.10 was 
attempted. The scFv was adapted to express as a fusion with two albumin-binding 
domains so that two albumin molecules (molecular weight 68 kDa) could be bound to the 
scFv to increase its mass to approximate to the mass of a whole antibody. The albumin- 
binding domain was originally identified in the streptococcal protein G (Nygren, 
Ljungquist et al. 1990) and has been used to indirectly immobilise proteins to solid phase 
via albumin for the panning of a phage display library (Grob, Baumann et al. 1998). After 
attempting to modify scFv 12.10 in this way, an invasion assay was performed with the 
modified scFv to see if invasion-inhibitory activity was restored.
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Finally, the DNA sequences obtained for the variable regions of mAb 12.8 and mAb
12.10 were used to construct recombinant mouse/human whole antibodies. The chimeric 
antibodies were made by Eilish Cullen of the Antibody Engineering Group, MRC 
Collaborative Centre, Mill Hill, London. As part of this project, these antibodies were then 
tested for their ability to bind to recombinant and native antigen and inhibit erythrocyte 
invasion. This work was done for three reasons. Firstly, and most importantly, 
demonstrating that whole antibodies constructed from these sequences can inhibit 
erythrocyte invasion offers unequivocal proof that the variable region sequences described 
in the previous chapter do indeed define the invasion-inhibitory antigen-binding sites of the 
antibodies. Secondly, recombinant versions of mAbs 12.8 and 12.10, with known 
sequences, enable production of antibodies of guaranteed standardised specificity. This 
should be helpful in standardising the degree of biological activity present in different 
batches of mAbs 12.8 and 12.10. Such standardisation should be useful, since mAbs 12.8 
and 12.10 are routinely used as the positive controls in erythrocyte invasion assays, and the 
level of biological activity in different batches of antibody derived from hybridoma cell 
cultures has appeared to vary in the past. Thirdly, to demonstrate the potential biological 
relevance of invasion-inhibitory antibodies, they should be tested for their ability to modify 
or prevent P. falciparum infection in an animal model such as the Aotus monkey. 
Recombinant antibodies would be suitable for this purpose. They are antibodies of known 
sequence and specificity, and can be readily produced to the high quality needed for use in 
animals. Chimeric mouse/human antibodies should be particularly suitable for this 
purpose, since they contain human rather than murine constant regions, and human 
sequences would be anticipated to be less potentially immunogenic than mouse sequences 
when injected into primates.
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4.2 Results
4.2.1 Construction of scFv DNA from the variable region sequences of 
mAbs 12.8 and 12.10
The variable region sequences obtained from mAbs 12.8 and 12.10 described in the 
previous chapter were used to construct DNA encoding single chain variable fragments 
(scFv) of these antibodies. The scFvs were constructed by a three-stage process involving 
three successive PCR reactions, as described in section 2.3.1. The process of construction 
of the scFvs is illustrated diagrammatically in Figure 2.1. The PCR product of the PCR 
creating the full-length scFv 12.8 DNA sequence is shown in Figure 4.1.
4.2.2 Repair of scFv 12.10 DNA sequence by site-directed mutagenesis
On sequencing the DNA encoding scFv 12.10, an unwanted single base pair 
mutation was found encoding the substitution of proline for serine at position 17 of the first 
framework region of the heavy chain. This was corrected using PCR to produce a site 
directed mutagenesis back to the correct sequence. The method is described section 2.3.2 
and illustrated in Figure 2.2. DNA sequencing confirmed that the mutation had indeed 
been removed.
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4.2.3 DNA sequences of scFv 12.8 and scFv 12.10
The scFv 12.8 and scFv 12.10 sequences were cloned into the vector pCR™2.1 
(Invitrogen) for DNA sequencing. Sequencing was carried out using a Perkin Elmer ABI 
Prism 377 DNA Sequencer as described. The DNA sequences and translations of scFv
12.8 and scFv 12.10 are shown in Figure 4.2.
4.2.4 Expression of scFv 12.8 and scFv 12.10
scFv 12.8 and scFv 12.10 were expressed and purified as described in sections 2.4.2 
-  2.4.3. Expressed scFv was detected by Western blot using anti-PentaHis antibody 
(Qiagen) as described. The scFv purity was assessed by SDS-PAGE gel staining with 
silver stain and Coomassie blue and the protein concentration was measured by absorbance 
at 280 nm, assuming that A280 = 1 for 520 jig/ml scFv 12.10.
scFv 12.10 expressed well, with 0.8pg protein expressed per ml of bacterial culture.
Expression levels for scFv 12.8, however, were very poor. Expressed scFv 12.8 
could be clearly seen by Western blot using Anti-PentaHis antibody, but could not be seen 
with Coomassie stain and was not clearly seen with SDS-PAGE gel silver staining. 
Expression levels of scFv 12.8 were too low to be accurately quantified by absorbance at 
280 nm. It was not possible to improve the expression level of scFv 12.8 by varying either 
the temperature or the duration of expression. This low expression level meant that it was 
not possible to obtain sufficient quantities of scFv 12.8 to assess its binding to recombinant 
or native MSP-119 by ELISA or IFA. Nor was it possible to test scFv 12.8 in the invasion 
assay, for which much more material is required than could be obtained.
The expression levels of scFv 12.8 and scFv 12.10 did not vary significantly 
between expression temperatures of 25°C for 8-12hr, 30°C for 4-12 hr and 37°C for 4-12 hr.
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Both scFvs were found in the bacterial culture supernatant as well as in the periplasmic 
fraction.
Western Blots of both scFv 12.8 and scFv 12.10 revealed some breakdown of the 
full-length protein. In both cases, detecting with Anti-PentaHis antibody, the full-length 
scFv was seen as a band at 30 kDa, and a breakdown product was seen at 18 kDa. 
Breakdown of scFv was reduced by expression at 30°C rather than 37°C and minimised, 
although not abolished, by expression over 8 hours at 25°C and by the addition of PMSF to 
the periplasmic fraction.
Figure 4.3 shows scFv 12.8 separated by SDS-PAGE using a 12% polyacrylamide 
gel and detected with Anti-PentaHis antibody (Qiagen). Both the 30 kDa full-length scFv 
and the 18 kDa breakdown product can be seen.
4.2.5 Binding of 12.10 scFv to M S P - I 1 9  by ELISA
A Nunc maxisorb 96-well ELISA plate was coated with 1 pg/ml recombinant 
MSP-I19-GST fusion protein in PBS as described in section 2.7.2. One hundred 
microlitres of scFv 12.10 was added to the wells in serial double dilutions, starting at a 
concentration of 100 pg/ml and going down to 3.13 pg/ml. The mouse hybridoma mAbs
12.8 and 12.10 were used as positive controls and the non-Plasmodium-binding humanised 
mAb BX (version 2) (supplied by Sue Potts, MRC Collaborative Centre) was used as a 
negative control. Positive and negative control antibodies were also added in serial double 
dilutions, starting at a concentration of 50 pg/ml. The plate was then incubated and 
washed as described, and 100 pi of 9E10 (murine hybridoma anti-c-myc mAb) culture 
supernatant was added to the wells containing scFv, and the plate was incubated at 37°C for 
1 hour. The plate was then washed again as described and the bound antibodies were
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revealed with 100 pi of a 1 in 5000 (v/v) dilution of either HRP-conjugated anti-mouse 
kappa (Harlan Sera-Lab) (to reveal bound mAbs 12.8, 12.10 and 9E10) or HRP-conjugated 
anti-human kappa light chain, bound and free (Sigma) (to reveal bound humanised mAb 
BX (version 2)). The plate was incubated and washed again as described and the colour 
was developed by adding 150 pi Neogen K-BLUE substrate (Sky Bio) to each well and 
leaving in darkness for 10 minutes then adding 50 pi Neogen RED STOP solution (Sky 
Bio). The plate was read on a BIO-RAD 3550 Microplate reader at 655 nm.
scFv 12.10 bound to MSP-I19-GST by ELISA and these results are illustrated in 
Figure 4.4.
4.2.6 Binding of 12.10 scFv to acetone-fixed P. falciparum  by IFA
Binding of scFv to parasites was assessed by indirect immunofluorescence (IFA) on 
acetone-fixed P. falciparum (FCB-1 and T9/96 strains) as described in section 2.7.1. 
Ni-NTA-purified scFv 12.10 was tested at concentrations of 30 pg/ml, 3 pg/ml and 0.3 
pg/ml. The slides were incubated and washed as described, and 15 pi of 9E10 (anti-c-myc) 
mouse hybridoma supernatant was added to each well to bind to the c-myc tag of the scFv. 
Bound antibody was revealed with FITC anti-mouse antibody as described.
scFv 12.10 was seen to bind to P. falciparum and yielded a very similar 
immunofluorescence pattern to that given by mAb 12.8 and mAb 12.10 (the 
immunofluorescence results are not shown).
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4.2.7 scFv 12.10 in the erythrocyte invasion assay, alone and bound to 
two albumin molecules
To determine whether scFv 12.10 retained the invasion-inhibitory property of the 
parent mAb 12.10, scFv 12.10 was tested in the erythrocyte invasion assay at a 
concentration of approximately 200 pg/ml. scFv 12.10 did not inhibit erythrocyte invasion 
in this experiment (data not shown).
In order to try to restore invasion-inhibitory activity to the scFv version of mAb
12.10, it was decided to incorporate either one or two albumin-binding domains to the 
C-terminus of the scFv. This was done in the hope that the addition of one or two bound 
albumin molecules to the scFv might restore invasion-inhibitory activity by increasing the 
bulk of the scFv so that its mass approximated to that of a whole antibody.
A new expression vector, pHENlH6ABD2, was created by Dr Jonathan Chappel of 
the Antibody Engineering Group, MRC Collaborative Centre, Mill Hill, London. This 
vector is identical to pHENlH6 except for the addition of two albumin-binding domains 
between the Notl site and the hexahistidine tag. The vector pHENlH6ABD2 is shown in 
Figure 2.4. The scFv 12.10 insert was ligated into this vector and expressed, as scFv
12.10-ABD2, with two albumin-binding domains fused to the C-terminus of the scFv. 
Expression levels were similar to those obtained with scFv 12.10 although, as with scFv
12.10, some breakdown of the proteins was observed on Western blot, despite the addition 
of PMSF at the time of elution of the protein from the Ni-NTA column. The binding of 
scFv 12.10-ABD2 to human albumin was confirmed by ELISA, and scFv 12.10-ABD2 was 
tested in the invasion assay at a concentration of 241 pg/ml. Albumin was present at a 
final concentration of 0.05% (w/v). scFv X509-ABD2 (made by Dr Jonathan Chappel)
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was used as a negative control (mAb X509 recognises MSP-133). In this experiment scFv
12.10-ABD2 did not inhibit erythrocyte invasion (data not shown).
4.2.8 Binding of chimeric 12.8 & 12.10 to M S P - I 1 9 - G S T  by ELISA
Using the mAb 12.8 and mAb 12.10 variable region sequences, chimeric 
mouse/human versions of mAbs 12.8 and 12.10 were made by Eilish Cullen of the 
Antibody Engineering Group (now AERES Biomedical) of the MRC Collaborative Centre, 
Mill Hill, London. An ELISA was carried out to confirm that the chimeric mAbs retained 
the ability to bind to MSP-119. An ELISA plate was coated with 1 pg/ml recombinant 
MSP-I19-GST fusion protein as described above. Chimeric mAbs 12.8 and 12.10 were 
added to the wells in serial double dilutions, starting at a concentration of 50 pg/ml and 
going down to 0.024 pg/ml. The mouse hybridoma mAbs 12.8 and 12.10 were used as 
positive controls and humanised mAb BXv2 was used as a negative control, in the same 
concentrations. The plate was then incubated and washed as described, and the bound 
antibodies were revealed with HRP-conjugated anti-mouse or anti-human antibodies and 
read as described above.
The chimeric versions of mAb 12.8 and mAb 12.10 bound to MSP-I19-GST by 
ELISA. Binding of the chimeric mAbs to MSP-I19-GST compared favourably with 
binding by the parent hybridoma mAbs 12.8 and 12.10, and these results are illustrated in 
Figure 4.5.
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4.2.9 Binding of chimeric 12.8 & 12.10 to parasites by IFA
The chimeric versions of mAh 12.8 and 12.10 were tested for their ability to bind 
acetone-fixed Plasmodium falciparum by IFA. The antibodies were tested against two 
strains of P. falciparum, T9/96 and FCB-1. The immunofluorescence experiments were 
carried out as described in section 2.7.1. The mouse hybridoma mAbs 12.8 and 12.10 
were used as positive controls and the non-Plasmodium-binding humanised mAb BX 
(version 2) (supplied by Sue Potts, MRC Collaborative Centre) was used as a negative 
control. All antibodies were tested at 30 jig/ml, 3 pg/ml and 0.3 pg/ml.
The chimeric mAbs 12.8 and 12.10 both showed strong binding to acetone-fixed 
P. falciparum by immunofluorescence, showing an immunofluorescence pattern identical 
to that of the parent hybridoma mAbs. These results are shown in Table 4.1.
4.2.10 Inhibition of erythrocyte invasion by chimeric mAbs 12.8 and
12.10
The chimeric versions of mAb 12.8 and mAb 12.10 were tested for their ability to 
inhibit P. falciparum erythrocyte invasion. The invasion assays were carried out as 
described in section 2.8.3. The assays were done in a flat-bottomed Costar 3596 96-well 
polystyrene plate. All antibodies were dialysed overnight into RPMI (without albumax). 
Murine hybridoma mAbs 12.8 and 12.10 and EDTA were used as positive controls and a 
non-P/tfsmoJ/wwz-speciflc murine mAb, BC1 (obtained from Alex Brown of the Antibody 
Engineering Group, MRC Collaborative Centre, and directed against an anti-cancer target 
antigen ) and RPMI alone were used as negative controls. Fresh washed O+ve human red 
blood cells were used and 3D7 P. falciparum schizonts were purified as described and 
supplied by Muni Grainger, Division of Parasitology, NIMR. Volumes were chosen to
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provide a final haematocrit in each well of 5%, and a parasitaemia at the start of the 
experiment of approximately 1%.
Each well contained a total volume of 50 pi made up as follows:
Antibody in RPMI 40 pi
AB+ve human serum 5 pi (10% v/v)
Glutamine 200 mM 0.5 pi (final concentration 2 mM)
RBCs and schizonts in RPMI 4.5 pi (haematocrit 5%, parasitaemia at time zero 1%)
Final concentrations of antibodies were as follows: 
Chimeric mAb 12.10 560 pg/ml
Hybridoma mAb 12.8 1280 pg/ml
Hybridoma mAb 12.10 4130 pg/ml
mAb BC1 800 pg/ml
The 96-well plate was incubated under an atmosphere of 7% CO2, 5% O2, 8 8 % N2 
at 37°C for 24 hours and then thin blood films were made from each well and stained with 
Giemsa stain. The percentage of erythrocytes invaded was calculated by counting one 
thousand erythrocytes on each film and noting the number parasitised.
Medium alone was tested in three separate wells, mAb BC1 was tested in four 
separate wells, chimeric mAb 12.10 was tested in five separate wells, and hybridoma mAbs 
12.8 and 12.10, and EDTA, were tested in one well each.
The percentage of red cells invaded in each well after 24 hours are shown in Table
4.2a).
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The chimeric mAb 12.10, at a concentration of 560 pg/ml, reduced the percentage 
of red cells invaded by P. falciparum by 57%.
This result is illustrated as a bar chart showing the percentage inhibition of 
erythrocyte invasion, in Figure 4.6.
In a second invasion assay, set up in an identical way to that described above, 
chimeric mAb 12.8 was tested at a concentration of 1200 pg/ml, with mAb BC1 as a 
negative control at 1280 pg/ml as before. In this experiment the parasitaemia at the start of 
the experiment was 0.1%. Each antibody was tested in three separate wells.
The percentage of red cells invaded in each well after 24 hours is shown in Table
4.2b).
The chimeric mAb 12.8, at a concentration of 1200 pg/ml, reduced the percentage 
of red cells invaded by P. falciparum by 54%.
4.3 Discussion
The work described in this chapter demonstrates that the antibody variable region 
sequences whose isolation was described in Chapter 3 are indeed the sequences encoding 
the invasion-inhibitory antigen-binding sites of mAbs 12.8 and 12.10. It has also been 
shown that these variable regions can retain their binding to their target antigen when 
engineered into a single chain variable fragment (scFv) format.
In additional experiments, not described here, both scFv 12.8 and scFv 12.10 were 
shown to bind to recombinant MSP-I19-GST by Biacore surface plasmon resonance.
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Biacore studies carried out by Dr Jonathan Chappel showed that scFv 12.10 binds 
recombinant MSP-I19-GST with a high affinity. The scFv 12.10 K<i was shown to be 6  x 
10'10M, which lies between the affinities previously determined for the Fab 12.10 (Kd 1.3 x 
10’loM) and the mAb 12.10 (Kd 1 x 10'nM) (Guevara Patino 1997).
It appears from this work that scFv 12.10 loses the invasion-inhibitory activity of 
the parent antibody, as anticipated from the lack of invasion-inhibitory activity in Fab and 
F(ab')2 fragments of the same antibody. It has been shown here, however, that this 
invasion-inhibitory activity is restored when the variable region sequences are 
re-engineered into a chimeric whole antibody format with human constant regions.
An initial attempt was made to restore invasion-inhibitory activity to scFv 12.10 by
increasing the bulk of the molecule through the addition of albumin-binding sites binding
two albumin molecules per scFv. There was not time in the course of this study to pursue
these attempts to completion. There was evidence of some breakdown of both scFv 12.10
and scFv-12.10-ABD2, and the intact scFvs were not purified away from the breakdown
products prior to their use in these invasion assays. Only limited quantities of
scFv-12.10-ABD2 were available and it may be that higher concentrations would be needed
to inhibit invasion. Also the actual binding of albumin to the albumin binding domain(s)
was not demonstrated in the invasion assay described, although scFv 12.10-ABD2 has been
shown to bind to human albumin by ELISA. It should not, therefore, be concluded that this
strategy cannot restore invasion-inhibitory activity to scFvs simply from the negative
results obtained in this limited study. Once the problems outlined above have been
addressed, the use of albumin bound to albumin-binding domains to bulk up scFvs will
merit further investigation. Other possible methods of restoring invasion-inhibitory
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activity to scFvs, based upon increasing the bulk of the molecule through the binding of 
antibodies to the scFv c-myc or hexahistidine tags, are discussed in Chapter 6 . It might 
also be helpful if the intact scFv could be purified away from the breakdown products prior 
to its use in these invasion assays. It could also be advantageous if an expression system 
could be found which minimises the breakdown of scFv and yields higher quantities of 
material to work with in the assays.
It was not possible to determine the properties of scFv 12.8 because of its poor 
expression levels in E. coli. Expression levels of this molecule might be improved if a 
different expression system, such as a baculovirus system, were used. Expression levels of 
scFv have also been achieved by altering amino acids in the framework regions (Saldanha, 
Martin et al. 1999) and such alterations might improve the expression of scFv 12.8. It 
would be of some interest to produce scFv 12.8 in sufficient quantity to discover whether 
scFv 12.8 also fails to retain the invasion-inhibitory property of the parent antibody. This 
experiment could however also be done using Fab 12.8, which has just been made (Dr 
Matthew Lock, Division of Parasitology, NIMR, unpublished data).
The chimeric antibodies express well and inhibit invasion. It would be very 
interesting to know whether invasion inhibitory antibodies can modify P. falciparum 
infection in a primate model. The human/murine chimeric versions of mAbs 12.8 and
1 2 . 1 0  should be an ideal source of material for such an experiment, since they are of a 
known sequence, they can be produced in sufficient quantity and to a high quality, and they 
should be less immunogenic to primates than the original murine antibodies. This 
experiment is planned and quantities of chimeric mAbs 12.8 and 12.10 are currently being
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expressed at AERES Biomedical (formerly the Antibody Engineering Group, MRC 
Collaborative Centre, Mill Hill, London) for this purpose.
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Figure 4.1
DNA encoding scFv 12.8, assembled by three-step PCR
Lanes 1,2,3 & 4 show the PCR product from four identical PCR reactions 
corresponding to PCR 3 in the three-step PCR construction of scFv 12.8, as described in 
section 2.3.1, and shown schematically (for scFv 12.10) in Figure 2.1. PCR products were 
separated on a 1% agarose gel with 1 0  ng/ml ethidium bromide, and photographed under 
ultraviolet light. A band can be seen in each lane corresponding to the predicted size of 
717 base pairs for scFv 12.8.
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Figure 4.2
scFv 12.8 and scFv 12.10 DNA and amino acid sequences
Above are shown the DNA sequences of scFv 12.8 and scFv 12.10. The scFvs are 
formed by the joining of the heavy chain variable region sequence (shown in blue) to the 
light chain variable region sequence (shown in red) via DNA encoding a flexible 18 amino 
acid linker (shown in green).
Below are shown the amino acid sequences of the scFvs. Heavy chain framework 
residues are shown in blue, heavy chain complementarity-determining region (CDR) 
residues are shown in violet, light chain framework residues are shown in red, light chain 
CDR residues are shown in pink, and linker residues are shown in green. A terminal 
arginine residue (R) introduced for cloning purposes, is shown in brown.
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Figure 4.2
scFv 12.8 DNA sequence
C A G A TC C A C TTG G TG C A G TC TG G A C C TG A G C TG A G G A A G CC TG G A G A G A C A G TC A A G A TC TC C TG C A A G G C TT
CTG G G TA TA C C TTCA CA A A C TA TG G A A TG A A CTG G G TG A A G C A G G A TA CA G G A A A G G G TTTA A A G TG G A TG G G
C T G G A T C A A C A C C TT C TC TG G A G A G C C A A C A T A T G C T G A TG A C TT C A A G G G A C G G TT TG C C TT C T C T TT G G A A
A C C TC TG C C A C C A C T G C C TA T T TG C A G A TC A A C A A C C T C A A A A A TG A G G A C A T G G C T A C A T A T TT C TG TG T A C
A G T C G G T A A T A G A C A A C TG G G G C C A A G G C A C C A C TC TC A C A G TC TC C TC A G G C TC TA C C TC TG G C TC TG G TA A
A C C G G G T TG C G G TG A A G G TT C C A C T A A A G G T C A A A T TG TT C T C A C C C A G T C T C C A G C A A T C A T G TC TG C A TC T
CCA G G G G A G A A G G TC A CC A TG A CCTG CA G TG CC A G CTCA A G TA TA G A TTA C A TG C A CTG G TA CCA G C A G A A G C
C A G G C A C C TC C C C C A A A A G A TG G A TT TA T G A C A C A T C C A A A C T G G C T TC TG G A G TC C C T G C T C G C TT C A G T G G
C A G TG G G T C T G G G A C C T C TT A T TC T C T C A C A A TC A G C A G C A T G G A G G C TG A A G A TG C TG C C A C T TA TT A C T G C
C A TC A G C G G A G TA G TTA C CC A TTCA CG TTC G G C TC G G G G A C A A A G TTG G A A A TA A A A C G A
scFv 12.10 DNA sequence
C A G G TC C A A C TG C A G C A G C C TG G G G CTG A A C TG G TG A A G C CTG G G G C TTC A G TG A A G C TG TC C TG C A A G G C TT
C T G G C T A CA C C TTC A C C A G C TA C TG G A TA CA C TG G G TG A A G C A G A G G C C TG G A C A A G G C C TTG A G TG G A TTG G
A G A G A TTA TTC C TA A C A A C G G TC G TA G TA A TTA TA A TG A G A A A TTC A A G A G C A A G G C C A C A C TG A C TG TA G A C
A A A TC C TC C A G C A C A G C C TA C A T G C A A C TC A G C A G C C T G A C A T C T G A G G A C TC T G C G G TC TA T TT C T G TG C A A
G A A A C TG G G CC TA C T G G T TC TT C G A T G TC TG G G G C G C A G G G A C C A C G G T C A C C G T C T C C T C A G G C T C TA C C T C
T G G C T C T G G TA A A C C G G G TTC C G G TG A A G G TTC C A C TA A A G G TG A C A TTG TG A TG A C C C A G TC TC A C A A A TTC
A TG TC CA CA TCA A TA G G A G A CA G G G TC A G C A TC A C C TG C A A G G C C A G TC A G G A TG TG A G TTC TG C TG TA G C C T
G G TA TC A A C A G A G A C C A G G A C A A TC TC C TA A A C TA C TG A TTTA C TC G G C A TC C TA C C G G TA C A C TG G A G TC C C
T G A TC G C T TC G C T G G C A G TG G A TC TG G G A C G G A TTTC A C TTTC A C C A TC A G C A G TG TG C A G G C TG A A G A C C TG
G C A G TTTA TTA C TG T C A G C A A C A TT C T A G TA C TC C G C TC A C G T TC G G TG C TG G G A C C A A G C T G G A G C T G A A A C
GA
scFv 12.8 amino acid sequence
10 20 30 40 50 60
Q IH L V Q S G P E  L R K P G E T V K I S C K A S G Y T F T  NYGMNWVKQD TGKGLKWMGW IN T F S G E P T Y  
70 80 90 100 110 120
A D D F K G R F A F  S L E T S A T T A Y  L Q IN N L K N E D  M A TY FCV Q SV  ID N W G Q G TTL T V S S G S T S G S  
130 140 150 160 170 180
G K P G S G E G S T  K G Q IV L T Q S P  A IM S A S P G E K  V T M T C S A S S S  IDYMHWYQQK P G T S P K R W IY  
190 200 210 220 230
D T S K L A S G V P  A R F S G S G S G T  S Y S L T IS S M E  A EDAATY YCH Q R S S Y P F T F G  S G T K L E IK R
scFv 12.10 amino acid sequence
10 20 30 40 50 60
Q V Q LQ Q PG A E L V K PG A SV K L  S C K A S G Y T F T  SYW IHW VKQR P G Q G L E W IG E  I IP N N G R S N Y  
70 80 90 100 110 120
N E K F K S K A T L  T V D K S S ST A Y  M Q L S S L T S E D  SAVYFCARNW  AYWFFDVWGA G T T V T V S S G S  
130 140 150 160 170 180
T S G S G K P G S G  E G ST K G D IV M  T Q SH K F M S T S  IG D R V S IT C K  A SQ D V SSA V A  W Y Q Q RPG Q SP 
190 200 210 220 230 240
K L L IY S A S Y R  Y TG V PD R FA G  S G S G T D F T F T  IS S V Q A E D L A  V Y Y C Q Q H SST  P L T F G A G T K L
E L K R
Figure 4.3
Western blot of scFv 12.8
As described in sections 2.4.2 and 2.4.3, scFv 12.8 was expressed in a pUC-derived 
expression vector in a 1 litre culture of E.coli TGI cells for 4 hrs at 30°C, and a periplasmic 
fraction was prepared from the cells. The expressed scFv was purified using the 
hexahistidine tag using 1ml of 50% Ni-NTA agarose slurry (Qiagen) and a 1ml nickel 
column (Qiagen) according to the manufacturer’s guidelines. Proteins were separated by 
SDS-PAGE on a 12% polyacrylamide gel under non-reducing conditions, transferred to an 
Immobilon nitrocellulose membrane and detected with anti-PentaHis antibody (Qiagen), 
using peroxidase-conjugated goat anti-mouse antibody and the ECL chemiluminescent 
detection system (Amersham Life Science).
Lane 1 was loaded with 40 pi of culture supernatant (without purification). Lane 2 
was loaded with 40 pi fresh periplasmic extract prior to Ni-NTA purification. Lane 3 was 
loaded with 20 pi of the first 200 pi volume of eluate after Ni-NTA purification. In each 
case a band is seen corresponding to the predicted size of 30 kDa for the intact scFv, which 
is found secreted into the supernatant as well as in the periplasm. A band of 18 kDa is also 
seen in lanes 2 and 3, which is presumed to be a breakdown product of the scFv. While 
some breakdown has occurred in the fresh periplasmic extract, more breakdown has 
occurred during Ni-NTA purification. Breakdown was minimised, although not altogether 
prevented, by expressing the scFv for 8 hrs at 25°C, and by the addition of PMSF to the 
Qiagen nickel column.
163
Figure 4.3
kDa
200 -  
97 -
68 -  
43 -  
29 -  
18 -
Jennings 3a  19/11/99 NP 
N.I.M.R. London, NW7 JAA.
Figure 4.4
Binding of scFv 12.10 to MSP-I1 9 -GST by ELISA
The binding of scFv 12.10 to recombinant MSP-I19-GST was examined by ELISA 
as described in section 2.7.2. The ELISA plate was coated with 100 pi 1 pg/ml 
recombinant MSP-119-GST fusion protein in PBS and blocked with 3% Marvel/PBS. Fifty 
microlitres of scFv was added at 100 pg/ml, and allowed to bind for 1 hr at 37°C. mAb
12.10 was used as a positive control, and mAb BX version 2 (BXv2) was used as a negative 
control. One hundred microlitres of 9E10 anti-c-myc mouse hybridoma cell culture 
supernatant was added to each well containing scFv, and bound antibody was detected with 
100 pi of a 1/5000 dilution in 3% marvel/PBS of peroxidase-conjugated anti-mouse kappa 
antibody (Harlan Sera-Lab). The colour was developed with Neogen K-BLUE substrate 
and Neogen RED STOP solution (Sky Bio). The plate was read on a BIO-RAD 3550 
Microplate reader at 655 nm.
It can be seen that this ELISA confirms that scFv 12.10 binds to recombinant MSP- 
119. The scFv 12.10 gives absorbances similar to those obtained with mAb 12.10, although 
the lower concentrations of scFv 12.10 were not tested. No binding of the negative control 
mAb to MSP-119 has occurred.
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Figure 4.5
Binding of chimeric mAbs 12.8 and 12.10 to MSP-11 9 -GST by ELISA
The binding of the mouse/human chimeric versions of mAbs 12.8 and 12.10 to 
recombinant MSP-119-GST was examined by ELISA as described in section 2.7.2. One 
hundred microlitres of mAb was added to each well, in serial 1:1 dilutions, starting with a 
concentration of 50 pg/ml, and murine hybridoma mAbs 12.8 and 12.10 were used as 
positive controls and humanised mAb BX version 2 was used as a negative control mAb. 
Bound chimeric antibodies were detected with 100 pi of a 1/5000 dilution in 3% 
marvel/PBS of peroxidase-conjugated goat anti-human kappa light chain antibody (Sigma).
The chimeric versions of mAb 12.8 and 12.10 and the parent murine mAbs 12.8 and
12.10 bind equally well to MSP-119. No binding of the negative control mAb is seen.
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Figure 4.6
Inhibition of erythrocyte invasion by chimeric mAb 12.10
The ability of the chimeric versions of mAbs 12.8 and 12.10 to inhibit invasion of 
erythrocytes by Plasmodium falciparum was tested in an in vitro assay as described in 
section 2.8.3. The results of the invasion assay with chimeric mAb 12.10 are shown here. 
The chimeric mAb 12.10 was tested at 560 pg/ml. The parent murine mAb 12.10 and the 
murine mAb 12.8 and EDTA were used as positive controls and the non-Plasmodium- 
specific murine mAb BC1 was used as a negative control. 3D7 parasites were used and the 
starting parasitaemia at time zero was 1%. The P. falciparum cultures were incubated for 
24 hours, and parasitaemias were calculated by counting one thousand erythrocytes on each 
thin blood film.
Using medium alone, (“full invasion”) the parasitaemia after 24 hours was 3.1%. 
Other parasitaemias are shown here as percentages of the full invasion parasitaemia. The 
parasitaemia after 24 hours with chimeric mAb 12.10 was only 43% of the full invasion 
parasitaemia, demonstrating that the chimeric version of mAb 12.10 does indeed inhibit 
erythrocyte invasion. Interestingly, more inhibition of invasion is shown with chimeric 
mAb 12.10 than with the parent murine mAb 12.10, which was used at 4130 pg/ml. This 
reflects our experience that the degree to which mAb 12.10 inhibits invasion appears to 
vary between different batches of antibody prepared from different culture flasks of 12.10 
hybridoma cells. The error bars represent the maximum and minimum parasitaemias 
obtained from counting multiple thin film slides.
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Table 4.1
Binding of chimeric 12.8 & 12.10 to parasites by IFA
Plasmodium falciparum  T9/96 strain
Concentration of antibody
Antibody 30 pg/ml 3 pg/ml 0.3 pg/ml
Mouse mAb 12.8 Strongly positive Strongly positive Positive
Mouse mAb 12.10 Strongly positive Positive Negative
Chimeric mAb 12.8 Strongly positive Positive Negative
Chimeric mAb 12.10 Strongly positive Positive Negative
mAbBAT Negative Negative Negative
Plasmodium falciparum  FCB-1 strain
Concentration of antibody
Antibody 30 pg/ml 3 pg/ml 0.3 pg/ml
Mouse mAb 12.8 Strongly positive Positive Negative
Mouse mAb 12.10 Strongly positive Positive Negative
Chimeric mAb 12.8 Positive Negative Negative
Chimeric mAb 12.10 Strongly positive Positive Negative
mAbBAT Negative Negative Negative
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Table 4.2
Inhibition of erythrocyte invasion by chimeric mAbs 12.8 and 12.10
Table 4.2a)
Inhibition of invasion by chimeric mAb 12.10
Reagent tested % parasitaemias on multiple 
counts
Mean % parasitaemia
Medium alone 3.2%, 3.1%, 2.9% 3.1%
mAb BC1 2.7%, 3.2%, 4.0%, 3.0% 3.2%
Chimeric mAb 12.10 1.5%, 1.3%, 1.4%, 1.4%, 
1.1%
1.3%
mAb 12.10 2.3% 2.3%
EDTA 0.5% 0.5%
Table 4.2b)
Inhibition of invasion by chimeric mAb 12.8
Reagent tested % parasitaemias on multiple 
counts
Mean % parasitaemia
mAb BC1 3.1%, 2.0%, 2.2% 2.4%
Chimeric mAb 12.8 1.2%, 0.8%, 1.3% 1.1%
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CHAPTER 5 
CONSTRUCTION AND PANNING OF HUMAN ANTIBODY PHAGE 
DISPLAY LIBRARIES
5.1 Introduction
This chapter describes the construction of two human phage display libraries of 
antibody fragments derived from malaria-exposed donors, and the results of the panning of 
those libraries with recombinant MSP-119-GST in order to isolate MSP-119-specific scFvs.
The decision was made to construct the libraries from peripheral blood mononuclear 
lymphocytes donated by malaria-exposed individuals. It is possible to isolate high affinity 
antibodies to a wide range of antigens using libraries constructed from donors who have not 
been immunised beforehand. For this to be done, however, it is necessary to use a very 
large library containing in the order of 1010 members (Vaughan, Williams et al. 1996). 
Furthermore, the aim of this work was not simply to isolate human antibody fragments 
specific for MSP-119, but to isolate them from individuals previously exposed to P. 
falciparum in order to gain insights into the natural human antibody response to malaria 
infection.
The village of Brefet on the south bank of the River Gambia in West Africa was 
chosen as the location for the collection of blood donations. Brefet was selected because it 
is within two hours journey from the Medical Research Council Laboratories at Fajara in 
The Gambia where the initial stages of the library construction could be carried out. Brefet 
was also chosen because malaria is prevalent in this area (Greenwood, Bradley et al. 1987),
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and because the people of Brefet have been the subject of a previous study showing that 
50% of adults possess antibodies to MSP-119 (Egan, Waterfall et al. 1997).
Clinical malaria in this area is highly seasonal, and occurs during a limited period at 
the end of the rainy season (Greenwood, Bradley et al. 1987). The best time to collect 
blood donations for a phage display library would be when the maximum number of MSP- 
119-specific PBMLs are circulating in the peripheral blood. The antigen stimulation 
associated with clinical malaria should cause MSP-119-specific lymphocytes to proliferate, 
but it is not known whether such lymphocytes would then remain in the peripheral blood or 
migrate to the reticuloendothelial tissue and be depleted peripherally. The decision was 
therefore made to construct two phage display libraries. One of these libraries was derived 
from blood donations collected in March (the middle of the dry season) when clinical 
malaria is very infrequent, and the other was derived from blood collected in October (the 
end of the wet season) when clinical malaria is more common.
Because a previous study found that only 50% of adults in this area had evidence of 
antibodies to MSP-119 (Egan, Waterfall et al. 1997), the libraries were constructed from 
blood donations from a fairly large number of individuals. An approximately equal 
number of male and female donors were chosen and most of the female donors chosen were 
multigravidae, so that the libraries might also contain representatives of any antibody 
responses made specifically during pregnancy.
The steps involved in constructing the library are summarised in Figure 2.5.
PBMLs were separated out from blood samples and the total RNA was extracted. Using
both primers specific for human variable region sequences and a NotI-d(T)is primer
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(Pharmacia Biotech), first-strand cDNA was synthesised. These steps were carried out in 
The Gambia, as it was thought that cDNA would be more likely than RNA to remain stable 
in transit from West Africa to London. The variable sequences of the human antibody 
heavy and light chains were then amplified. To maximise the library diversity, the PCR 
primers used were designed to hybridise with each of those gene families which have 
previously been shown to generate functionally rearranged antibody variable region 
sequences. In a further PCR step, the heavy or light chain variable sequences were joined 
to the DNA encoding the flexible scFv linker. In a final PCR step the heavy and light 
chain variable sequences were joined via the linker DNA to create DNA encoding full- 
length scFvs with appropriate restriction sites for cloning. The scFvs were ligated into the 
phagemid vector pHENlH6  (shown in Figure 2.3) and electroporated into TGI E. coli to 
create the libraries. Using the cDNA obtained in The Gambia, the libraries were 
constructed at the MRC Collaborative Centre at Mill Hill by Dr Jonathan Chappel, and 
sections 5.2.3 -  5.2.9 and Figures 5.1 -  5.5 in this chapter describe and illustrate his work.
In an alternative approach to the library construction, MSP-119-specific PBMLs 
were pre-selected and separated out from part of each blood donation using MSP-119-coated 
dynabeads (Dynal). Whole RNA was prepared from these PBMLs and an attempt was 
made to amplify antibody variable region sequences from cDNA derived from these cells. 
This was done to try to maximise the likelihood of MSP-119-specific variable region 
sequences being represented in one of the libraries eventually constructed. It was not 
known at the outset how many members the libraries were going to have, but the size of a 
library is important since it is known that high affinity antibodies can usually be isolated 
only from fairly large libraries (Griffiths, Williams et al. 1994). The pre-selection strategy
171
was therefore attempted as a backup measure in case the other libraries should prove not to 
be large enough to contain the antibody fragments of interest.
The libraries were panned with MSP-119. A recombinant version of MSP-119 was 
used, expressed in E. coli as a fusion with glutathione-S-transferase (GST) as previously 
described (Burghaus and Holder 1994). In a separate series of experiments, carried out by 
Dr Jonathan Chappel and not described here, the libraries were also panned against whole 
P. falciparum merozoites. Both merozoites in which secondary processing had proceeded, 
and merozoites in which secondary processing had been prevented, were used. The strain 
of P. falciparum used (T9/96 or FCB-1) to pan the libraries was alternated between panning 
rounds, in an attempt to isolate only phage binding to antigens conserved between strains. 
The results of these experiments are not shown in this thesis, although they are referred to 
in the course of the discussion of the results obtained with recombinant MSP-119.
Both the panning of the library and the production of specific scFv for further 
analysis (described in Chapter 6 ) were carried out using the TGI strain of E. coli. As 
discussed in section 1.3.2, an amber stop codon in pHENlH6  separates the scFv sequence 
from the gene encoding the phage pill structural protein. TGI E. coli suppresses the 
amber stop codon, reading it as glutamine, so that the scFv is expressed as a single fusion 
protein with the phage pill protein. If the suppression of the amber stop codon were 
complete in TGI E. coli, it would not be possible to produce soluble scFv alone, as it would 
always be expressed fused with the phage pill protein. In fact the suppression of the 
amber stop codon in TGI E. coli is far from complete. This has the advantage that both 
scFv/pIII fusion protein (for phage display) and soluble scFv (for analysis) can be produced
in the same cell, and consequently most manipulations are performed in the TGI strain.
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5.2 Results
5.2.1 Number and viability of PBMLs obtained from malaria-exposed 
donors
Peripheral blood mononuclear lymphocytes (PBMLs) were obtained from twenty 
malaria-exposed blood donors in the village of Brefet, The Gambia, in March 1997, and 
these were used to construct the first phage display library (the March library). PBMLs 
were again obtained from fifteen of the same donors in October 1997 and used to construct 
the second phage display library (the October library).
PBML numbers and cell viability were determined by examining cells in a 
haemocytometer after staining with trypan blue. The numbers of PBMLs recovered from 
the first six donors in March 1997, and the numbers of these cells which appeared viable 
with trypan blue, are shown in Table 5.1.
One third of each donated blood sample from March 1997 was used to perform a 
total RNA extraction from the PBMLs immediately, and it was from this one third of 
donated blood that the March library was made. (Another third of each sample was used to 
attempt EB V transformation of PBMLs, and the remaining third was used to attempt RNA 
extraction from pre-selected MSP-119-specific PBMLs.)
The total number of PBMLs from which the March Library was constructed was 
3.26 x10s.
Either one third or one half of each donated blood sample obtained in October 1997 
was used to extract total RNA immediately, and it was from these RNA extractions that the 
October library was eventually made. (The other two thirds or one half of each donated 
sample were again used to attempt RNA extraction from pre-selected MSP-119-specific
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PBMLs.) The percentages of PBMLs which appeared viable on trypan blue staining were 
similar to those in March 1997, i.e. over 95%. The total number of PBMLs from which
Q
the October library was constructed was 1.5 x 10 . The number of cells used to construct 
the libraries represents the theoretical maximum for the number of different heavy and light 
chains contained in the final libraries. The total numbers of PBMLs obtained from the 
fifteen donors bled in October 1997, and the numbers used in the eventual construction of 
the library, are shown in Table 5.2.
5.2.2 RNA extraction from PBMLs
PBMLs were isolated and then pooled and total RNA was extracted from the pool 
of PBMLs on the same days as the blood was donated. RNA was extracted as described in 
section 2.5.3, and eluted into 2 x 150 pi DEPC H2O. Fifty microlitres of this RNA solution 
was diluted 1:20 into 1 ml DEPC H2O and the A260 measured in a quartz cuvette 
(previously immersed in 1:1 concentrated HCl/methanol to destroy RNAses). The RNA 
concentration was calculated by assuming that an RNA solution of 40 pg/ml gives an A260 
of 1. An average of 13.9 pg total RNA was obtained per 20 ml blood donation. The 
results of the RNA quantification are shown in Table 5.3.
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5.2.3 Amplification of antibody variable region sequences from human 
donor PBML cDNA
The variable regions of the heavy and light chain genes were amplified by PCR 
from the PBML cDNA, using a range of primers, as described in section 2.5.6. Thirty-two 
reactions, with 32 different combinations of primers, were performed using AmpliTaq. All 
the PCR reactions yielded products of approximately 350-400 bp as expected. 11 of the 
reactions yielded faint bands with AmpliTaq and were repeated with Deep Vent DNA 
polymerase, yielding stronger bands. The reaction products are shown in Figure 5.1. The 
amplified variable region sequences were excised from the gel and gel-purified. The 
quantity of DNA recovered from each reaction ranged from 180 -  1000 ng.
5.2.4 scFv assembly stage 1: Attaching heavy chain sequences and light 
chain sequences to scFv linkers
The amplified variable region sequences were joined together to construct scFv 
fragments by PCR in a two stage process, illustrated schematically in Figure 2.5. In the 
first stage, DNA encoding a flexible 15 amino acid linker was attached either to the 3’ end 
of the Vh sequence or the 5’ end of the V* or VK sequences. To attach the appropriate 
linkers to the appropriate heavy and light chain sequences, 10 different PCR reactions were 
carried out as shown in Table 2.8. All 10 reactions yielded products of approximately 
400-450bp as expected, and these reaction products are shown in Figure 5.2.
The bands were excised from the gel and gel-purified, yielding between 500 and 
2500 ng of DNA per reaction.
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5.2.5 scFv assembly stage 2: Attaching VH-linker to linker-VK or 
linker-Vj, to make complete scFvs with restriction sites
The PCR products from the above reactions, consisting of either Vh , or V*. or VK 
sequences, attached to linker DNA, were then used as templates in a second PCR reaction. 
This was designed to join the Vh sequences to the V* or VK sequences via the linker to make 
DNA encoding complete scFv fragments. This assembly step is illustrated schematically 
in step 4 of Figure 2.5. The primers were designed to also incorporate Sfil and Notl 
restriction sites for subsequent cloning. Eight reactions were performed, linking the Vh 
sequences to the VKi ,Vk2 ,VK3 ,VK4 ,Vks and V\\ Nn -3 V\ix sequences respectively, in order 
to make all the desired combinations of heavy and light chain gene families. These PCR 
reactions were carried out as described in section 2.5.9 using the PCR primers shown in 
Table 2.9. All 8 reactions yielded products of approximately 800 bp as expected, and these 
reaction products are shown in 5.3.
5.2.6 Addition of long extensions beyond the Sfil & Notl restriction sites 
by PCR
In order to be able to digest the scFv DNA with Sfil and Notl for insertion into the 
phagemid vector, a further PCR was carried out with long primers, using the products from 
the above PCR as templates. This PCR was designed to add long extensions, overlapping 
the flanking sequences of pHENlH6, beyond the Sfil restriction site at the 5’ end and the 
Notl restriction site at the 3’ end of the scFv DNA. These long extensions were added to 
improve the efficiency of SfiVNotl digestion. This PCR is illustrated schematically in step 
5 of Figure 2.5. The primers are shown in Table 2.10 and the reactions were carried out as 
described in section 2.5.10. Two reactions were carried out, one using V h-V k scFv  DNA
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as a template and one using V r-V x scFv  DNA as a template. Both reactions were carried 
out in 10 separate reaction tubes. The PCR reactions both yielded products of the expected 
size.
Prior to setting up this PCR, a Sfil & Notl & Ncol restriction digest was carried out 
with the template scFv DNA to ensure that none of the scFv contained any internal Sfil or 
Notl or Ncol restriction sites. There was no evidence of any of the scFv DNA being 
digested by any of these enzymes.
5.2.7 Sfil/Notl restriction digest of V h-V k and V h-V x scF v  DNA
The V h-V k and V r-V x scFv  DNA from the above PCR was chloroform-extracted, 
ethanol precipitated and resuspended and then Sfil/Notl digested. Digestion occurred 
appropriately and the digested products were of the anticipated sizes and are shown in 
Figure 5.4.
The Sfil/Notl digested Vr-Vk and Vr-Vx scFv  DNA products were gel purified and 
quantified. 7.5 pg of Vr-Vk and 7.5 pg of Vr-Vx DNA was recovered.
5.2.8 Ligation of scFv inserts into phagemid vector and transformation of 
E. coli TG1-TR cells
The Sfil/Notl digested scFv inserts were ligated into the phagemid vector pHENlH6  
and the ligation products were purified and electroporated into E. coli TG1-TR competent 
cells as described in sections 2.5.12 -  2.5.13. Using 50 pi of TG1-TR cells each, 50 
electroporations were carried out using V h-V k scFv  DNA and 50 electroporations were 
carried out using V r-V x scF v  DNA. Each lot of 50 electroporated cells was pooled and 
(after removal of a 2.5 ml aliquot of cells for titration) plated. The next day the colonies
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were scraped from the plates and resuspended and stored as two lots of 48 1ml aliquots 
(either V h-V k scF v  or V h-V x. scF v ) as glycerol stocks at -70°C.
The aliquots removed for titration were plated and the number of colonies were 
counted to estimate the number of scFv members in the whole library. The results are 
shown in Table 5.4.
5.2.9 Presence and diversity of scFv inserts
After transformation and plating, 50 colonies of the Vr-Vk transformed cells and 
50 colonies of the Vh-Vx transformed cells were randomly picked and PCR screened for the 
presence of inserts. All 100 of these colonies yielded a PCR product of the expected insert 
size. Part of each of these products was digested with the frequent-cutting restriction 
enzyme BstNl to make an initial assessment of the diversity of the inserts. Diverse BstNl 
restriction patterns were obtained and are shown in Figure 5.5.
5.2.10 PBML numbers pre-selected with M SP-li9-GST-coated 
dynabeads
A proportion of PBMLs were set aside to attempt to separate out those PBMLs 
expressing MSP-119-specific antibody on the cell surface, for subsequent RNA extraction. 
8x10s tosyl-activated dynabeads 450 (Dynal) were coated with recombinant MSP-I19-GST. 
The PBMLs were pooled and the coated dynabeads were added to a concentration of 2xl07 
beads/ml and the cells and beads were shaken together and those cells sticking to the beads 
were separated out on a Dynal magnet. Cell count and cell viability were assessed as 
above, counting only those cells visibly attached to a bead. RNA extraction was then 
attempted as described above.
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From 8.1 x 10 PBMLs (comprising one third of the total PBMLs obtained from the 
first six 20 ml blood donations in March 1997), 3 x 105 cells (i.e. approximately 0.5% of 
the starting number) were separated out by recombinant MSP-li9-GST-coated magnetic 
beads.
5.2.11 Attempted antibody variable region amplification from 
cDNA of preselected PBMLs
RNA extraction was carried out on these preselected cells as described above. The 
quantity of RNA obtained was too low to be accurately estimated by spectroscopy. cDNA 
synthesis was carried out as above, but attempts at antibody variable region amplification 
from this cDNA were not successful.
5.2.12 Numbers of phage retrieved by panning against recombinant 
MSP-119-GST
Aliquots from each of the March and October phage display libraries were pooled 
for panning against antigen. The initial amount of phage used in the panning experiments 
was 1 x 1014 colony-forming units (cfu). The pooled library phage was panned against 
recombinant MSP-I19-GST as described in sections 2.6.2 -  2.6.4. The number of phage 
recovered on successive rounds of panning is expected to fall initially, as non-binding 
phage is eliminated, and then to rise sharply, as high affinity antigen-binding phage is 
selected and amplified. This expected pattern was seen when panning against recombinant 
MSP-I19-GST. After the first round of panning, 1.5 x 106 cfu were recovered. After the 
second round 6.4 x 104 cfu were recovered. After the third round 1.4 x 107 cfu were
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recovered, and after the fourth round 1.0 x 10 cfu were recovered. These results are 
illustrated in Figure 5.6.
5.3 Discussion
The results in this chapter describe the successful construction of two phage display 
libraries derived from blood donations from malaria-exposed donors. The phage numbers 
obtained by successive rounds of panning of the combined libraries with recombinant 
MSP-119 are consistent with the successive enrichment of MSP-119-binding phage.
The combined size of the two libraries (approximately 1.3 x 109 members) is 
sufficiently large to anticipate that they will yield high affinity antibody fragments 
(Griffiths, Williams et al. 1994). The results of the BstNl restriction digest of 100 
randomly selected clones suggest that the library is indeed diverse. In an additional 
experiment to estimate diversity, a number of clones were randomly selected from the 
unpanned libraries and sequenced by Jonathan Chappel and Alicia Sedo of the MRC 
Collaborative Centre. These clones were found to be diverse in sequence and were derived 
from a wide range of different variable gene families (data not shown).
In retrospect, there was a degree of redundancy in the number of PCRs used to 
amplify the linker DNA prior to its incorporation with either the heavy chain or light chain 
variable sequences. Linker DNA was prepared in 8 8  separate PCRs as described in section 
2.5.7. These PCRS were designed to produce overlapping regions at both ends of the 
linker DNA, designed to anneal to the 3’ end of the heavy chain sequences and the 5’ end 
of the k  or X light chain sequences in all possible combinations. Using the linkers thus
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amplified, it is theoretically possible to create DNA encoding full-length scFv in a single 
PCR, using heavy chain, light chain and linker sequences as templates in the same reaction. 
This would involve essentially omitting step 3 as illustrated in Figure 2.5. Phage display 
libraries have been made in this way (Marks, Hoogenboom et al. 1991) but attempts to 
assemble the scFv in these libraries by such a single step PCR were not successful. An 
intermediate step was therefore introduced (step 3 in Figure 2.5) to join the linker DNA to 
either the heavy chain or the light chain sequences, but not both at once. The linker PCR 
primers involved in this step, HuLinkBACK and HuLinkFor, do not preserve both of the 
overlapping linker ends created in the 8 8  PCRs described above, but with this intermediate 
step, those overlapping ends are no longer both required. This is because in the final 
assembly PCR (step 4 in Figure 2.5) the Vn-linker and linker-VL anneal to each other via 
the two complementary strands of the linker itself.
It is not clear why the attempt to amplify antibody variable region sequences from 
cDNA derived from pre-selected PBMLs was unsuccessful. The most likely explanation is 
that the quantity of total RNA which was prepared from these cells was insufficient for the 
synthesis of adequate quality first strand cDNA. Although the proportion of PBMLs 
binding MSP-li9-coated dynabeads was quite high (about 0.5% of the total) the actual 
numbers of pre-selected PBMLs used for each RNA preparation was smaller than the 
minimum number recommended by the Qiagen RNeasy Midiprep kit. The yield of RNA 
might be improved with the addition of carrier RNA to the cells prior to the RNA 
extraction, were the experiment to be repeated. In retrospect, however, the success of this 
pre-selection approach was not essential to the project to create libraries from which MSP- 
119-specific scFv can be isolated, as the libraries made from unselected PBMLs were
successfully constructed and proved able to yield scFvs of interest.
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Figure 5.1
Amplification of antibody variable region sequences from human donor 
PBML cDNA
Variable region sequences were amplified using 32 different primer combinations in 
32 separate reactions, using AmpliTaq, as described in section 2.5.6. The PCR primers 
and reactions used are shown in Table 2.4 and Table 2.5 respectively. This figure shows 5 
pi of each 50 pi reaction resolved on a 2.5% agarose gel.
Lanes 1-10 show amplified Vh sequences, i.e. the variable part of the rearranged gene 
encoding the heavy chain of the antibody. These are:
Vnla (lane 1), Vh2x (lane 2), Vn3a (lane 3), Vh3x (lane 4), Vn4a (lane 5), Vh4x (lane 6 ), 
Vn4y (lane 7), Vh5x (lane 8 ), Vn6 a (lane 9), Vh7x (lane 10).
Lanes 11-19 show amplified V k sequences, i.e. the variable part o f  the rearranged gene 
encoding the k light chain o f  the antibody. These are:
Vida (lane 11), Vx2a (lane 12), Vk2x (lane 13), Vx3a (lane 14), Vk3x (lane 15), Vx4a 
(lane 16), Vic5a (lane 17), Vic6 a (lane 18), Vk6x (lane 19).
Lanes 20-32 show amplified VA. sequences, i.e. the variable part of the rearranged gene 
encoding the X light chain of the antibody. These are:
Vkl (lane 20), VMx (lane 21), VA2x (lane 22), VA3a (lane 23), VA3b (lane 24), VX3x(lane 
25), VMx (lane 26), VMy (lane 27), VA,5x (lane 28), VA.6  (lane 29), VAJx (lane 30), VA,8 x 
(lane 31), VAT Ox (lane 32).
Standard DNA marker sizes are indicated.
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Figure 5.2
scFv assembly stage 1:
Attaching heavy chain sequences and light chain sequences to scFv 
linkers
This figure illustrates the first stage of a two-stage process by which the amplified 
variable region sequences were joined together to construct scFv fragments by PCR, as 
described in section 2.5.8. In the first stage, DNA encoding a flexible 15 amino acid linker 
was attached either to the 3’ end of the Vh sequence or the 5’ end of the V*. or VK 
sequences. To attach the appropriate linkers to the appropriate heavy and light chain 
sequences, 10 different PCR reactions were carried out as shown in Table 2.8. Ten 
microlitres of each 100 pi reaction were resolved on a 2.5% agarose gel, shown here.
Lanes 1-10 show the products of PCR reactions 1-10, performed as described in 
Table 2.8
DNA size markers were used as previously described.
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Figure 5.3
scFv assembly stage 2:
Attaching VH-linker to linker-VK or linker-Vx to make complete scFvs 
with SfillNotl restriction sites.
This figure illustrates the second stage of the PCR assembly of scFv from Vh and 
Vx or Vk sequences, as described in section 2.5.9.
The PCR products shown in Figure 5.2, consisting of either Vh or V x  or V K 
sequences attached to linker DNA, were then used as templates in a second PCR reaction. 
This was designed to join the Vh sequences to the V x  or V K sequences via the linker to make 
DNA encoding complete scFv fragments, and the primers were designed to incorporate Sfil 
and Notl restriction sites for subsequent cloning. Eight reactions were performed, linking 
the Vh sequences to the V Ki ,Vk2 ,Vk3 , V K4 ,VK5 and V x i V x2-3 V x7x  sequences respectively, in 
order to make all the possible combinations of heavy and light chain gene families. These 
PCR reactions were carried out using the PCR primers shown in Table 2.9 Ten microlitres 
of each 100 pi reaction were resolved on a 2.5% agarose gel, shown here.
The bands represent DNA encoding whole scFv. The lanes are labelled according 
to the gene family of light chain which has been joined to the heavy chain.
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Figure 5.4
Sfil/Notl restriction digest of Vh-Vk and Vh-Vx scFv DNA
This figure shows uncut scFv DNA, ^-d igested  scFv DNA and S/H/AM-digested 
scFv DNA, produced by digestion of the scFv DNA shown in Figure 5.3, as described in 
section 2.5.11. Restriction digests were performed after the addition of long DNA
overlaps to facilitate digestion, as described in section 2.5.10.
The digestion products are resolved on a 2.5% agarose gel.
Lanes 1-3 show V h-V k sc F v  D N A  uncut (lane 1), cut with Sfil (lane 2) and cut with
SfiVNotl (lane 3).
Lanes 4-6 show V h-V x scFv D N A  uncut (lane 4), cut with Sfil (lane 5) and cut with 
SfiVNotl (lane 6).
The DNA size markers are the same as in Figure 5.3.
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Figure 5.5
Estimation of diversity of library scFv inserts by BstNl digestion
This figure shows the different restriction-digest patterns of 50 randomly selected 
scFvs from the October library.
Fifty colonies of the V h-V k transformed cells and 50 colonies of the V h-V x 
transformed cells were randomly picked and PCR screened for the presence of inserts. All 
100 of these colonies yielded a PCR product of the expected insert size. Part of each of 
these products was digested with the frequent-cutting restriction enzyme BstNl to make an 
initial assessment of the diversity of the inserts. The products of this digestion were 
resolved on a 4% NuSieve agarose gel.
Figure 5.5 a) shows the V h-V k scF v  inserts amplified by PCR screen from 50 
randomly selected colonies.
Figure 5.5b) shows the same V h-V k scF v  inserts after digestion with BstNl.
A large number of different digest patterns are seen, suggesting a high degree of 
DNA sequence diversity among the library scFv inserts.
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Figure 5.6
Quantity of phage recovered from successive rounds of panning
The phage display libraries were subjected to four rounds of panning with 
recombinant MSP-I19-GST in order to isolate MSP-119-specific scFvs, as described in 
sections 2.6.2 -  2.6.4. The initial amount of phage used in the panning was 1 x 1014 
colony-forming units (cfu). The number of phage recovered on successive rounds of 
panning was expected to fall initially, as non-binding phage is eliminated, and then to rise 
sharply, as high affinity antigen-binding phage is selected and amplified. This expected 
pattern was seen on panning with MSP-119 and is shown in this figure. These results 
suggested that MSP-119-specific scFv had indeed been selected for and amplified. Note 
that the scale on the y-axis is logarithmic.
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Table 5.1
Recovery and viability of PBMLs from individual donors, March 1997
Donor Volume of blood 
donated
No. of PBMLs 
recovered
No. of viable cells 
(%)
Z5 20ml 5.0 x 107 > 95%
Z15 20ml 1.2x10' > 95%
Z21 20ml 5.2 x 107 > 95%
Z71 20ml 3.2 x 107 > 95%
Z88 20ml 6.0 x 107 > 95%
Z168 20ml 2.2 x 10' > 95%
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Table 5.2
Number of PBMLs recovered and used to construct the October 
library
Donor Volume of 
blood donated
No. of PBMLs 
recovered
No. of PBMLs used 
to make library
Z157 20ml 2.63 x 107 0.88 x 107
Z152 20ml 3.36 x 107 1.12 xlO7
Z149 20ml 2.23 x 107 0.74x10'
Z151 20ml 4.16 x 10' 1.39 xlO7
Z142 20ml 1.73 xlO 7 0.58 x 107
Z49 20ml 0.49 x 107 0.16 x 107
Z168 20ml 2.36 x 10v 0.79 x 10'
Z88 20ml 1.67 x 107 0.56 x 107
Z71 20ml 1.69 x 10' 0.56 x 10'
Z141 20ml 3.48 x 10' 1.16 x 10'
Z158 20ml 1.56 xlO7 0.78 x 107
Z176 20ml 1.36 x 107 0.68 x 107
Z16 20ml 5.24x10' 2.62 x 10'
Z15 20ml 3.38 x 107 1.69 xlO7
Z21 20ml 2.13 x 107 1.07 xlO7
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Table 5.3
Quantity of total RNA obtained from blood donations
PBML pool 
used in library 
construction
No. of donors A260 RNA
concentration
Total RNA 
obtained
March 1 6 0.295 236 pg/ml 70.8 pg
March 2 6 0.398 318 pg/ml 95.5 pg
March 3 8 0.373 298 pg/ml 89.4 pg
October 1 8 0.300 240 pg/ml 72.0 pg
October 2 2 0.104 31.2 pg/ml 09.4 pg
October 3 5 0.624 499 pg/ml 149.7 pg
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Table 5.4
Estimation of the size of the March and October phage display
libraries
The March library The October library
No of blood donors used 20 15
No of PBMLs used 3.3 x 10s 1.5 x10s
No. of Vh“Vk members 3.9 x 10s 1.0 x10s
No. of Vh-Vx members 4.5 x 10s 3.5 x 10s
Total No. of members 8.4 x 10* 4.5 x 10s
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CHAPTER 6
CHARACTERISATION OF HUMAN LIBRARY-DERIVED ANTI-
MSP-lio SCFVS
6.1 Introduction
* The panning of the phage display libraries with recombinant MSP-119 led to the 
isolation of increasing numbers of phage with successive rounds of panning, as 
described in the previous chapter. This chapter describes the work done to demonstrate 
that there are MSP-119-binding clones among the amplified phage, to isolate as many 
different MSP-119-binding clones as possible, and to characterise the properties of these 
clones.
Firstly the polyclonal phage from successive panning rounds was assessed for 
the presence of MSP-119-binding scFv. To do this, the total polyclonal scFv obtained 
from each successive round of panning was examined for binding to acetone-fixed 
P. falciparum by IFA. The IFA signal from the unpanned library and the first two 
rounds of panning was negative as expected, but the signal from the third and fourth 
rounds of panning was similar to that obtained with mAbs 12.8 and 12.10, indicating 
successful isolation and amplification of MSP-119-binding scFvs from the library. This 
was confirmed by demonstrating that the polyclonal scFv also bound to P. falciparum 
merozoite lysate on a Western blot.
Individual MSP-119-binding clones were then isolated from the polyclonal phage 
by ELISA of scFvs from 160 randomly selected clones. Of these clones, 114 (71%) 
bound to MSP-119. In order to assess the DNA sequence diversity of these clones, the
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diversity of the restriction fragment patterns produced by the frequent cutting enzyme 
BstNl was examined, and 11 different restriction patterns were identified.
To determine which of these scFvs might be most likely to have 
invasion-inhibitory potential, the ability of individual scFvs to block the binding of the 
invasion-inhibitory mAbs 12.8 and 12.10 to MSP-119 was examined by competition 
ELISA. The majority of MSP-119-binding scFvs appeared to partially block the 
binding of these mAbs, suggesting that the scFv epitopes at least overlap the 
invasion-inhibitory epitopes recognised by mAbs 12.8 and 12.10. Of these scFvs, 20 
clones were selected, on the basis of their BstNl restriction digest patterns, for DNA 
sequencing. Of these 20 clones, some were found to contain identical inserts but a total 
of 6  different scFv sequences were found. There was more sequence diversity in the 
light chains than in the heavy chains. All 6  sequences were similar to each other. 
Representative clones for each of the different sequences were expressed and the 
expression levels of the different scFvs determined. The binding of each of these scFvs 
to P. falciparum was confirmed by IFA.
Those scFvs which could be expressed in sufficient quantity were tested for the 
ability to inhibit erythrocyte invasion in vitro. No invasion-inhibitory scFvs were 
identified, although this is not surprising given that Fab fragments of mAb 12.10 do not 
retain the invasion-inhibitory activity of the parent mAb (Guevara Patino 1997). An 
initial attempt was made to examine ways in which invasion-inhibitory activity might be 
restored to the scFvs in the future. An attempt was made to increase the size of the 
scFvs used in the invasion assay to the size of a whole antibody by the addition either 
mAb 9E10 or anti-PentaHIS antibody (Qiagen) to the scFv so that these antibodies 
could bind to the scFv c-myc or hexahistidine tag respectively. This was done on the
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assumption that increasing the size of the scFv back to a size approximating to that of a 
whole antibody might restore any invasion-inhibitory activity present in the parent 
antibody.
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6.2 Results
6.2.1 Binding of polyclonal scFv from panning rounds 1-4 to 
P. falciparum  by IFA
In order to ascertain whether successive rounds of panning against recombinant 
MSP-I19-GST had indeed isolated P. falciparum merozoite-binding scFvs, polyclonal 
scFv from each round of panning was tested for its ability to bind P. falciparum 
parasites by immunofluorescence. Soluble antibody was purified from phage recovered 
from each round of panning by periplasmic extraction followed by purification on a 
Qiagen mini-His column. IFA was carried out using acetone-fixed parasites, and the 
polyclonal scFv was tested against both T9-96 and FCB-1 strains of P. falciparum. 
The polyclonal scFv was tested at a concentration of 20 pg/ml. The monoclonal 
antibodies 12.8 and 12.10 were used as positive controls, and polyclonal scFv prepared 
from the unpanned March and October libraries was used as a negative control. The 
polyclonal scFv from the unpanned libraries and from the first and second rounds of 
panning against recombinant MSP-I19-GST showed no appreciable binding, but the 
polyclonal scFv from the third and fourth rounds produced an immunofluorescence 
pattern similar to that of the positive control mAbs. The immunofluorescence patterns 
obtained with polyclonal scFv from successive rounds of panning against recombinant 
MSP-I19-GST are shown in Figure 6.1.
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6.2.2 Binding of polyclonal scFv from panning rounds 1-4 to 
P. falciparum  by Western blot
To confirm that the polyclonal scFv from later rounds of panning did bind native 
merozoite protein, binding was also demonstrated by Western blot, as described in 
section 2.7.5. T9/96 and FCB-1 P. falciparum merozoites were incubated for 1 hour at 
37°C with 1 mM MgCh, 1 mM CaCh, and the protease inhibitors Leupeptin, Antipain, 
Aprotinin & TLCK in 200 pi PBS. The merozoites were then boiled for 10 minutes 
with 200 pi non-reducing buffer and the proteins were resolved by SDS-PAGE and 
transferred onto a nitrocellulose membrane. The polyclonal scFv was added to the 
membrane at a final concentration of 1 pg/ml for 1 hour. The membrane was incubated 
with 9E10 supernatant and peroxidase-conjugated goat anti-mouse IgG/lgM was added 
and detected using the ECL chemiluminescent detection system (Amersham Life 
Science).
The results are shown in Figure 6.2
Polyclonal scFv from the fourth round of panning against recombinant 
MSP-I19-GST recognised both MSP-I19 and MSP-I42 (from which MSP-I19 is derived 
at secondary processing). Interestingly, polyclonal scFv obtained by Dr Jonathan 
Chappel, by panning against whole merozoites in which processing had been allowed to 
proceed, gave almost identical patterns, recognising MSP-I19 and MSP-I42.
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6.2.3 Identification of individual M SP-li9-GST-binding scFv clones by 
ELISA
Individual MSP-119-binding scFv clones were identified by ELISA on a 96-well 
plate. Individual colonies from the third and fourth rounds of panning against 
MSP-I19-GST were picked and transferred to a 96-well master plate and grown 
overnight. A replica plate was inoculated from the master plate and grown to induce 
scFv expression. Fifty microlitres of 50% glycerol was added to each well of the 
master plate, which was then stored frozen at -70°C. Pre-blocked culture supernatants 
containing scFv were transferred to an ELISA plate coated with MSP-119-GST.
Eighty clones were picked from the third round of panning and 80 clones were 
picked from the fourth round of panning.
Ninety-two percent of the scFvs from the third round of panning and 53% of the 
scFvs from the fourth round of panning bound to MSP-119.
6.2.4 Assessment of clone diversity by BstNl digest
An initial assessment of the sequence diversity of the MSP-119-binding scFvs 
was made. This was done by examining restriction fragments produced by the frequent 
cutting restriction enzyme ifa/Nl. Selected scFv DNA sequences were amplified by 
PCR using the primers RSP 48 and fdTET. The completed PCR reactions were then 
digested with BstNl at 60°C for 2 hours and the digestion products were resolved on a 
3% agarose gel.
From the scFv obtained by panning against MSP-119-GST, 78 clones were 
examined, of which 6 8  were MSP-119-binders and 10 were non-binders (as previously 
demonstrated by ELISA).
The amplified undigested scFv and the corresponding restriction digest products 
are shown in Figure 6.3.
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On this random sample of 64 MSP-119-binding clones, 11 different BstNl 
restriction digest patterns were identified, suggesting therefore that some degree of 
diversity existed among the MSP-119-binding scFvs obtained from the libraries.
6.2.5 Investigation of scFv-binding MSP-119 epitopes by competition 
ELISA
In order to see whether the MSP-119-binding scFvs bind to epitopes overlapping 
those of the invasion inhibitory mAbs 12.8 and 12.10, or whether they bind to some 
other region of the molecule, a competition ELISA was carried out. This was designed 
to determine whether the scFvs could compete with mAbs 12.8 and 12.10 for binding 
sites on the MSP-119 molecule.
ELISA plates were coated with MSP-119-GST at 0.5 pg/ml for competition with 
mAb 12.8 and at 0.05 |ig/ml for competition with mAb 12.10. The scFvs were 
expressed in a 96-well replica plate inoculated from the master plate, as above, and the 
pre-blocked scFv-containing supernatants were transferred to the ELISA plate and 
allowed to bind. The plates were washed and then mAb 12.8 (at 0.5 pg/ml) or mAb 
12.10 (at 0.05 pg/ml) were allowed to bind also.
The results are shown in Figure 6.4.
Most of the scFv which bound to MSP-119-GST by ELISA gave a reduction in 
signal from mAb 12.8 of more than 40%, and a reduction in signal from mAb 12.10 of 
more than 25%. This suggests that the epitopes to which the scFvs bind may overlap 
the epitopes of mAb 12.8 and mAb 12.10.
198
6.2.6 DNA and amino acid sequences of MSP-11 9 -binding scFvs
From those scFvs obtained from the third and fourth rounds of panning against 
recombinant MSP-119-GST, 20 clones were selected for sequencing. The clones were 
chosen on the basis of their binding to MSP-119-GST by ELISA, their variety of 
restriction fragment patterns on BstNl digest and their ability to inhibit the binding of 
mAbs 12.8 and 12.10 in the competition ELISA. Each clone was given a name 
consisting of two letters and two numbers, which identify the antigen used for panning, 
the round of panning from which the clone was derived, and the position of the clone on 
the original 96-well plate of glycerol stocks described in section 6.2.3. Thus the scFv 
T3D6 refers to the scFv clone obtained by panning against MSP-119-GST (denoted by 
the letter T), from the third round of panning, and located in position D6  on the 96-well 
master plate.
A number of the scFv clones were found on sequencing to be identical, and from 
among the 20 clones sequenced, six different scFv sequences were found. These scFv 
clones are scFvs T3B4, T3C2, T3C8, T3D3, T3D6 and T4D4. There is more diversity 
among the light chain variable regions of these clones than among the heavy chain 
variable regions.
Two significantly different heavy chain sequences were identified. The 
commoner heavy chain is present in scFvs T3B4, T3C2, T3C8, T3D6 and T4D4, 
although the CDR 1 of scFv T4D4 differs from the others in this group by one residue. 
The other heavy chain sequence is found in scFv T3D3, and differs from the commoner 
heavy chain in both CDR 2 and CDR 3.
Five different light chain sequences were identified among these 6  scFvs. 
Variation is seen in all three CDRs. Full sequence information was not obtained on 
two of the scFv, T3B4 and T3C8, which were not sequenced through the whole of the 
third CDR and the fourth framework region.
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The amino acid sequences of the scFvs are shown in Figure 6.5.
6.2.7 Expression levels of selected MSP-119-binding scFvs
Selected scFvs were made by periplasmic extraction from a culture volume of 10 
ml and purified on mini-His columns (Qiagen). Purified scFv was eluted in a volume 
of 200 pi. The quantity of purified scFv obtained from 10 ml of culture was estimated 
by measuring the absorbance at 280 nm, assuming that 600 pg/ml of scFv gives an A280 
of 1.0.
The results are shown in Table 6.1.
6.2.8 Binding of selected scFvs to P. falciparum  parasites by IFA
Selected purified scFv clones were tested for their ability to bind to 
acetone-fixed T9/96 & FCB-1 P. falciparum by IFA. mAb 12.10 was used as a 
positive control and scFv D1.3 (anti-hen’s egg lysozyme) was used as a negative 
control.
Immunofluorescence patterns were graded as negative, poorly positive, positive 
or very positive depending on the strength of the signal compared with that of mAb 
12.10. All the library scFvs tested gave a positive immunofluorescence pattern similar 
to that obtained with mAb 12.10.
The results are shown in Table 6.2.
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6.2.9 Examination of selected scFvs for invasion-inhibitory activity
Selected scFvs were tested for the ability to inhibit erythrocyte invasion in vitro. 
Invasion assays were carried out as described in section 2.8.3. The scFvs T3B4, T3C2, 
T3D3, T3D6, and T4D4 were tested. The scFvs were dialysed in RPMI and tested at a 
final concentration of approximately 200 jig/ml. None of the scFvs tested inhibited 
erythrocyte invasion. The same scFvs were also tested in the presence of 9E10 
hybridoma supernatant (final concentration 10% [v/v]) or anti-PentaHIS antibody 
(Qiagen) (final concentration 25 pg/ml or 50 pg/ml). This was done because it was 
hoped that these mAbs might increase the size of the scFv by binding to the c-myc and 
hexahistidine tags respectively, and thereby restore putative invasion-inhibitory activity. 
None of the scFvs tested inhibited erythrocyte invasion in these experiments (data not 
shown).
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6.3 Discussion
The work described in this chapter demonstrates that it is possible to isolate 
human antibody fragments that recognise MSP-119 from phage display libraries derived 
from malaria-exposed human donors. It has been shown here that the scFvs isolated by 
panning the libraries with recombinant MSP-119 do indeed recognise both recombinant 
MSP-119 and native merozoite MSP-119 and whole P. falciparum parasites. Binding to 
recombinant MSP-119 has been shown by ELISA, binding to native MSP-119 (in both 
strains FCB-1 and T9/96) has been shown by Western blot, and binding to whole 
acetone-fixed P. falciparum parasites (again in both strains FCB-1 and T9/96) has been 
shown by IFA.
It has also been shown that a number of different anti-MSP-li9 antibody 
fragments can be isolated in one series of panning rounds with a single antigen. This 
was indicated by the BstNl restriction digest patterns and confirmed by DNA 
sequencing of the scFvs obtained.
Furthermore this work suggests that the scFvs that bind to MSP-119 compete 
with the invasion-inhibitory mAbs 12.8 and 12.10 for binding to antigen. This has 
been demonstrated by competition ELISA, in which the binding of the 
invasion-inhibitory mAbs to recombinant MSP-119 was reduced by MSP-119-specific 
scFvs but not by those scFvs which do not themselves bind to MSP-119 by ELISA.
None of the scFvs selected for testing in this study showed any inhibition of 
erythrocyte invasion in the in vitro assay. Preliminary experiments were done to 
attempt to restore putative invasion-inhibitory activity to these scFvs by increasing their
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size, but no invasion-inhibitory effect could be detected. Further experiments are 
needed to optimise such strategies and determine whether they can restore 
invasion-inhibitory activity to scFvs in the future.
It is estimated that successive rounds of panning enrich the population of phage 
specific for the antigen by one in 10 at each round (McCafferty, Griffiths et al. 1990). 
It can be seen however from the results of the ELISA described in section 6.2.3, that in 
a test of 80 randomly chosen clones from the third and fourth panning rounds, the 
proportion of isolated scFv fragments specific for MSP-119 actually decreased between 
the third and fourth rounds of panning. This probably occurs because by the fourth 
round of panning, scFvs on phage are being selected for some property other than 
binding to the antigen of interest. It is possible that plastic-binding phage are being 
selected, and this has been described previously (Adey, Mataragnon et al. 1995). It is 
also possible that mutated scFvs with unwanted stop codons in the DNA sequence are 
being selected because a truncated scFv will relieve the cells of a metabolic burden, 
conferring a selection advantage on such mutants. Given these considerations, and also 
considering that further rounds of panning can only enrich specific phage already 
isolated in previous panning rounds, it seems very unlikely that a fifth round of panning 
would lead to the isolation of any further scFvs of interest.
Among the scFvs obtained by panning the libraries with recombinant 
MSP-119-GST and selected for sequencing, the sequences are all relatively similar to 
each other. More diversity is found among the light chains than among the heavy 
chains. There are essentially two different heavy chains among the scFvs, with a third 
minor variant. The two heavy chains differ from each other both in the second and the 
third complementarity determining regions (CDRs). There are five different light chain
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sequences, and variations are seen in all three light chain CDRs. The greater diversity 
seen among the light chain sequences is consistent with previous observations of light 
chain promiscuity and probably reflects the lesser contribution made by the light chain 
than the heavy chain to the antigen specificity of antibodies and scFvs. Interestingly, 
Dr Jonathan Chappel panned these libraries with whole merozoites which had 
undergone secondary processing of MSP-1, and obtained very similar scFv sequences to 
those shown here. One scFv obtained from merozoite panning, N4E4E9, has an amino 
acid sequence identical to that of scFv T3D6 except for some differences in the fourth 
framework region of the light chain. The close similarity between the scFvs obtained 
by panning with either processed merozoites or recombinant MSP-119 suggest that 
natural antibody responses to the merozoite after secondary processing are directed 
more towards MSP-119 than any other antigen remaining on the merozoite surface.
The affinity of the scFvs described here for MSP-119 was not determined. 
However, Dr Jonathan Chappel used Biacore to analyse the affinity of the scFv N4E4E9 
for recombinant MSP-119-GST immobilised on a carboxymethyl dextran hydrogen 
sensor chip (Pharmacia Biacore). scFv N4E4E9 was found to have a Kd of 3.5 x 10'9. 
As the amino acid sequence of scFv N4E4E9 is very similar to that of the scFvs 
described here, and almost identical to one, it is likely that the scFvs described in this 
chapter will also have affinities of the order of 1 0 '9.
In order to determine which scFvs may have the potential to inhibit erythrocyte 
invasion it is important to determine as clearly as possible where their epitopes are 
located on the MSP-119 molecule. As has been discussed, antibodies to MSP-119 may 
be classified as inhibitory (those which block invasion), blocking (those which block the 
neutralising effect of the inhibitory antibodies) or neutral (those which neither inhibit
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invasion nor block the invasion-inhibitory antibodies). It is known that 
malaria-exposed people make all three types of antibody and so the scFvs obtained by 
panning with MSP-119 may be derived from parent antibodies from any of these three 
groups. Those scFvs whose binding sites do not overlap with the invasion-inhibitory 
mAbs 12.8 and 12.10 are probably unlikely to have invasion-inhibitory potential 
themselves. Those scFvs whose binding sites do overlap with those of mAbs 12.8 and
1 2 . 1 0  may be derived from parent antibodies that are either invasion-inhibitory or 
blocking. In selecting scFvs for further study therefore, those that can block the 
binding of mAb 12.8 or mAb 12.10 to MSP-119 are likely to be of more interest than 
those which cannot.
The results of the competition ELISA described in this chapter suggest that the 
MSP-119-binding scFvs obtained recognise epitopes on the MSP-119 molecule which are 
either identical to, or overlap with, those epitopes recognised by mAbs 12.8 and 12.10. 
The epitopes of mAbs 12.8 and 12.10 overlap each other, so it is not surprising that 
scFvs may be found whose epitopes overlap with both. The competition ELISA 
described here was carried out in two 96 well plates in order to screen the same 160 
library clones (80 from the third round and 80 from the fourth round of panning) as 
were screened for binding to MSP-119 in the ELISA described in section 6.2.3. In fact 
almost all the clones which showed binding to MSP-119 in the ELISA also showed some 
inhibition of binding of mAbs 12.8 and 12.10 in the competition ELISA. This suggests 
that all the MSP-119-binding scFvs tested bind to similar or identical epitopes, and that 
if engineered back to full antibodies they would either be invasion-inhibitory or 
blocking but not neutral. There are, however, ways in which this experiment could be 
repeated in a different way to give clearer results. Because the competition ELISA 
described here was done to screen 160 clones, the amount of scFv present in each well
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was not controlled and will have varied with the level of expression of the different 
scFvs. Also, the library scFvs were tested for their ability to block whole antibodies 
rather than scFv forms of mAb 12.8 and mAb 12.10. This is not ideal because the 
avidity of whole IgG will be greater than that of monovalent scFv. At the time this 
experiment was done scFv 12.10 was not yet available in a form which could be 
distinguished from the library scFvs on detection. The experiment could be repeated 
using the scFv 12.10 fused with two albumin binding domain tags as previously 
described. The ELISA plate could then be coated with albumin, and then the scFv 
12.10-ABD2 could be bound to the albumin and then recombinant MSP-119 could be 
bound to scFv 12.10-ABD2. The library scFv could then be tested for their ability to 
bind to the MSP-119. The scFv version of mAb 12.8 did not express well enough to be 
used in such a way. However, Fab fragments of mAb 12.8, which would be 
distinguishable from the human library scFv because they are murine, have recently 
been made using papain (Dr Matthew Lock, Division of Parasitology, NIMR; personal 
communication) and could be used instead of scFv. It is likely that the inhibition of 
binding of the invasion-inhibitory mAbs by the library scFvs would be greater if 
monovalent versions of the mAbs were tested in this way.
Another way of determining which epitopes are recognised by these scFv would 
be to use Biacore surface plasmon resonance to perform epitope mapping. The mAbs 
12.8 or 12.10 could be bound to the Biacore chip, and MSP-119 could be then captured 
by the bound antibody. If the scFv obtained could still bind to the MSP-119, this would 
imply that they recognise an epitope on MSP-1 pother than that recognised by mAb 12.8 
or mAb 12.10.
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The experiments carried out to attempt to restore putative invasion-inhibitory 
activity to the library scFvs could be refined in a number of ways. The scFvs under test 
should be quantified after they have been purified away from any breakdown products 
to ensure that the concentration of intact scFv is accurately determined. The scFv 
should be tested at high concentrations. In the case of mAbs 12.10, a concentration of 
around 500 pg/ml is required to produce at least 50% inhibition of erythrocyte invasion 
by T9-96 P. falciparum parasites. A scFv expressed with a c-myc and hexahistidine tag 
has a mass of approximately 30% that of a whole antibody. It might therefore be 
anticipated that the concentration required for an invasion-inhibitory scFv to inhibit 
would only be 30% that of the concentration required for a whole antibody, and that by 
analogy with mAb 12.10 an scFv might inhibit invasion at around 170 pl/ml. An 
antibody has two antigen-binding domains however, whereas a scFv has only one, and 
so twice the above concentration of scFv may be required to be equivalent to the 
invasion-inhibitory concentrations of mAbs 12.8 and 12.10. This is not known, 
however, and so concentrations considerably higher than this should be tested. 
Furthermore, antibodies directed against the scFv tags (mAb 9E10 or anti-PentaHIS 
antibody) should be used in a purified form. They should also be used at a 
concentration sufficient to bind all of the scFv present, and again by analogy with mAb
12.10 it would be appropriate to use mAb 9E10 or anti-PentaHIS antibody at a 
concentration of at least 500 pg/ml. The binding of these antibodies to the scFv under 
test could be confirmed using an ELISA in which scFv is first bound to MSP-119 and 
then mAb 9E10 or anti-PentaHIS are tested for their ability to bind the scFv. Other 
potential strategies for restoring invasion-inhibitory activity to scFvs are discussed 
further in Chapter 7.
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With a combined size of 1.3 x 109 members, these phage display libraries 
derived from malaria-exposed donors are large. The results described in this chapter 
clearly demonstrate that the libraries are also diverse and of a high quality, and that 
antibody fragments to antigens of interest can be isolated from them. The libraries are 
therefore a valuable resource from which antibody fragments to a wide variety of 
malaria antigens may be isolated in other studies in the future.
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Figure 6.1
Binding of polyclonal scFv from successive rounds of library panning 
to P. falciparum  by immunofluorescence
Polyclonal scFv from each successive round of panning against MSP-119 was 
examined for the ability to bind acetone-fixed P. falciparum parasites by 
immunofluorescence as described in section 2.7.1. Shown here are the 
immunofluorescence patterns obtained from polyclonal scFv obtained from the March 
phage display library before panning, and from the combined March and October phage 
display libraries after one, two, three and four rounds of panning against recombinant 
MSP-119-GST. T9/96 parasites have been used. mAb 12.8 has been used as a positive 
control.
It can be seen that mAb 12.8 yields a characteristic immunofluorescence pattern 
revealing P. falciparum schizonts. No immunofluorescence is seen with the polyclonal 
scFv from panning round 1, and very little immunofluorescence is seen from panning 
round 2. By panning round 3, however, the polyclonal scFv yields an 
immunofluorescence pattern very similar to that obtained with mAb 12.8, and a similar 
positive signal is seen, although less brightly, with polyclonal scFv from panning round 
4. These results prove that MSP-119-specific scFvs have been successfully isolated and 
amplified from the libraries after three rounds of panning. The slight reduction in the 
immunofluorescent signal in round 4 may reflect the fall in the proportion of MSP-119- 
binding scFvs present after the fourth round of panning, which was demonstrated by the 
examination of 80 randomly selected clones from each round by ELISA, as described in 
section 6.2.3.
209
Figure 6.1
mAb 12.8
Panning round 1
Panning round 3
i - #
: :
Before panning
Panning round 2
Panning round 4
Figure 6.2
Binding of polyclonal scFv from the fourth round of library panning to 
P. falciparum  by Western blot
Binding of polyclonal scFv obtained from the fourth round of panning to P. 
falciparum merozoite proteins was examined by Western blot as described in section 
2.7.5. T9/96 or FCB-1 merozoites were prepared as described, resolved by SDS-
PAGE, and transferred to a nitrocellulose membrane. The membrane was then cut into 
strips and incubated with various polyclonal scFv, and bound scFv was revealed with 
anti-c-wyc 9E10 antibody as described. Above is the result using T9/96 merozoites, 
and below using FCB-1 merozoites. Different lanes were loaded with polyclonal scFv 
obtained from a number of different panning experiments using different antigens. 
Only the panning with recombinant MSP-119 is described in this thesis, and scFv 
obtained with MSP-119 is used in Lane 9. The lanes were probed as follows:
Lane 1 Polyclonal scFv from March library, unpanned
Lane 2 Polyclonal scFv from October library, unpanned
Lane 3 Polyclonal scFv from 4th round of panning with unprocessed merozoites
(rounds 1, 2 & 4 with FCB-1, round 3 with T9/96, March library only)
Lane 4 Polyclonal scFv from 4th round of panning with unprocessed merozoites
(rounds 1,2 & 4 with T9/96, round 3 with FCB-1, March library only)
Lane 5 Polyclonal scFv from 4th round of panning with unprocessed merozoites
(rounds 1, 2 & 4 with FCB-1, round 3 with T9/96, October library only)
Lane 6  Polyclonal scFv from 4th round of panning with unprocessed merozoites
(rounds 1, 2 & 4 with T9/96, round 3 with FCB-1, October library only)
Lane 7 Polyclonal scFv from 4th round of panning with processed merozoites
(rounds 1, 2 & 4 with FCB-1, round 3 with T9/96)
Lane 8  Polyclonal scFv from 4th round of panning with processed merozoites
(rounds 1,2 & 4 with T9/96, round 3 with FCB-1)
Lane 9 Polyclonal scFv from 4th round of panning with MSP-119-GST
Lane 10 scFv D1.3 (anti-hen’s egg lysozyme)
Lane 11 scFv X509 (anti-MSP-l33)
Lane 12 scFv 89.1 (anti-MSP-l83)
Lane 13 mAb 12.8 (anti MSP-14 2  and MSP-11 9 )
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Figure 6.3
Assessment of DNA sequence diversity of MSP-11 9 -binding scFvs by
BstNl restriction digest
This figure shows the different restriction-digest patterns of 78 randomly 
selected scFvs, 36 selected from the third round of panning against MSP-119 and 36 
selected from the fourth round of panning against MSP-119.
The 78 colonies were randomly picked and PCR screened for the presence of 
inserts. All 100 of these colonies yielded a PCR product of the expected insert size. 
Part of each of these products was digested with the frequent-cutting restriction enzyme 
BstNl as described in section 2.6.5 to make an initial assessment of the diversity of the 
inserts. The products of this digestion were resolved on a 4% NuSieve agarose gel.
A large number of different digest patterns are seen, suggesting a high degree of 
DNA sequence diversity among the MSP-119-specific scFv inserts.
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Figure 6.4a)
Inhibition of binding of mAbs 12.8 and 12.10 to MSP-I19 by scFvs by 
competition ELISA: Effect of non-MSP-119-binding scFvs
A competition ELISA was designed to determine whether the scFvs obtained by 
panning against MSP-119 could compete with mAbs 12.8 and 12.10 for binding sites on 
the MSP-119 molecule, as described in section 2.7.4. Competition ELISA plates were 
coated with recombinant MSP-119-GST at 0.5 pg/ml for competition with mAb 12.8 and 
at 0.05 pg/ml for competition with mAb 12.10. The scFv were expressed in a 96-well 
plate as described and the pre-blocked scFv-containing supernatants were transferred to 
the ELISA plate and allowed to bind. The plates were washed and then mAb 12.8 (at 
0.5 pg/ml) or mAb 12.10 (at 0.05 pg/ml) were allowed to bind also. Bound mAb was 
then revealed as described previously.
This figure shows the results of the negative control experiment. The bar chart 
shows the effect which scFvs from the fourth round of panning, which had been shown 
by ELISA not to bind to MSP-119, have on the binding of mAbs 12.8 and 12.10. The 
binding of mAb 12.8 and mAb 12.10 is shown as a percentage of the binding (as 
measured by absorbance at 655 nm) of mAb 12.8 and mAb 12.10 in the absence of any 
scFv. As expected, scFvs from the fourth round of panning which do not bind MSP-119 
do not inhibit the binding of mAbs 12.8 and 12.10 to MSP-119.
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Figure 6.4b)
Inhibition of binding of mAbs 12.8 and 12.10 to MSP-I19 by scFvs by 
competition ELISA: Effect of MSP-119-binding scFvs
This figure shows the effect of MSP-119-binding scFvs from the third and fourth 
rounds of panning on the binding of mAbs 12.8 and 12.10 to MSP-119.
In some cases the binding of mAb 12.8 (as measured by absorbance at 655 nm) 
is reduced by over 60% and the binding of mAb 12.10 is reduced by over 30%. This 
result suggests that at least some of the anti-MSP-li9 scFvs compete with mAbs 12.8 
and 1 2 . 1 0  for a similar, or identical, epitope.
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Figure 6.5
Amino acid sequences of M SP-119-binding scFvs
This figure shows an alignment of six selected scFvs obtained by panning the 
phage display libraries with recombinant MSP-119, and one scFv (N4E4E9) obtained 
(by Dr Jonathan Chappel) by panning the libraries with P. falciparum merozoites in 
which secondary processing had been allowed to proceed. Residues which differ from 
the consensus sequence are highlighted in pink. Complementarity-determining regions 
(CDRs) are outlined in green.
There is more diversity among the light chain variable regions of these clones 
than among the heavy chain variable regions. Two significantly different heavy chain 
sequences are seen. The commoner heavy chain is present in scFvs T3B4, T3C2, 
T3C8, T3D6 and T4D4, although the CDR 1 of scFv T4D4 differs from the others in 
this group by one residue. The other heavy chain sequence is found in scFv T3D3, and 
differs from the commoner heavy chain in both CDR 2 and CDR 3.
Six different light chain sequences are seen among these 6  scFvs. Variation is 
seen in all three CDRs. Full sequence information was not obtained on two of the 
scFv, T3B4 and T3C8, which were not sequenced through the whole of the third CDR 
and the fourth framework region.
It is interesting that a scFv obtained by panning with processed merozoites 
(N4E4E9) is all but identical to a scFv (T3D6) obtained by panning with recombinant 
MSP-119.
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Table 6.1
Expression levels of selected MSP-119-binding scFv clones
scFv Amount of protein from 1ml of culture
T3A2 2 . 2  pg/ml
T3A10 3.4 pg/ml
T3B4 3.2 pg/ml
T3C2 3.4 pg/ml
T3C8 4.0 pg/ml
T3D3 1.3 pg/ml
T3D6 4.4 pg/ml
T4A4 3.8 pg/ml
T4B3 0.4 pg/ml
T4B8 1.3 pg/ml
T4D4 3.8 pg/ml
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Table 6.2
Binding of selected M SP-119-binding scFv clones to P. falciparum  parasites by
Immunofluorescence patterns were graded as negative, poorly positive, positive or very 
positive depending on the strength of the signal compared with that of mAb 12.10.
scFv Result with FCB-1 Result with T9/96
T3A2 negative negative
T3A10 very positive ND
T3B4 negative poorly positive
T3B6 ND positive
T3C2 very positive very positive
T3C8 very positive very positive
T3D3 negative poorly positive
T3D6 positive positive
T4A4 very positive very positive
T4B3 positive very positive
T4B8 positive positive
T4D4 positive positive
D1.3 negative negative
mAb 12.10 very positive very positive
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CHAPTER 7 
GENERAL DISCUSSION
The work described in the first part of this thesis shows that it is possible to 
engineer murine hybridoma monoclonal antibodies which can inhibit erythrocyte 
invasion by Plasmodium falciparum into recombinant partially humanised antibodies 
which retain invasion-inhibitory activity. It has also been shown that one of these 
mAbs can be engineered into a single chain variable fragment (scFv) which expresses 
well and retains the ability to bind to the target antigen with good affinity.
The demonstration of antigen binding and inhibition of invasion by the 
recombinant mouse/human chimeric versions of the hybridoma mAbs 12.8 and 12.10 
provides confirmation that the sequences of the variable regions of the parent 
hybridoma mAbs have been correctly identified. The chimeric mAbs will also be 
suitable reagents with which to determine whether invasion-inhibitory mAbs can 
modify or prevent clinical malaria in a primate model of malaria. These chimeric 
mAbs have a number of advantages over mAbs purified from hybridoma cell cultures. 
Firstly they should be less immunogenic in primates because they have been engineered 
with human antibody constant regions. Human antibody constant region sequences 
will be much closer to primate sequences than murine sequences would be, and these 
antibodies should evoke a correspondingly more muted immune response in primates 
than would be evoked by murine mAbs. Secondly, being recombinant constructs of 
known sequence, these mAbs provide a completely standardised form of the antibodies 
which can be produced to the rigorously high standard necessary for testing in primates. 
A previous study designed to test these invasion-inhibitory mAbs in Aotus monkeys had
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to be abandoned because the purified hybridoma mAbs were contaminated with 
lipopolysaccharide (LPS) at quantities which precluded their safe use in primates. It 
has also been observed that different batches of mAb 12.10 prepared from different 
cultures of 1 2 . 1 0  hybridoma cells may vary in the degree to which they inhibit 
erythrocyte invasion. It is hoped that controlled expression of recombinant forms of 
these mAbs under rigorous conditions may prevent some of these variations in quality.
Because the concentrations of antibody required to inhibit invasion in vitro are 
quite high, at around 400 pg/ml, the quantity of antibody which is anticipated to be 
required in order to test these antibodies in primates is correspondingly large. The 
expression levels of both chimeric mAbs 12.8 and 12.10 are good, and chimeric mAb
12.10 is currently being produced in large quantities at AERES Biomedical (formerly 
the Antibody Engineering Group of the MRC Collaborative Centre at Mill Hill, 
London). This is being done with the intention that chimeric mAb 12.10 should be 
tested for the ability to modify or prevent P. falciparum infection in Aotus monkeys, in 
collaboration with the Walter Reed Army Institute for Research, Washington D.C.
If the chimeric antibodies do modify or control P. falciparum infection in a 
primate model, the question of their potential use as therapeutic agents in humans would 
naturally arise. The number of therapeutic antibodies in standard use in resource-rich 
countries is steadily increasing, and it may be anticipated that their cost will fall as this 
expansion continues. At present, cost is a central issue in the usefulness of any new 
malaria therapy, and the main burden of disease falls upon countries least able to afford 
expensive treatments. Furthermore, currently available drugs, used judiciously, can 
still normally control individual infections. This situation may change however, 
particularly if multidrug resistance in malaria worsens and spreads to cause major public
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health problems in countries (for instance in South East Asia) with greater economic 
resources. In such a situation, it is conceivable that therapeutic antibodies for malaria 
may have a future.
The single chain variable fragment (scFv) engineered from the sequences 
obtained for the variable regions of the heavy and light chains of mAb 12.10 binds to 
MSP-119 with good affinity. Like Fab 12.10, the scFv version of 12.10 does not appear 
to retain invasion-inhibitory activity. The scFv version of mAb 12.10 will therefore be 
useful as a model with which to test different strategies for restoring putative invasion- 
inhibitory activity to human scFvs derived from phage display libraries. A number of 
possible strategies for achieving this are discussed below.
The work described in the second part of this thesis shows that it is possible to 
isolate high affinity human monoclonal antibody fragments to MSP-119 from a phage 
display library derived from malaria-exposed donors. A number of different single 
chain variable fragments (scFvs) were isolated by panning two medium-sized libraries 
(with a combined size of approximately 1 x 1 0 9 members) with recombinant 
MSP-119-GST. These scFvs were shown to bind to recombinant MSP-119-GST by 
ELISA and were shown to bind to native Plasmodium falciparum parasites by 
immunofluorescence and by Western blot. These scFvs also partially blocked the 
binding of the invasion-inhibitory murine mAbs 12.8 and 12.10, suggesting that the 
scFvs recognise epitopes which overlap with those epitopes recognised by the 
invasion-inhibitory mAbs. Selected scFvs were tested in an in vitro assay of 
erythrocyte invasion. None of the scFvs showed any inhibition of invasion, but further 
experiments are needed to examine possible ways in which putative invasion-inhibitory 
activity might be restored to antibody fragments presented in the scFv format.
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It is likely that any scFv with the potential to inhibit erythrocyte invasion in a 
manner analogous to that of the murine hybridoma mAbs 12.8 and 12.10 would need to 
be engineered back into a format approaching that of a whole antibody before any 
invasion-inhibitory activity would be displayed. This seems likely because Fab and 
F(ab’ )2 fragments of mAb 12.10 do not retain the invasion-inhibitory property of the 
parent antibody (Guevara Patino 1997). The most unequivocal way of engineering 
scFv to be more like the parent antibody is to actually use the sequence of the scFv to 
construct a whole recombinant antibody. Biological activity has been restored to scFvs 
in this way in a number of studies (Miescher, Zahn-Zabal et al. 2000), and techniques 
have been developed to facilitate the transformation of scFvs into whole antibodies 
(Ames, Tometta et al. 1995) (Mahler, Marquis et al. 1997). In one study, biological 
activity has also been restored to an scFv against the glycoprotein antigen of the rabies 
virus by expressing the scFv as a fusion with the human IgGl Fc region (Ray, Embleton 
et al. 2001). The problem with these approaches is that they are labour-intensive and 
time-consuming, and are therefore unsuitable for screening large numbers of scFvs 
efficiently. An ideal technique for rapid screening would readily increase the size of 
the scFv (approximately 30 kDa) to that of a whole antibody (approximately 150 kDa) 
without requiring each scFv to be engineered individually. For some biological 
properties of antibodies the Fc portion of the antibody has to be restored to the scFv to 
recruit other essential immune effector mechanisms (Ray, Embleton et al. 2001). In the 
case of protective antibodies against MSP-119 however, as discussed in section 1.2.4, 
there is evidence that these other effector functions, and the Fc portion of the antibody, 
are not required for protection (Rotman, Daly et al. 1998) (Vukovic, Hogarth et al. 
2000).
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A number of different strategies might be used to bulk up the scFvs to a size 
approaching that of a whole antibody. Three such strategies have already been 
discussed. Two involve the binding of a second antibody to a tag at the C-terminus of 
the scFv. Purified mAb 9E10 might be bound to the c-myc tag or anti-PentaHIS 
antibody might be bound to the hexahistidine tag. Anti-PentaHIS antibody is a very 
expensive reagent, whereas mAb 9E10 can be produced in quantity quite easily from 
9E10 hybridoma cells. Furthermore 9E10 has already been used successfully to restore 
biological activity to a scFv with a c-myc tag. A scFv against influenza haemagglutinin 
regained the ability to inhibit haemagglutination (and by implication to neutralise 
influenza virus) when used in conjunction with mAb 9E10 (Keith Ansell, MRC 
Collaborative Centre, Mill Hill, London, unpublished data). Another approach already 
discussed in the context of scFv 12.10 is to express the scFvs as a fusion with two 
albumin-binding domains. In the presence of albumin, two albumin molecules 
(molecular weight 68 kDa) would bind to each scFv, increasing the mass of the scFv by 
around 136 kDa.
An alternative and possibly more robust strategy for increasing the mass of the 
scFv would be to express the scFv as a fusion with another protein which would itself 
increase the mass by the required amount. The additional mass would then be 
covalently bound, which might prove more reliable under a wider range of conditions 
than relying on the non-covalent binding of a second antibody or of albumin.
It is possible that other antibodies are generated by natural infection which 
inhibit erythrocyte invasion by a different mechanism to that of the known 
invasion-inhibitory mAbs 12.8 and 12.10. If this is the case, scFv fragments of such 
antibodies might retain invasion-inhibitory activity without the requirement for an
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increase in size to that of the parent antibody. There is some evidence that such 
invasion-inhibitory antibodies may exist. A study of blood samples from malaria- 
exposed children aged up to 15 years from Nigeria has demonstrated the presence of 
antibodies which inhibit secondary processing of MSP-1 but which do not compete with 
mAbs 12.8 and 12.10 for binding to MSP-119 (Roseangela Nwuba, Division of 
Parasitology, NIMR, unpublished data). In another study, antibodies raised against a 
recombinant mutated form of MSP-119 incorporating three amino acid substitutions 
showed substantially more inhibition of erythrocyte invasion than that produced by 
mAbs 12.8 and 12.10. The same antibodies showed no more inhibition of secondary 
processing than that shown by mAbs 12.8 and 12.10, suggesting that some other 
mechanism is involved in their inhibition of erythrocyte invasion (Chairat Uthaipibull, 
Division of Parasitology, NIMR, unpublished data).
The scFvs isolated from these phage display libraries by panning with 
recombinant MSP-119 do not appear to be particularly diverse from the examples which 
were sequenced. Essentially only two different heavy chains were detected and they 
were quite similar to each other. There was more diversity among the light chains but 
they probably contribute less to antibody specificity than the heavy chains. 
Interestingly, those scFvs obtained by Dr Jonathan Chappel by panning the libraries 
with whole merozoites (in which secondary processing of MSP-1 had been allowed to 
proceed) showed very similar, or in some case near identical, sequences to those 
obtained by panning with recombinant MSP-119 and described in this work. Those 
scFvs derived from merozoite panning gave a near identical pattern on binding to 
merozoite proteins on a Western blot as did the scFvs derived from MSP-119 panning. 
This suggests that the antigen which most readily generates an antibody response on the 
surface of processed merozoites is MSP-119. Furthermore, virtually all the scFvs which
222
bound to MSP-119 in the ELISA also blocked the binding of mAbs 12.8 and 12.10. It 
seems possible therefore that all the MSP-119-binding scFvs isolated in the third and 
fourth rounds of panning in fact bind to the same or a very similar epitope. If that 
epitope does indeed overlap with the epitope recognised by mAbs 12.8 and 12.10, as 
suggested by the competition ELISA, then the scFvs, if restored to a whole antibody 
format, would presumably be either invasion-inhibitory or blocking, but not neutral. 
The scFv N4E4E9 was obtained by Dr Jonathan Chappel of the MRC Collaborative 
Centre by panning these libraries with whole processed P. falciparum merozoites. The 
sequence of N4E4E9 is very similar to the sequences of the scFvs described in this 
work, and almost identical to one of them, scFv T3D6. Dr Jonathan Chappel 
engineered scFv N4E4E9 back into a whole recombinant antibody and showed that as a 
whole antibody, N4E4E9 does not appear to have much inhibitory effect in the in vitro 
assay of secondary processing of MSP-1 (unpublished data). It seems quite possible 
therefore that the panning of these libraries with either recombinant MSP-119 or whole 
merozoites has resulted, at the third and fourth rounds of panning, in the isolation of a 
panel of closely related blocking antibodies rather than invasion-inhibitory antibodies. 
If this does prove to be the case, it will be necessary to consider other panning strategies 
which may be more likely to isolate scFv with invasion-inhibitory potential from these 
libraries.
There are a number of ways in which the strategy described in this work might 
be modified in order to isolate a wider variety of MSP-119-binding scFvs from these 
libraries. It is unlikely that a fifth round of panning against recombinant MSP-119 
would yield any further scFvs of interest beyond those already obtained by four rounds 
of panning, for the reasons discussed in section 5.3. One approach which might lead to 
the identification of a more diverse population of MSP-119-specific scFvs could be to
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examine the scFvs isolated from the second round of panning against MSP-119. So far, 
only scFvs from the third and fourth rounds of panning against MSP-119 have been 
examined. It is possible that MSP-119 binding scFvs will have been sufficiently 
enriched after two panning rounds that some may be detected if a sufficient number of 
randomly selected clones are examined by ELISA. The scFvs from the second round 
of panning were not examined individually in this study. Polyclonal scFv from the 
second round was examined for binding to P. falciparum by IF A (see Figure 6.1) and 
did not give a strong signal. There did appear to be some slight immunofluorescence 
signal, however, in contrast to the complete absence of signal from the polyclonal scFv 
retrieved after one round of panning. It may be therefore that some scFvs with 
invasion-inhibitory potential are present in the phage obtained from the second round of 
panning, but that these scFvs are out-competed by other scFvs in subsequent rounds of 
panning. This might occur if they have a lower affinity for MSP-119 than the scFvs 
which were isolated in this study, or if they are at some other selective disadvantage.
The disadvantage of selecting scFvs from the second round of panning is that 
they may have a relatively low affinity for MSP-119, since higher affinity scFvs tend to 
be selectively enriched only on repeated rounds of panning. The scFvs of most interest 
are those with affinities comparable to the affinities of antibodies generated by a 
secondary immune response. There are however a number of techniques for improving 
the affinities of antibody fragments isolated by phage display. The affinity of isolated 
heavy chain variable regions (V h) has been improved by making random amino acid 
substitutions in the first and second complementarity determining regions (CDRs) 
(Davies and Riechmann 1996) and also by making substitutions in the second and third 
CDRs (Thompson, Pope et al. 1996). CDRs can be targeted for random mutagenesis 
followed by further affinity-based selection by phage display in a process termed CDR
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walking (Barbas, Hu et al. 1994) and this process has been used to improve the affinity 
of a prototype anti-HIV-1 antibody 420-fold (Yang, Green et al. 1995). Affinity of 
scFvs has also been improved by introducing variations in the sequence of the linker 
that joins the heavy and light chain variable domains of the molecule (Turner, Ritter et 
al. 1997). Thus if MSP-119-specific scFvs were isolated from the second round of 
panning but were found to be of low affinities, there are a number of techniques by 
which their affinities might be improved.
Another recognised strategy for re-panning a library to get a different population 
of scFvs against a given antigen than those initially isolated is that of epitope masking. 
In this procedure, a highly immunogenic epitope on an antigen is blocked, or masked, 
with a scFv which has already been isolated against that epitope. This prevents the 
previously dominant epitope being exposed when panning is repeated, permitting the 
isolation of a broader range of scFvs, directed against other epitopes, which were not 
previously selected for. This technique has been used successfully to access 
neutralising human antibodies to a weakly immunogenic epitope of the HIV-1 gpl20 
antigen (Ditzel, Binley et al. 1995). The libraries described in this thesis could be 
panned again with MSP-119, having masked the previously dominant epitope with one 
of the scFvs already obtained, to enable the isolation of other scFvs with invasion- 
inhibitory potential analogous to that of mAbs 12.8 and 12.10. As discussed above, it 
is also possible that other epitopes exist on the MSP-119 molecule, capable of generating 
invasion-inhibitory antibodies which do not recognise the same epitopes as mAbs 12.8 
or 12.10. To search for scFvs against such epitopes, the libraries could be panned using 
an epitope-masking strategy in which MSP-119 is blocked with Fab 12.8 or Fab 12.10.
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It may be that the scFvs isolated so far would act as blocking antibodies rather 
than invasion-inhibitory antibodies if they were restored to a whole antibody format. 
To avoid the isolation of scFvs with the potential only for blocking activity, the libraries 
could be panned with mutant forms of MSP-119. A number of such mutants have been 
constructed, some of which are recognised by the invasion-inhibitory mAbs 12.8 ands 
1 2 . 1 0  but are not recognised by any of a panel of known blocking antibodies 
(Uthaipibull, Aufiero et al. 2001). The libraries could be panned again with a mutant 
form of MSP-119 that does not bind any of the known blocking antibodies. This may 
permit the isolation of different scFvs, recognising similar epitopes to those recognised 
by the scFvs obtained in this study, but with potential invasion-inhibitory properties 
rather than blocking properties.
In summary, therefore, there are a number of methods by which putative 
invasion-inhibitory activity might be restored to antibody fragments isolated in the scFv 
format. If such a technique can be developed and validated using the scFv form of 
mAb 12.10, it can then be applied to the scFvs described in this study. If the scFvs 
described in this study prove not to have invasion-inhibitory properties, there are a 
number of ways in which the libraries might be panned again in order to search for 
scFvs which do have the potential to inhibit invasion. Given the wealth of evidence 
that anti-MSP-li9 antibodies do have an important role in naturally acquired human 
immunity to P. falciparum, it seems likely that such antibody fragments are represented 
in these libraries, and that they can be isolated and identified provided the search is 
conducted in the right way.
The work described in this thesis has shown that MSP-119-specific human 
monoclonal antibody fragments can be isolated from phage display libraries made from
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malaria-exposed donors. It has also shown that murine MSP-119-specific mAbs which 
inhibit the invasion of erythrocytes by P. falciparum can be engineered into a partially 
humanised form and still retain their invasion-inhibitory activity. This work provides a 
basis for the further dissection of the human antibody response to MSP-119 at the 
molecular level. It also provides a basis from which the role of invasion-inhibitory 
antibodies in protection may be investigated in vivo and their potential as therapeutic 
agents may be further investigated.
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